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Engineered carbon based nanoparticles (CNP) such as fullerenes and multiwalled carbon 
nanotubes (MWCNTs) are increasingly used in industries and in nanomedicine as a platform for 
drug delivery.  Following environmental/occupational exposure through inhalation CNP are 
translocated to extra-pulmonary sites, raising concerns on their potential effects on vasculature 
particularly in vulnerable life-stages such as pregnancy.  Distribution of intravenously delivered 
C60 in maternal organs varies between pregnant and non-pregnant life-stages, presumed to be 
associated with changes in reactivity of various vascular beds during pregnancy.  The overall 
goal of this dissertation was to describe and elucidate intracellular mediators driving changes in 
contractility of vascular segments from three distinct vascular beds following exposure to CNP 
during pregnancy.  In vitro experiments on aortic endothelial cells and wire myographic studies 
on vessel segments from Sprague Dawley rats exposed to C60/PVP (polyvinylpyrorrolidone 
formulated C60) or MWCNTs were used to identify changes in vascular tissue contractility and 
to determine the contribution of Rho-kinase pathway.  Intravenous administration of C60/PVP 
increased contraction in the uterine artery, aorta and umbilical vein while pulmonary exposure to 
MWCNTs increased contraction in the uterine artery.  These changes were confined to 
pregnancy, suggesting a higher susceptibility of the uterine vasculature to CNP mediated 
changes during pregnancy.  Both in vitro and wire myographic studies suggested an increase in 
Rho-kinase activity with C60/PVP exposure (but not with MWCNT exposure), suggesting that 
C60/PVP mediated increase in contractility may be driven by a common pathway involving Rho-
kinase via activation of endothelium and/or altering signaling within smooth muscle.  MWCNT 
exposure induced contractions may be mediated by inflammatory mechanisms as suggested by 
the increased inflammatory endothelial markers.  Our comparisons with naïve rats and untreated 
endothelial cells indicated a critical role played by the dispersion medium used for CNP delivery 
in determining contractile effects.  These CNP exposures may be detrimental to fetal growth 
resulting in the observed reduction of fetal weight gain following acute exposure to both CNP.  
The conclusions drawn from this work contribute to both nanomedicine and nanotoxicology, 
focusing on safe applications of nanotechnology.  It also widens our understanding on the life-
stage related changes in susceptibility to environmental insults. 
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VEGF vascular endothelial growth factor 
VSMC vascular smooth muscle cells 
vWF Von Willebrand factor 
ΔCt   Ct, target – Ct, housekeeping gene 
  ΔΔCt    ΔCt, stimulated - ΔCt, control 
 
 
 
CHAPTER 1 
Preamble and Specific Aims 
1.1.     Preamble 
Occupational, therapeutic and environmental exposures to engineered nanoparticles create poorly 
understood threats to human health particularly in vulnerable life stages such as pregnancy.  
Carbon based nanoparticles (CNP) fullerene (C60) and multiwalled Carbon Nanotubes 
(MWCNTs) both translocate to systemic circulation following inhalational exposure and are 
distributed to extra-pulmonary sites (136, 167, 186), but may exert differential effects on the 
vasculature due to their physicochemical properties.  Radiolabelled C60 is reported to distribute 
throughout both maternal and fetal circulations following intravenous (IV) exposure (202).  The 
substantial remodeling of uterine and umbilical vasculature during pregnancy may enhance the 
susceptibility of those tissues to changes in vascular reactivity following nanoparticle exposure.  
Distribution of C60 in maternal organs varies between pregnant and non-pregnant life stages 
(202) which is presumed to be associated with the changes of vascular tissue contractility of 
various vascular beds during pregnancy.  The overall goal of this dissertation was to describe and 
elucidate intracellular mediators responsible for changes in contractility of vascular segments 
from three distinct vascular beds (placental, mesenteric and thoracic aorta) following exposure to 
carbon based nanoparticles during pregnancy.   
 
Our preliminary experiments indicated that C60 exposure increases the contractile responses of 
the main uterine artery segments during pregnancy.  Previous experiments with MWCNT 
exposures showed an increase in the contractile responses of other vascular tissues in non-
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pregnant life stages and it remains to be addressed if pregnancy exacerbates the vascular 
responses to MWCNT exposure.  These changes could be driven by a common pathway 
involving RhoA-Rho kinase (ROCK) via activation of the vascular endothelium and/or changing 
the signaling within vascular smooth muscle cells (VSMC).  The changes in the vasoconstrictor 
responses may have detrimental effects on the fetal growth, which can be manifested as a decline 
in the fetal weight gain. 
 
1.2.        Hypotheses  
We hypothesized that acute exposure to C60 and MWCNTs during late stages of pregnancy 
activates vascular endothelium and increases vascular tissue contractility via activation of RhoA-
Rho kinase pathway.  In addition, we hypothesized that there will be distinct responses of aortic, 
uterine and mesenteric arteries due to the different physicochemical properties of C60 and 
MWCNTs and their route of exposure.   
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1.3.   Specific Aims  
The above hypotheses were tested by the following Specific Aims as outlined in Figure 1.1. 
Specific Aim 1.  Determine the contribution of direct in vitro exposure to C60 and MWCNTs on 
endothelial cell activation.   
1.1. Characterize dose- and time-dependent changes in endothelial cell viability and activation 
following in vitro exposure to C60 and MWCNTs.   
1.2 Determine the changes in RhoA-Rho kinase signaling and eNOS expression in 
endothelial cells following exposure to C60 and MWCNTs.   
 
Specific Aim 2.  Identify changes in vascular tissue contractility following exposure to C60 and 
MWCNTs during late stages of pregnancy and the contribution of RhoA-Rho kinase 
pathway in meditating these changes. 
2.1. Establish the contribution of C60 and MWCNT exposure on changes in contractile 
responses of aortic, uterine and mesenteric arterial vessels during pregnancy. 
2.2. Determine the contribution of RhoA-Rho kinase signaling as a mediator of vascular bed 
sensitivity to C60 and MWCNT exposures. 
 
Specific Aim 3.  Identify changes in umbilical blood vessel vasomotor responses following C60 
and MWCNT exposure and the impact on fetal growth.   
3.1. Determine the changes in contractile responses of umbilical veins following acute C60 
and MWCNT exposure by intravenous and intratracheal administration. 
3.2. Characterize and define any differential effects of C60 and MWCNT exposure on fetal 
weight and fetal cytokine expression.  
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Figure 1.1.  Summary of the Aims of the dissertation and their inter-relationship as 
applied to vascular endothelium and vascular smooth muscle cells of the 
vessel wall during pregnancy  
 
CNP = engineered nanoparticles: MLCP = myosin light chain phosphatase.   
The red arrows indicate inhibitory steps; green arrows indicate excitatory steps; black arrows 
indicate translocation of CNP; solid lines represent established pathways and dashed lines 
represent pathways that are not well established.  Text in blue represents VSMC pathways and 
text in peach represents endothelial pathways.
 CHAPTER 2 
Background 
 
2.1. Pregnancy 
Human pregnancy is a unique physiological state in which the entire maternal body undergoes 
functional adaptations to support the nutritional requirements of the developing fetus/es.  These 
changes begin during the pre-implantation stage (i.e. luteal/secretory phase of the menstrual 
cycle) and culminate as extensive remodeling and functional adaptations predominantly in 
reproductive organs to support progression of a successful pregnancy.  Such modifications 
occurring during the transition from a non-pregnant state to a late pregnant state may render the 
pregnant mother and fetus susceptible to environmental insults.  This chapter will describe the 
physiological changes and potential harmful effects by exposure to carbon based nanoparticles 
(CNP) during pregnancy that may predispose the mother and fetus to display adverse 
physiological responses. 
 
2.1.2. Adaptations in the cardiovascular system during pregnancy 
Implantation of the fetus in the uterine endometrium is followed by embryonic and fetal 
development with increasing nutrition and energy demands across the placental interface towards 
later stages of pregnancy.  Placentation creates an additional low-pressure circulation, which is 
compensated by systemic blood volume expansion and increased blood flow.  Concomitant 
vasodilatation and increase in vascular diameter lead to reduced blood pressure during mid-
stages of pregnancy.  Uterine and placental vasculature undergoes rapid, expansive remodeling 
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in response to these amplified demands for blood supply and increased sheer stress.  Depending 
on the site and stage of pregnancy, the vascular remodeling is influenced by systemic hormonal 
changes and localized variations in uterine circulation (118, 153, 154).   
 
Physiological responses in the uterine vasculature during pregnancy are predominantly 
vasodilatory, mediated by augmented basal production of endothelium derived dilator factors 
such as nitric oxide (NO), cAMP and prostacyclin (149, 153).  Additionally, functional veno-
arterial communications among umbilical and uterine vessels contributes to further changes, 
which operate locally depending on the site of implantation (28, 60).  Site dependent variations 
in myogenic tone of uterine blood vessels during late pregnancy also contribute to sustain this 
site and stage dependent burdens (151).  The changes in the sensitivity to different 
vasoconstrictor agents including phenylephrine, endothelin and angiotensin and also changes in 
the uterine and placental vasculature during pregnancy support a suppressed vasoconstrictor 
response (i.e. promote vasodilatory status).  In particular, the receptor type predominance and 
sensitivity to endothelin 1 and angiotensin II are shifted towards relaxation responses in a normal 
pregnancy and their derangements are associated with adverse conditions such as pre-eclampsia 
and low birth weight (44, 51, 72, 75, 77, 87).  The heart, aorta, mesenteric and renal blood 
vessels also undergo similar or paradoxical physiological changes to compensate for increased 
circulation in the uterine vascular bed and overall circulatory demands (2, 34, 41, 48, 219). 
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2.1.3. Sprague Dawley rodent model of pregnancy 
The commonality of hemochorial placentation in both humans and rodents is important in the 
perspective of a pregnancy model, despite the placental derivation from different tissues in the 
two species (54).  Pressure differences and particle transfer properties are similar between human 
and rodent placentae (132) making it an appropriate, efficient model to study nanoparticle 
exposure during pregnancy.  Sprague Dawley rats have a gestation period of 21-22 days with a 
high accuracy in obtaining timed pregnant rats for exposure studies.  Considering the 
developmental stages, the maturation of organs in the rodent model occurs later compared to a 
human pregnancy.  Early post-natal changes in the rodent model are compatible with third 
trimester fetal changes in a human pregnancy (33, 201).  The size and mean weight (250-300 g) 
of both pregnant and non-pregnant animals also facilitate tissue sample collection, dissection and 
mounting of vessels into myographic chambers.   
 
2.2. Factors determining vascular tissue contraction and relaxation responses  
The contractile mechanism of blood vessels is located in vascular smooth muscle cells (VSMC) 
and is controlled at two levels: vascular endothelium and VSMC, with adaptations in the baseline 
control levels to support the changes in blood supply during pregnancy.  The release of both 
endothelial derived constrictor and relaxation factors (EDCF and EDRF) can modulate 
contractile mechanism of VSMC.  Production and release of these regulatory substances are 
controlled by activation of cell membrane spanning receptors (e.g. angiotensin, endothelin and 
serotonin receptors), reactive oxygen species and cyclooxygenase signaling.   
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The main EDRF is nitric oxide (NO) and its production is enhanced as a normal physiological 
response during pregnancy (13, 72, 149, 213).  Muscarinic receptor stimulation by acetylcholine 
in the endothelial cells promotes eNOS (endothelial nitric oxide synthase) activity, increasing the 
endothelial NO production leading to a vasodilatory response in the VSMC via cGMP (61, 83, 
113).  Elements of NO dysfunction have been identified during preeclampsia (87, 97) and 
following exposure to particulate matter, diesel (30) and metal-based nanoparticles (35, 138).  In 
addition, bradykinin, serotonin, histamine and norepinephrine (via α2 receptors) also mediate 
vasodilatory effects via different mechanisms (61, 72). 
 
The vasoconstrictor agents studied in this dissertation, phenylephrine, endothelin 1, serotonin, 
angiotensin II and serotonin, induce contractile responses acting via G protein coupled receptors.  
Some of these agents have multiple receptors subtypes often with distinct topological 
arrangements and mediating paradoxical effects.  Phenylephrine is an α adrenergic receptor 
agonist which stimulates Gq protein coupled receptors in the VSMC leading to vasoconstriction 
and regional variations in α adrenergic function are reported during pregnancy (38).  Endothelin 
1 acts through ETA and ETB receptors.  Both ETA and ETB receptors mediate vasoconstriction in 
the VSMC via activation of Gq protein coupled receptors (146, 236).  However, ETB receptors on 
the endothelial cell surface promote vasodilation by stimulating NO production (236) and the 
receptor profiles are altered in hypertensive disorders (179).  In pregnancy, the ETA mediated 
vasoconstriction is attenuated by the ETB receptor function leading to a suppressed pressor 
response (51).  Angiotensin II, which is a component of the renin-angiotensin axis mediates 
vasoconstriction via AT1 receptors (125, 236) and vasodilation via AT2 receptors.  AT2 
receptors are up-regulated in normal pregnancy and modulate the contractile responses of the 
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AT1 receptors (72, 77, 164).  The alteration of the receptor profiles of both endothelin 1 and 
angiotensin II is reported to be associated with hypertensive disorders including preeclampsia 
(44, 103, 179).  Serotonin has multiple receptors (5HT1-7) and mediates both contraction and 
relaxation effects.  The receptor distribution and activation are determined by the tissue type and 
concentration of serotonin (124).   
 
The cyclooxygenase (COX) signaling is a well-studied mechanism which plays a major role in 
determining the reactivity of blood vessels (233).  The key players in this pathway are lipid 
derivatives originating from arachidonic acid and have two signaling pathways composed of 
COX 1 and COX 2 to leading to production of leukotrienes, thromboxanes and prostaglandins.  
The COX mediated increase in the release in the EDCF promotes vasoconstriction (233).  The 
fine balance between the constrictors and relaxants included in the COX pathway contributes to 
the optimum contractile state of the blood vessel depending on the vascular bed properties.  COX 
signaling associated prostaglandins along with NO contribute to maintaining the optimum 
vascular tone during pregnancy (172).   
 
The principle cation involved in the vascular smooth muscle contraction mechanism is Ca
2+
 and 
the Ca
2+
 concentration or sensitivity of the contractile apparatus to calcium govern the 
contraction and relaxation responses of VSMC (32, 236).  All the above mentioned mechanisms 
converge to regulate the critical second messenger signal of Ca
2+
 activation, which initiates and 
cycles the contractile response by binding to the contractile apparatus on myosin. The increase in 
the intracellular Ca
2+
 levels may be through the release from the sarcoplasmic reticulum and/or 
influx of extracellular Ca
2+ 
via the voltage or ligand gated ion channels in the cell membrane 
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(122). The Ca
2+ 
handling in the VSMC is dependent on the phenotype of
 
the smooth muscle cell, 
which is determined by the tissue type and demands (122).  
 
The above mentioned contractile mechanisms can be altered through different pathways in 
various disease conditions and toxico-pathologies such as hypertension, inflammation, 
preeclampsia and particulate matter/diesel/cigarette smoke exposure (48, 62, 168, 182, 204).  
Generation of reactive oxygen species, derangement of mitochondrial function, activation of 
cyclooxygenase pathway and RhoA – Rho kinase (ROCK) pathway are other common 
mechanisms involved in these pathologies.  These contractile mechanisms are also  the potential 
targets of therapeutic interventions of these disease conditions including preeclampsia (89, 174).   
 
2.2.1. Rho kinase signaling 
Multiple vasoconstrictor agents including phenylephrine, endothelin 1, angiotensin II and 
serotonin act through Gq protein coupled receptors to regulate smooth muscle contraction in the 
vasculature.  Downstream of this receptor, the RhoA-ROCK pathway plays a critical role in 
mediating contractile response in VSMC (59, 236) and influence in vascular endothelial cell 
function (88, 91, 137).  The active form of RhoA promotes activation of the Rho kinase ROCK 
that inhibits the dephosphorylation of myosin light chains (MLC) via increasing the inactive 
form of MLC phosphatase (MLCP).  This mechanism along with the increase in the Ca
2+
 
level/sensitivity in the VSMC, promote the contractile response (59, 236) as outlined in Figure 
2.1.   
 
11 
 
The involvement of Rho signaling in mediating vascular reactivity has been documented in 
association with several cardiovascular pathologies (174, 247).  During pregnancy, an increase in 
RhoA expression has been identified in a preeclampsia model (58) which was associated with 
increased vasoconstrictor response in maternal uterine circulation and placental ischemia.  Rho-
kinase signaling is reduced during normal pregnancy (67) and alterations in the expression of  
ROCK isoforms are associated with pregnancy related vascular complications such as pre-
eclampsia (9).  RhoA-ROCK signaling mediated changes in vascular tissue contractility has been 
demonstrated following particulate matter exposure in non-pregnant animals (204, 248).  In 
addition, RhoA-ROCK pathway plays a significant role in endothelial dysfunction and is 
emerging as a major therapeutic target in several vascular disorders (7, 74, 247).  RhoA mediated 
reduction in synthesis and activation of eNOS contributes to diminution of vasodilator response 
(56, 127).  The NO induced decrease in the calcium sensitivity of resistance arteries mediated via 
activation of myosin light chain phosphatase is antagonized by the RhoA-ROCK pathway 
promoting the contractile response (19).  ROCK signaling also contributes to modulation of 
vascular remodeling and the two ROCK isoforms are differentially expressed in a normal 
pregnancy supporting the rapid remodeling status of maternal vasculature (227).  Nevertheless, 
the contribution of RhoA-ROCK signaling in changing contractile responses and endothelial 
activation following nanoparticle exposure has not been adequately addressed. 
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Figure 2.1.   Contribution of RhoA-Rho kinase signaling to the contractile response of the    
  vascular smooth muscle cells 
 
VSMC: vascular smooth muscle cells, PE: phenylephrine, ANG II: angiotensin II, ET-1: 
endothelin 1, 5HT: serotonin, PLC: phospholipase C, IP3: inositol triphosphate, ROCK: Rho 
kinase, MLC: myosin light chain, MLC-P: phosphorylated myosin light chain, MLCK: myosin 
light chain kinase, MLCP: myosin light chain phosphatase, MLCP-P: phosphorylated myosin 
light chain phosphatase 
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2.3. Wire myography for studying contraction and relaxation responses   
Vascular tissue contractile responses discussed in this dissertation were assessed using a wire 
myograph system.  This system was first described by Mulvany and Halpern in 1977 (133) and is 
widely used as an ex vivo system to study contractile properties and functional responses of 
isolated small blood vessels, 100-400 µm in diameter from different species (194).  The blood 
vessel segments used in these studies were dissected and isolated devoid of surrounding fat tissue 
and mounted onto a DMT Model 610M four-channel multi-myograph system using 40 µm 
stainless steel wires.  Larger blood vessels such as thoracic aortic segments were mounted on 
stainless steel pins.  Vessels were maintained at 37º C bathed in a physiological saline solution 
(PSS; mM) 140 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgSO4, 1.2 MOPS (3-[N-morpholino]-propane 
sulfonic acid), 5.6 D-glucose, 0.02 EDTA, and a pH of 7.4) with continuous bubbling of medical 
grade air.  The force generated/wall tension of the blood vessel is measured via a force 
transducer when the vessel is physically stretched or responds to pharmacological agents added 
to the tissue bath.  Stress generation of vessel segments was calculated by normalizing this force 
to surface area (length x width x 2) of the vessel segment under isometric conditions.  Each 
arterial vessel segment rest length was established at 90% of internal circumference (IC) 
produced at tensions equivalent to 100 mmHg (13.3 kPa) using Laplace’s law, following 
equilibration (133).  This protocol allowed standardization of experimental conditions, an 
important consideration when examining pharmacological differences between vessels by 
evaluating the contractile behavior (194).   
 
In addition, a pressurized vessel system was used to study distinct physiological changes such as 
pressure and flow dependent responses following nanoparticle exposure (232).  This system used 
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isobaric conditions to evaluate agonist mediated vasoconstriction/relaxation of a vessel segment, 
when compared to isometric conditions used in a wire myograph, which revealed different 
sensitivities to agonists due to the unique variances between the cannulated and wire mounted 
vessel preparations (23). 
 
2.4. Serum cytokines, changes during pregnancy and influence on vasoactive responses 
A variety of serum cytokines produced by activated inflammatory cells such as macrophages, T 
cells and monocytes act via different pathways to enhance the vasoconstrictor or dilatory 
response under both physiological and pathological conditions.  Activated endothelium and 
VSMC also contributes to the cytokine pool.  Some of these cytokines such as VCAM1, ICAM1, 
SELE (E-Selectin) and CCL2 (MCP1) are considered as markers of inflammation.  These 
cytokines can modify the generation of reactive oxygen species, glutathione levels, vasodilatory 
mediators such as nitric oxide, prostacyclin, endothelium-derived hyperpolarizing factor, 
bradykinin and vasoconstrictors such as endothelin 1 and angiotensin II (195).  Persistent 
elevations in serum cytokines are associated with several cardiovascular pathologies including 
atherosclerosis, hypertension, preeclampsia and increased coronary vasoconstriction (216).  The 
expression of inflammatory mediators IL6, IL8 and CCL2 (MCP1) along with cell adhesion 
molecules VCAM1, ICAM1 and SELE have been documented to increase following exposure to 
different nanoparticles in both in vivo and in vitro systems (203, 254).  TNFα is reported to 
increase the expression of endothelial derived cell adhesion molecules (180, 252), increase 
vascular permeability (80) and induce vasoconstriction (84) or dilation (199) depending on the 
circumstances.  Both IFNγ and IL1β are reported to be associated with reduced vasoconstrictor 
responses (120, 131, 209).  On the other hand, pro-thrombogenic agents such as vWF are 
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increased towards later gestation (26) and endothelial derived PAI1 is reported to be down 
regulated in a normal pregnancy (24).  Derangements of these hemostatic molecules under 
different pathological conditions may be detrimental to the fetus.  Some of the above cytokines 
including IL6, IL10, TNFα, IFNγ, IL1β, CCL2, PAI1 and vWF which are relevant to vascular 
responses, pregnancy and inflammation were evaluated in this dissertation to identify changes in 
the cytokine profile following CNP exposure during pregnancy.   
 
Considering the unique physiological state of pregnancy, a shift in T cell dependent 
immunological responses can be identified as a physiological response in a normal pregnancy.  
Th1 and Th2 pathways mutually inhibit the responses of each other (i.e. reciprocal regulation) 
and the bias towards Th2 during pregnancy is known to be feto-protective (96, 166, 206).  Out of 
the cytokines evaluated in this dissertation, TNFα and IFNγ represent the Th1 pathway while IL6 
and IL10 represent the Th2 pathway (206, 250).  Apart from these immunological deviations, 
endothelium mediated growth factors such as VEGF are increased and contribute to the essential 
vascular remodeling during pregnancy (154, 205, 222).  In addition, there are recent reports on 
the role of VEGF in controlling vascular tone and vasodilation (211).  Hence, this important 
growth factor was also included in the serum analysis of both the dam and the fetus. 
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2.5. Nanotechnology, nanomedicine and nanotoxicology 
A nano-object is a material with one, two, or three external dimensions in the size range from 
approximately 1 – 100 nm (1).  These materials may be produced naturally by lightning, volcanic 
eruptions and forest fires.  More importantly, they are manufactured in different forms and used 
in various commercial, biomedical and research technological applications.  Nanotechnology is a 
rapidly expanding enterprise, entering almost all spectra of industry as the unique properties of 
purposely-engineered nanoparticles make them extremely versatile.  Carbon based and metal-
based nanostructures suspended in different media are just two subgroups of nanomaterials that 
have various forms.  Some of these are functionalized to enhance their efficacy and 
biocompatibility (40, 57, 253).  A result of their expanding utilization is the potential for 
unintentional exposure, especially in production facilities by inhalation, ingestion and trans-
dermal routes.  Nanoparticles also make up a rapidly evolving area of nanomedicine where they 
are used as essential materials in diagnostic imaging, drug delivery, cancer chemotherapy, gene 
therapy and as plasma cleaning agents (111, 191).  Some of these diagnostic/therapeutic 
applications involve intravenous (IV) administration of nanoparticles leading to direct exposure 
of the vasculature, potentially inducing changes in vascular reactivity.  Intravenous 
administration of nanoparticles for diagnostics/therapeutics is reported to generate higher 
concentrations of these materials in blood than other routes of administration (101, 190).  These 
evolving biomedical applications raise additional concerns for their clinical use particularly 
under vulnerable physiological stages like pregnancy.  A significant area for concern regarding 
nanoparticles is the potential toxicant effect based on their surface to mass ratio providing more 
contact and interactions within biological systems.   
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Historically, the experience within the asbestos industry with its many adverse health outcomes, 
we realize the consequences of not evaluating the long-term toxicological effects of new 
materials prior to their expanded human exposure.  There is a lag between the development of 
new technology on engineered materials and the implementation of its application, which 
provides an opportunity to expand the understanding of its use consequences through various 
toxicological studies.  In the current circumstances where the safety of novel technology is 
persistently questioned, nanotechnology, nanomedicine and nanotoxicology should progress in 
parallel to ensure the sustainability and safety of these novel applications (141, 142).   
 
2.6. Carbon based nanoparticles  
Carbon based nanoparticles (CNP) are composed entirely of elemental carbon, hence 
hydrophobic in the non-functionalized forms.  They are manufactured predominately by 
electrical arc discharge, laser ablation and chemical vapor deposition processes (102, 117, 249).  
Despite elemental carbon being their basic structural unit, the variability in size, shape and 
surface properties of these CNP result in various electronic, optical, thermal, mechanical, 
chemical and functional properties.  These characteristics are utilized in different industrial 
applications including electronics, optoelectronics, photovoltaics, and sensing devices (40).  On 
the other hand, these properties are also utilized in medical applications as vectors for gene/drug 
delivery (253), scaffolds of tissue engineering (73), contrast agents (46, 49) leading to 
diagnostic, therapeutic and theronostic benefits (245, 246).  CNP are also proposed to be used as 
immunomodulators (159) and to probe different molecular functions (126) . Several forms 
including carbon black, graphene nanosheets, fullerenes, single and multi-walled carbon 
nanotubes (SWCNTs and MWCNTs) are commonly used in industrial and biomedical 
18 
 
applications.  Two distinct forms of non-functionalized CNP were utilized for the studies 
described in this dissertation: Fullerene (C60) and Multi Walled Carbon Nanotubes.  The choice 
of these two forms allowed for an experimental approach to investigate the diversity of 
physiochemical properties of major groups of non-functionalized CNP.   
 
2.6.1. Fullerenes (C60) 
Fullerenes are molecules comprised entirely of carbon, in the form of a hollow sphere composed 
of linked hexagonal carbon rings.  They were commonly referred to as “Buckyballs” and have 
multiple forms depending on the number of carbons in the molecule (i.e. C 20, C60, C70, C76, 
C82 and C84).  The average diameter of a C60 molecule is 0.7 - 1.0 nm and the the structure of 
C60 is represented in Figure 2.2.  These materials can be used in many biomedical applications 
such as contrast agents (e.g. gadofullerenes in magnetic resonance imaging), drug carriers and in 
cosmetic products (10, 46, 129, 192, 193) and be targeted to specific tissues following 
functionalization.   For our experiments, we used pristine, non- functionalized C60 formulated 
with the water-soluble polymer polyvinylpyrorrolidone (PVP), a formulation that is used in C60 
base products including cosmetics.  In the literature, C60 molecules are reported to have pro-
inflammatory (242), anti-inflammatory and pro- and anti-oxidant properties (8, 45, 121, 156) 
suggesting it as a molecule with controversial properties depending on the context of application.  
Inhaled C60 is reported to translocate via the alveolar capillary membrane to the circulatory 
system (136) and distributes to peripheral organs (186).  C60 is also reported to distribute to both 
maternal and fetal tissues following intravenous exposure during pregnancy and because of their 
dimensions (0.7 - 1.0 nm) were subject to placental transfer (202).   
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Figure 2.2. The structure of C60 
From “Biomedical potential of the reactive oxygen species generation and quenching by 
fullerenes (C60)” by Z. Markovic and V. Trajkovic (121) 
 
 
 
2.6.2. Multi walled carbon nanotubes (MWCNTs) 
MWCNTs (Figure 2.3) consists of multiple rolled layers of graphene assembled along a common 
long axis amounting to diameters in the range of  2 – 100 nm, depending on the number of 
encapsulated tubes forming the nanotube structure (1, 40).  The length and the flexibility of these 
nanotubes vary on the mode of production.  MWCNTs are highly modifiable  CNP, which 
increases their versatility in incorporating them to electronic/optoelectronic nanodevices (178) 
and biomedical products (15, 46).  The inherent property of multiple surface defects on these 
nanotubes facilitates functionalization with –COOH, -NH2 and PEG components, targeting to 
different tissues in biomedical applications.  The functionalized forms are used for sustained 
drug release in cancer chemotherapy (16, 235) and they provide targeted drug delivery 
minimizing potential adverse effects of the cytotoxic drugs and avoiding multi-drug resistance 
(29).  These are also used as contrast agents utilized in medical imaging techniques (46).  The 
rapidly expanding application of these materials in both industrial and research based production 
20 
 
facilities of MWCNTs (69) are sites thought to have elevated frequency of occupational 
exposure (27, 39).  The common mode of exposure of MWCNTs is inhalation from an 
environmental and occupational perspective.  The inhalation of carbon nanotubes cause adverse 
pulmonary effects such as impairment of lung functions and initiating pulmonary inflammatory 
responses resulting in fibrosis (50, 76, 130, 224) .  These are also known to translocate to extra-
pulmonary sites (3, 93, 101, 167).  Alternatively, they may be directly introduced into the 
vascular system through intravenous access as done with biomedical applications.  Delivered in 
this fashion, MWCNTs are reported to activate the vascular endothelium and induce production 
of reactive oxygen species (68, 155).  In general, it is the MWCNTs and their size, length, 
surface and dispersant medium related properties that contribute to their toxico-pathology (50, 
63, 64, 226).  The contamination with metal (e.g. iron) components during their manufacture also 
contributes to their toxicity.  
 
Figure 2.3.   Structure and formation of MWCNTs 
Modified from “Electronic and optoelectronic nano-devices based on carbon nanotubes” by M. 
Scarselli, P. Castrucci and M. De Crescenzi (178)
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2.7. Influence of nanoparticle exposure on vascular tissue contractility 
The changes in local or systemic circulating cytokines can induce changes in vascular tissue 
contractility via various mechanisms including inflammation and various immunological 
responses (e.g.  release of vasoconstrictor/relaxation agents from activated immune cells).  
Increased expression of inflammatory mediators IL6, IL8 and CCL2 along with cell adhesion 
molecules VCAM1, ICAM1 and SELE have been documented following exposure to different 
nanoparticles in in vivo, ex vivo and in vitro systems (198, 203, 254).  Some of these changes are 
mediated through generation of reactive oxygen species (104).  In vitro studies have 
demonstrated particle size and shape dependent differential effects on cytotoxicity, genotoxicity 
and oxidative stress (243).  These differential effects have also been demonstrated in in vivo 
studies.  Nanoparticle exposures in non-pregnant states are known to change the contractility of 
different vascular beds (37, 138) through their ability to activate the endothelium via generation 
of reactive oxygen species (ROS) (144).  Changes in vascular tissue contractility following both 
particulate matter and nanoparticle exposure are known to be mediated through activation of the 
cyclooxygenase (COX) pathway (95).  Considering diversity of evidence, the study of 
nanoparticle-mediated toxicity requires greater attention on different vascular beds and on the 
susceptibility of the life stages.   
 
2.7.1. Nanoparticle exposure during pregnancy and potential effects on fetal growth 
The consequences of CNP exposure on maternal/fetal vascular tissue contractility have not been 
extensively investigated despite the possibility of general environmental, occupational and 
therapeutic/diagnostic exposures during pregnancy.  In particular, CNP can be a component of 
ambient ultrafine particulate matter (PM) thus subjecting the general population, including 
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pregnant mothers to inhalational exposure.  Recent epidemiological data suggests a higher 
incidence of inflammatory mediated diseases in the cardiovascular system including 
atherosclerosis (5) pregnancy induced hypertension (171), low birth weight (105) and thrombosis 
(36) associated with higher exposure levels of particulate matter.  Other chemical constituents in 
the complex nature of ultrafine particles associated with cigarette smoke and air pollutants also 
induce changes in vascular tissue contractility during pregnancy (62) and lead to multiple 
negative fetal outcomes (163).  Pre- and postnatal exposure to diesel exhaust which is a complex 
mixture of combustion products of diesel fuel (most of which are carbon based) are reported be 
associated with changes in growth, sexual development, hormone levels, spermatogenesis, 
weights of the reproductive and accessory organs, behavior, inﬂammatory and genotoxic 
endpoints in rodent offspring (53).   
 
Importantly, as the size of particle decreases, their penetrability to different tissues and to sub-
cellular locations increases often resulting relatively low concentrations of particles detectable in 
the systemic circulation (93, 109).  The extensive remodeling status of uterine vasculature 
particularly during late stages of pregnancy may render it more vulnerable to effects of 
nanoparticle exposure, thereby altering fetal blood supply and growth.  Studies with gold 
nanoparticles have reported that the feto-maternal transfer and hence fetal effects of nanoparticle 
exposure are dependent on the stage of pregnancy as well as surface modification of 
nanoparticles (244).  Embryo toxicity due to cadmium based nanoparticles and placental 
accumulation of quantum dots in the placenta have been reported (251).  Low dose exposure to 
single walled carbon nanotubes (SWCNTs) have been reported to induce both fetal and placental 
defects (160), suggesting that exposure to other carbon based nanoparticles during both early and 
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late pregnancy can induce changes in fetal growth.  Hougaard et al exposed C57BL/6J mice with 
intratracheal instillation of MWCNTs during the gestational and preconceptional periods and 
reported lung and liver deposits four months post-exposure.  They also reported delayed 
parturition suggesting possible detrimental effects for both pregnant dams and fetuses (81).  In a 
recent study, it was reported that radiolabelled C60 distributes throughout both maternal and fetal 
circulations following intravenous exposure in Sprague Dawley rats.  The same study also 
reported a variance in the distribution of C60 in maternal organs between pregnant and non-
pregnant life stages (202), which presumed changes occurred in vascular reactivity of various 
vascular beds during pregnancy, mediated by systemic and local cytokines and/or hormonal 
changes (60, 153).   
 
Some of these nanoparticles can also be transferred across placenta and induce changes in the 
fetal side (52).  Studies using ex vivo perfusion model of human placentae have identified that 
nanoparticles of up to 240 nm in diameter can cross the placenta (230).  Many metal-based 
nanoparticles have been studied in association with pregnancy and fetal growth.  Titanium, 
cadmium and nickel based nanoparticles induce detrimental changes in both placenta and fetus 
(18, 52, 241).  Intravenous exposure to 0.8 mg of 70 nm silver nanoparticles was reported to 
result in placental abnormalities, failure to form spiral artery canals and reduced blood flow in 
the fetal sinuses (241).  None of these studies have focused on the contribution of the vascular 
tissue contractility to the fetal outcome following nanoparticle exposure.  Increased vascular 
contractility may result in reduced blood supply to the fetus/es.  Fetal under-nutrition due to 
reduced blood supply can have both immediate and long-term implications.  The immediate 
outcome of having a relatively lower birth weight is reported to have a higher association with 
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hypertension, insulin resistance, hypercholesterolemia and coronary artery disease in later life 
(11).  These changes may be mitigated at several levels including gene transcription, translation  
and post-translational modifications in proteins.  On the other hand, there could be epigenetic 
alterations such as DNA methylations and histones modifications induced in-utero and 
transmitted through the next generation manifesting as different pathologies at a later stage in 
life.   
 
2.8. Significance 
The expanding use of carbon-based nanoparticles (CNP), it is essential to understand how CNP 
exposure could potentially influence maternal as well as fetal vascular tissue contractility as they 
can be used to identify both adverse effects and new mechanisms that are appropriate for 
biomedical applications.  Considering the sensitivity of life stages to exposures, this question is 
directly applicable to two disciplines: nanotoxicology and nanomedicine.  Data generated by this 
project may be used in developing risk-assessment models for CNP exposure during pregnancy 
as well as providing the basis for an understanding of the mechanism responsible of adverse 
physiological responses.  The significance of understanding the toxic effects may be used as 
assessment for producing biocompatible CNP for industrial and medical applications. 
Studying two different CNP types in different suspensions may identify the potential 
biocompatible applications while, minimizing the CNP influence on vascular reactivity.  
Specifically this work will define a contribution of the RhoA-Rho kinase pathway on different 
nanoparticle mediated changes in endothelial cells and VSMC contractile responses.   
 
  
 
CHAPTER 3 
Differences in the Vascular Tissue Contractility in Naïve Pregnant and Non-Pregnant 
Female Sprague Dawley Rats 
 
3.1. Introduction 
The transition of a non-pregnant female to the pregnant life stage involves multiple anatomical 
and physiological modifications, which makes pregnancy a physiological state that may be 
uniquely susceptible to environmental insults.  The uterine and placental vasculatures undergo 
rapid, expansive remodeling following fertilization and implantation.  These changes are 
influenced by systemic hormonal changes and localized variations in uterine and placental 
circulation depending on the site of implantation and stage of pregnancy (66, 132, 153, 220).  
The physiological remodeling in the uterine vasculature during pregnancy in general involves 
diminished pressor and increased vasodilation responses.  The latter is mediated by augmented 
basal production of endothelium derived vasodilator factors such as NO, cAMP and prostacyclin 
(118, 149, 153).  The increase in circulating estrogens, progesterone and relaxin hormone levels 
in turn help to regulate the systemic vascular adaptive responses in the state of pregnancy (51, 
231).  On the other hand, there are also local site dependent variations in the vessel diameter and 
myogenic tone of the uterine vasculature during late pregnancy (151, 210, 220) thought to be 
regulated by the veno-arterial communication between umbilical and uterine vessels (28, 60). 
 
The uterine and mesenteric vascular beds are known to be sensitive to hormonal changes during 
pregnancy and the stages of the estrous cycle (34, 41, 42).  Functional alterations are also 
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reported from both vascular beds during pregnancy associated with abnormal cardiovascular 
states such as pre-eclampsia (2).  The aorta is a conduit vessel from which both of  these vascular 
beds originate, and is noted for changes in reactivity during late stages of pregnancy in order to 
support blood flow to the placental tissues (48, 51). 
 
Angiotensin II and endothelin 1 are two important vasoconstrictors whose multiple receptor 
subtype expression changes during pregnancy and thus modulates the placental blood flow and 
maternal blood pressure (72, 123, 164).  Derangements of receptor distribution and function are 
known to contribute to pregnancy related disorders of the cardiovascular system such as 
preeclampsia and at high altitude environments, predisposing to intrauterine growth restriction 
(44, 77, 87).  The vasculature responses to these agents were a focus in these experiments as they 
were postulated to be responsible for a proposed nanoparticle induced vascular derangements 
during pregnancy. 
 
There were two main objectives of the experimental assessment of vascular reactivity from the 
naïve pregnant and non-pregnant female rats.  First, was defining baseline differences in blood 
vessel responses between pregnant and non-pregnant life stages of the targeted vascular beds.  
This assessment needed to be accomplished prior to understanding any potential effects of 
carbon nanoparticle exposure on the vascular tissue contractility.  This approach aids in 
determination of any shift in responses due to the pregnancy, independent of any prior 
nanoparticle exposure.  Second, the experimental conditions and the assessment technique 
needed to be established and validated in order to be effectively used to identify any changes 
related to nanoparticle exposure.  These experiments utilized pregnant Sprague Dawley rats 
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between 17-19 days of gestation and non-pregnant female rats from the same age group (10-12 
weeks).  Considering a total gestational period of 21-22 days in rats, the investigated gestational 
time frame was comparable with the early third trimester of a human pregnancy. 
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3.2. Materials and Methods 
3.2.1. Sprague Dawley rats 
Ten to twelve weeks old, naïve pregnant and non-pregnant female rats were used to study the 
contraction and relaxation responses of uterine, mesenteric, thoracic and umbilical vessels.  All 
animal handling procedures were approved by the Institutional Animal Care and Use Committee 
of the East Carolina University (ECU, see Appendix).  Timed pregnant and non-pregnant female, 
Sprague Dawley rats were purchased from Charles River Laboratories (Raleigh, NC, USA).  All 
rats were acclimated for one week in ECU Department of Comparative Medicine’s animal 
facility, housed 1-2 rats per cage, under 12 h light/dark cycles with standard rat chow and water 
provided ad libitum.  The weight gain was monitored once in every two days in the pregnant rats 
to confirm progression of the pregnancy and all pregnant rats were sacrificed between 17-19 
days of gestation (GD). 
 
3.2.2. Tissue and sample collection  
The rats were anesthetized in a transparent sealable receptacle with a separate compartment 
containing gauze soaked with 70% isoflurane (Webster Veterinary, USA) in propylene glycol 
(Amersco, OH, USA).  After placement in the induction chamber and the respiration was 
monitored until plane 3 level anesthesia was achieved, a midline incision was made and the rats 
were euthanized by pneumothorax.  One milliliter of blood was withdrawn directly from the 
right ventricle of each animal.  A pooled sample of fetal blood was collected from three fetuses 
in the mid-uterine region of each pregnant dam.  Maternal and fetal blood samples were kept on 
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ice until processing without anticoagulants, then centrifuged (20,400 xg for 20 min), serum 
extracted and stored at -80º C for subsequent cytokine analysis.   
 
The uterine horns with the vascular arcades, the small intestinal loop with superior mesenteric 
arcade and thoracic aorta were all carefully excised.  All vessel segments were immediately 
immersed in ice cold physiological saline solution (PSS; mM) 140 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 
MgSO4, 1.2 MOPS (3-[N-morpholino]-propane sulfonic acid), 5.6 D-glucose, 0.02 EDTA, and a 
pH of 7.4.  Arterial segments with a length of 0.5 - 2 mm from the main uterine artery (diameter 
150 - 300 μm), the first order mesenteric artery (diameter 150 - 250 μm), and thoracic aorta 
(diameter 2 - 3 mm) were isolated for myographic studies.  The main uterine artery was cleaned 
and isolated from the mid region of both pregnant and non-pregnant uterine horns.  Umbilical 
cords from separate fetuses from the mid-uterine region were cleaned and two segments of the 
umbilical veins (diameter 400 - 550 μm) were isolated.  Thoracic aortic segments that were not 
used for myographic studies were snap-frozen and stored in -80º C for further biochemical 
analysis. 
 
3.2.3. Cytokine analysis  
Milliplex MAP Cytokine/Chemokine Panel and Immunoassay (EMD Millipore MA, USA) was 
used to evaluate selected serum cytokines and chemokines (IL6, IL10, TNFα, CCL2, IL1β and 
VEGF) from both maternal and fetal serum according to the manufacturer’s directions.  Assays 
were run using Luminex 100/200 (Luminex, Austin, TX) and results analyzed using Luminex 
xPONENT® software versions 2.3/3.1. 
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3.2.4. Wire myographic studies  
The vessel segments were mounted into a DMT 610M multi-channel wire myograph system 
(Danish Myo Technology, Aarhus N, Denmark) using either 40 μm wires or pins depending on 
the diameter of the vessel.  All vessel segments were bathed in PSS bubbled with medical grade 
air in the chamber throughout myographic studies.  The optimal resting tension for each arterial 
segment (uterine, mesenteric and thoracic aorta) was established at 90% of internal 
circumference (IC) produced at tensions equivalent to 100 mmHg (13.3 kPa).  The viability of 
the vessel segments was assessed using K
+
 depolarization response with K
+
PSS (109 mM K
+
, 
with equal molar substitution of Na
+
 for K
+
), and segments that generated a stress response of 
more than 1 mN/mm
2
 were considered viable.  Following a series of wash outs with PSS the 
endothelial function of the vessel preparations was assessed by adding 3.0 μM acetylcholine 
during 1.0 µM phenylephrine pre-contraction.  A functional endothelium was considered present 
when > 70% (> 20%  for uterine vessels) of the pre-stimulus force was lost with the 
acetylcholine application. 
 
The arterial vessel segments were then subjected to cumulative concentrations of phenylephrine 
(0.001 – 30 µM), endothelin 1 (0.0001 – 1 µM) and acetylcholine (0.0001 – 30 µM).  
Considering the receptor profiles of different vascular beds, angiotensin II (0.0001 – 0.1 µM) 
was used to study the uterine arteries while serotonin (0.001 – 1 µM) was used for mesenteric 
arteries.  The force generated by each vessel segment in mN was recorded using Lab Chart (ADI 
Instruments, CO, USA) and normalized to vessel segment surface area (length x width x 2) to 
report the active stress generated (mN/mm
2
). 
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The umbilical vein segments were stretched and set to an IC equal to 90% of the IC when the 
wall tension is equivalent to 20 mmHg (5.1 kPa) (100).  The viability was assessed using 109 
mM K
+
PSS.  Considering the reported limited responsiveness of these vein segments (100), they 
were pre-contracted with the thromboxane-mimetic U46619 (1 µM) and subjected to cumulative 
concentrations of acetylcholine (0.0001 – 30 µM), followed by sodium nitroprusside (1 µM). 
 
3.2.5. mRNA analysis of aortic tissue homogenates 
Total tissue homogenates from thoracic aortic samples of naïve pregnant and non-pregnant rats 
were utilized to determine mRNA expression levels.  Thoracic artery segments were 
homogenized in Trizol reagent (Invitrogen Corp.  Grand Island, NY, USA) using a Minibead 
Beater (Biospec Products, Bartlesville, OK, USA).  The total mRNA was extracted, converted to 
cDNA and real time-PCR was done using Quantitect primer assays and SYBR green master mix 
(Qiagen, USA).  The cycle threshold (Ct) values for the targets and the internal reference were 
obtained using an Applied Biosystems StepOnePlus Real-Time PCR system (ABI, Carlsbad, CA, 
USA).  The ΔCt values were calculated by normalizing the Ct values to the expression levels of 
either of two housekeeping genes, GAPDH and ACTB (β-actin). 
 
3.2.6. Measurement of fetal and placental weight 
The body weights of pregnant and non-pregnant dams were recorded just before sacrifice.  After 
recording the litter size, 2 - 3 fetuses from each pregnant dam were isolated from the mid region 
of the uterine horn and individual weights were measured using Ohaus Explorer Analytical 
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Balance (Ohaus Corporation, NJ, USA).  The placentae attached to the same fetuses were 
obtained without membranes and blot weight of each placenta was recorded. 
 
3.2.7. Statistical analysis 
GraphPad Prism 5 software (San Diego, CA) was used for statistical analysis and data is 
presented as mean ± SEM (standard error of mean).  Repeated measures analysis of variance 
(114) and Bonferroni post hoc test were used to compare the cumulative concentration responses 
and the differences at each concentration was considered statistically significant if p < 0.05 .  
Each response curve was also compared across the groups using a regression analysis by 
examining the best-fit values (114).  The Hill equation was used to calculate the EC50 values for 
concentration responses from myographic studies where the contraction or relaxation phases 
were analyzed separately.  A two tailed t test was used compare GD differences of the mean 
fetal/placental weight, EC50 values and cytokine levels between naïve pregnant and naive non-
pregnant groups. 
  
33 
 
3.3. Results 
3.3.1. Maternal serum cytokine analysis 
The mean values of the serum cytokine levels of naive pregnant and non-pregnant rats are 
reported in Table 3.1.  Overall, the inflammatory cytokines were reduced in the pregnant group 
when compared to the non-pregnant group.  The mean CCL2 level was reduced by 65.0% and 
the mean TNF level was reduced by 83.3%.  On the other hand, the mean VEGF level was 
increased by 8.5 fold in the pregnant group. 
 
Table 3.1.   Cytokine levels in maternal and fetal serum from naïve Sprague Dawley rats 
The mean and the SEM are reported for maternal (n = 4 - 9) and fetal (n = 5) cytokines. 
 
 
Maternal serum 
Fetal serum 
Cytokine  NP-naive P-naive 
IL1β (pg/ml) 56.0 ± 38.5 14.6 ± 7.1 1455.0 ± 372.5
#
 
IL6 (pg/ml) 1245.0 ± 826.0 77.9 ± 72.8 75.7 ±16.8 
IL10 (pg/ml) 21.7 ± 9.0 5.8 ± 3.7 70.0 ± 17.0
#
 
INFγ (pg/ml) 338.4 ± 135.3 198.5 ± 50.5 283.3 ± 42.5
#
 
CCL2 (pg/ml) 823.2 ± 223.9 288.1 ± 96.0* 903.4 ± 310.8
#
 
VEGF (pg/ml) 53.7 ± 15.4 510.2 ± 11.9* 469.5 ± 83.0 
TNF(pg/ml) 40.9 ± 12.8 6.8 ± 3.9* 5.9 ± 5.9 
PAI1 (pg/ml) N/A 918.7 ± 222.6 N/A 
vWF (ng/ml) N/A 236.6 ± 159.8 N/A 
 
P = pregnant, NP = non-pregnant, N/A = not available 
* indicates p < 0.05  when compared between naïve pregnant and naïve non-pregnant, while 
#
 indicates p < 0.05  when compared between naïve pregnant maternal serum to fetal serum. 
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3.3.2. Contraction and relaxation responses of different vascular beds 
3.3.2.1. Main uterine artery 
The maximum stress generation was reduced in the main uterine artery segments from the 
pregnant rats in response to all three vasoconstrictor agents; to phenylephrine by 29.6% (3.1 
mN/mm
2
), to endothelin 1 by 33.7% (3.5 mN/mm
2
) and to angiotensin II by 46.0 % (2.9 
mN/mm
2
), when compared to the vessel segments from non-pregnant rats (Figure 3.1.A, C and 
E).  The sensitivity to phenylephrine and was increased in the pregnant group as suggested by the 
65.4% lower EC50 value when compared to the non-pregnant (Figure 3.1.B).  Similarly, the EC50 
value for the contraction phase of endothelin 1 was reduced by 86.2% (Figure 3.1.F).  The 
percentage relaxation from the maximum stress generation to the pre-contraction stress level at 
higher concentrations of angiotensin II was 30.23 ± 10.1% in naïve pregnant and 32.1 ± 6.0 in 
naïve non-pregnant (p = 0.874).  The percentage relaxation at higher concentrations of 
endothelin 1 was 31.2 ± 12.2 % in naïve pregnant and 10.4 ± 1.2 in naïve non-pregnant (p = 
0.136).  The relative relaxation in the presence of acetylcholine was also not different between 
the two life stages (Figure 3.1.G and H).   
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Figure 3.1. Changes in the contractile responses of the main uterine artery from naïve 
pregnant and non-pregnant rats 
The contraction and relaxation response profiles as assessed by wire myography of the main 
uterine artery from 17-19 days pregnant and non-pregnant female Sprague Dawley rats (A, C, E 
and G).  The stress generation in response to cumulative concentrations of phenylephrine (PE; 
A), angiotensin II (ANG II; C) and endothelin 1 (ET-1; E) are plotted.  The percentage 
relaxation from a 30 M phenylephrine pre-stimulation stress level in response to cumulative 
additions of acetylcholine is graphed (Ach: G).  * indicates p < 0.05  when naïve pregnant 
compared to non-pregnant using repeated measures ANOVA (n = 6 - 8).  The p values 
associated with the curves were derived following the comparison of each concentration 
response curve across the naive groups using a regression analysis when examining the best-fit 
values.  The EC50 values for PE (B), ANG II (D), ET-1 (F) and Ach (H) were determined using 
the Hill equation and the p values were derived using a two tailed t test. 
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3.3.2.2. First order mesenteric artery 
The maximum stress generation in response to phenylephrine, endothelin 1 and serotonin 
stimulations of mesenteric artery segments from naïve pregnant rats were not significantly 
different from those levels generated by segments from non-pregnant animals.  However, 45.8% 
(2.51 mN/mm
2
) lower stress generation was observed at intermediate (0.1 – 10.0 µM) 
concentrations of phenylephrine in the segments from pregnant rats as compared to levels 
generated by segments from non-pregnant rats (Figure 3.2.A, C and E).  The EC50 values for 
these concentration responses were not different suggesting a similar sensitivity to the agents 
between non-pregnant and pregnant groups (Figure 3.2.B, D and F).  The relaxation responses at 
higher concentrations of ET-1 were greater in segments from naïve pregnant (56.9 ± 14.2 %) 
when compared to segments from naïve non-pregnant (17.9 ± 3.2, p = 0.015).  The relaxation 
response to acetylcholine was not different between the two groups (Figure 3.2.G and H).   
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Figure 3.2.   Changes in the contractile responses of the mesenteric artery from naïve 
pregnant and non-pregnant rats 
The contraction and relaxation response profiles as assessed by wire myography of the first order 
mesenteric artery from gestational day 17-19 pregnant and non-pregnant female Sprague Dawley 
rats (A, C, E and G).  The stress generation in response to cumulative additions of phenylephrine 
(PE; A), endothelin 1 (ET-1; C) and serotonin (5HT; E) are plotted.  The percentage relaxation 
from a 30 M phenylephrine pre-stimulation stress level in response to cumulative additions of 
acetylcholine is graphed (Ach: G).  * indicates p < 0.05  when naïve pregnant compared to non-
pregnant using repeated measures ANOVA (n = 6 - 8).  The p values associated with the curves 
were derived following the comparison of each concentration response curve across the naive 
groups using a regression analysis when examining the best-fit values.  The EC50 values for PE 
(B), ET-1 (D), 5HT (F) and Ach (H) were determined using the Hill equation and the p values 
were derived using a two tailed t test. 
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3.3.2.3.   Thoracic aorta 
The contractile responses and EC50 values of the cumulative concentration responses to 
phenylephrine (0.001 – 10 µM) were not different in segments from the naïve pregnant and non-
pregnant groups (Figure 3.3.A and B).  The stress generation in response to intermediate 
concentrations (0.001 – 0.1 µM) of endothelin 1 was reduced by 35.9 - 59.1% (~ 1 mN/mm2) 
(Figure 3.3.C) and the EC50 value was increased by 5.6 fold in the naïve pregnant group 
suggesting lower sensitivity (Figure 3.3.D) to endothelin 1 compared to the non-pregnant aortic 
segments.  The magnitude of the relaxation response to intermediate concentrations (0.01 – 0.3 
µM) of acetylcholine was increased by 20.8% for segments from the naïve pregnant rats along 
with a 51.6% lower EC50 value suggestive of higher sensitivity (Figure 3.3.E and F) to 
acetylcholine compared to the non-pregnant state. 
 
Figure 3.3.   Changes in the contractile responses of the thoracic aorta from naïve 
pregnant and non-pregnant rats 
The contraction and relaxation response profiles as generated by wire myography of thoracic 
aortic segments from gestational day 17-19 pregnant and non-pregnant female Sprague Dawley 
rats (A, C and E).  The stress generation in response to cumulative additions of phenylephrine 
(PE; A) and endothelin 1 (ET-1; C) are plotted.  The percentage relaxation from a 10 M 
Phenylephrine pre-stimulation stress level in response to cumulative additions of acetylcholine is 
graphed (Ach: E).  * indicates p < 0.05  when naïve pregnant compared to non-pregnant using 
repeated measures ANOVA (n = 4 - 8).  The p values associated with the curves were derived 
following the comparison of each concentration response curve across the naive groups using a 
regression analysis when examining the best-fit values.  The EC50 values for PE (B), ET-1 (D) 
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and Ach (F) were determined using the Hill equation and the p values were derived using a two 
tailed t test. 
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3.3.3. Contribution of Rho-kinase activity on the vascular tissue contractility  
3.3.3.1. Maintenance of stress in the presence of a Rho kinase inhibitor 
Vessels segments from naïve pregnant and non-pregnant rats in general did not respond 
differently to the addition of cumulative concentrations of the Rho-kinase inhibitor, HA1077, 
during phenylephrine pre-stimulation contraction (Figure 3.4.A, C and E).  The only difference 
observed was that the main uterine artery segments from the pregnant rats relaxed 12.1% more 
than the non-pregnant vessel segments at the highest concentration of HA1077 (Figure 3.4.A).  
The EC50 values were not different between the two groups (Figure 3.4.B, D and F). 
 
Figure 3.4.   Changes in stress generation in the presence of the Rho-kinase inhibitor 
HA1077 of arterial blood vessels from pregnant and non-pregnant rats 
The reduction in the stress generation is reported as the percentage relaxation from a 
phenylephrine (30 µM for uterine/mesenteric and 10 µM for aortic vessels) pre-stimulation stress 
level in response to cumulative addition of the Rho kinase inhibitor (HA1077) to the vessel 
segments from gestational days 17-19 pregnant and non-pregnant female Sprague Dawley rats 
(A, C and E).  A: main uterine artery; C: first order mesenteric artery; E: thoracic aorta.  
*indicates p < 0.05  when naïve pregnant compared to non-pregnant using repeated measures 
ANOVA (n = 4 - 8).  The p values associated with the curves were derived following the 
comparison of each concentration response curve across the naive groups using a regression 
analysis when examining the best-fit value.  The EC50 values for the main uterine artery (B), 
mesenteric artery (D) and thoracic aorta (F) were determined using the Hill equation and the p 
values were derived using a two tailed t test. 
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3.3.3.2. RhoA, ROCK and eNOS mRNA expression in thoracic aorta  
The ΔCt values for RhoA, ROCK and eNOS in thoracic aorta homogenates were determined 
using real time-PCR in relation to either GAPDH or ACTB (β-actin) housekeeping genes and 
reported in Figure 3.5.A and C.  The fold changes were calculated using naïve pregnant values as 
the reference and reported in Figure 3.5.B and D.  No consistent differences in the expression of 
these targets were identified from the thoracic aorta homogenates. 
 
Figure 3.5. mRNA expression in aortic tissue homogenates from naïve pregnant and 
non-pregnant rats 
Mean ΔCt values and fold changes were obtained from the real time-PCR analysis of ROCK1, 
ROCK2, RhoA and eNOS mRNA expression in the thoracic aorta of naive pregnant and non-
pregnant female Sprague Dawley rats.  Real time-PCR was done on total tissue homogenates of 
the thoracic aorta samples collected immediately after sacrifice (n = 3 - 4).  The Ct values were 
normalized to two housekeeping genes GAPDH (A) and ACTB (β actin; C) mRNA expression 
levels.  The fold changes were calculated as the expression in naïve non-pregnant group 
compared to the naïve pregnant group based on ΔCt values obtained in relation to GAPDH (B) 
and ACTB (D) by using the ΔΔCt method. 
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3.3.4. Changes in the fetal components across gestational days 
3.3.4.1. Changes in umbilical vein contractility  
The contractile responses of the umbilical vein were assessed using wire myography and data are 
categorized according to the day of gestation (GD), as reported in Figure 3.6.  There were no 
statistical differences between the gestational day groups but there was a greater response to 
K
+
PSS and 1 µM U46619 (Figure 3.6.A-B) and 1 µM SNP (Figure 3.6.C) in the oldest 
gestational day (GD 19) group.  In addition, we probed for any acetylcholine mediated response 
and found neither a contraction nor a relaxation response of the umbilical vein to this agent in 
our wire myograph preparations (data not shown). 
 
Figure 3.6.   Changes in contractility of umbilical veins from naïve pregnant rats  
Changes in contractility as assessed by wire myography of the umbilical veins obtained from 
fetuses in naïve pregnant rats are categorized according to the day of gestation (GD).  A: Stress 
generation in response to K
+
 depolarization (K
+
PSS).  B: Stress generation in the presence of 1 
µM of the thromboxane agonist U46619.  C: The percentage relaxation response with the 
addition of 1 µM SNP during pre-contraction with U46619 (n = 12). 
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3.3.4.2. Changes in fetal and placental weight  
The mean weight of naïve pregnant dams at the time of sacrifice was 287.2 ± 11.0 g (n = 10).  
The mean and range of litter size was 10.6 (range of 8 - 13).  Mean weights of the fetuses and the 
associated placentae from the naïve pregnant dams are reported in Figure 3.7.A and B, and are 
grouped according to GD at sacrifice.  The mean fetal weight was increased by 65.7% (613.4 
mg) between GD 17-18 and by 87.7% (1356.4 mg) between GD 18-19.  A significant increase in 
the placental weight was detected only between GD 18-19 (by 26.7%) during the gestation 
period studied. 
 
Figure 3.7. Changes in fetal and placental weights in naive pregnant rats  
Changes in fetal (A) and placental (B) weights from naive pregnant rats are categorized 
according to the day of gestation (GD).  Three fetuses and placentae were obtained from each 
pregnant dam (n = 6 – 15 fetuses). 
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3.3.4.3. Fetal serum cytokine analysis 
The fetal cytokine levels from the pooled samples (from threes fetuses from each dam) are 
reported in Table 3.1 (page 33).  The fetal cytokine levels were higher when compared to the 
maternal  cytokine levels for IL1β (99.6 fold, when naïve pregnant/P-naive level is considered as 
1 fold), IL10 (12.6 fold), INFγ (1.4 fold) and CCL2 (3.13 fold).  The fetal serum levels of  IL6, 
VEGF and TNF were within a range similar to those from naïve pregnant serum cytokines, but 
in contrast to the levels reported for naïve non-pregnant state (NP-naive). 
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3.4. Discussion 
The central observation of these experiments was the differential responsiveness of the blood 
vessels during the two life stages (i.e. pregnant and non-pregnant) as studied in female Sprague 
Dawley rats.  The predominant differences observed were in the main uterine artery, likely 
associated with the extensive anatomical and functional remodeling of this vascular bed during 
pregnancy to support placental blood supply and fetal growth.  The comparison between naïve 
pregnant and naïve non-pregnant female rats of the same age and species facilitated the 
establishment of baseline responses to allow for subsequent comparison of the contractile 
responses of blood vessels following exposure to carbon based nanoparticles (see Chapter 4 and 
5).  Since the consequences of the use of different vehicles employed to deliver nanoparticles 
have not been distinctly defined in literature, these studies on naïve pregnant and non-pregnant 
rats also provided an appropriate control to compare the vehicle treated responses.  These studies 
will facilitate the ability to identify and differentiate the vehicle from nanoparticle mediated 
effects on vascular reactivity during pregnancy as discussed in later chapters. 
 
Several serum cytokines that were assessed in this study including IL6, IL10, INFγ, CCL2 
(MCP1) and TNFα have been reported to be altered in pre-eclamptic mothers and elevated levels 
are associated with poor pregnancy outcome (92, 207).  The baseline difference between 
pregnant and non-pregnant status is likely associated with the known shift in the immunological 
state during pregnancy (207).  The increase in the steroid hormone levels are proposed to 
suppress the inflammatory cytokines during pregnancy to prevent the rejection of the fetal tissues 
through an immunological response (206, 207).  In our study, the pro-inflammatory cytokines 
such as TNF and CCL2 were reduced during pregnancy supporting this hypothesis.  The Th1 
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predominant pro-inflammatory immunological response is reported to be incompatible with 
normal pregnancy (166) and the bias towards Th2 response protects the fetus (206).  We report 
both Th1 and Th2 cytokines including IL1β, IL6, IFNγ and IL10 were reduced in the pregnant 
compared to non-pregnant group.  However, the significant decrease in TNF levels in naïve 
pregnant rats support a suppressed Th1 immunological response.  The overall higher 
concentration of cytokines seen in the fetal serum may be attributed to the differences in hemo-
concentration between maternal and fetal blood and the use of a pooled blood sample from the 
fetal side.  Similar observations between maternal and fetal cytokines have been reported with 
MCP1 (147), but the values were similar between fetal and maternal sides for the other cytokines 
(21, 31, 147).  The use of different species (human or murine vs. rat), types of assays used and 
the use of amniotic fluid instead of fetal blood in these studies may have contributed to 
differences in our values and those reported in the literature.  The vascular endothelial growth 
factor (VEGF) was increased during pregnancy in both maternal and fetal serum supporting 
extensive cardiovascular remodeling promoted by endothelial growth factors.  Gestation stage 
dependent changes in VEGF have been reported in human studies (205) and its role in 
maintaining progesterone levels to sustain the pregnancy have also been reported (222). 
 
The maximum stress generation in response to several vasoconstrictor agents including 
phenylephrine, endothelin 1 and angiotensin II were reduced in uterine artery segments from 
pregnant animals when compared to those from non-pregnant animals.  This common response 
could be complimentary to the strong vasodilatory environment that prevails in the uterine artery 
during pregnancy and mediated largely by enhanced production of NO (149, 150, 153).  Reduced 
EC50 values in the pregnant group suggest an increase in the sensitivity to phenylephrine and 
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endothelin 1 mediated vasoconstriction during pregnancy.  This paradoxical increase in 
sensitivity to the contractile response to -adrenergic stimulation despite the blunted pressor 
responses in the whole animal during pregnancy has been reported previously (38).  The 
downstream signaling mechanisms and receptor distribution may contribute to the diminished 
stress generation during pregnancy, despite the higher sensitivity to these contractile agents 
(196).  The reduction in angiotensin II mediated stress generation can be attributed to the 
regulation of AT1 receptor mediated contractile response by vasodilatory AT2 receptor 
modulation resulting in a pressor refractoriness to angiotensin II during pregnancy (164).  The 
angiotensin signal modulation is known to be mediated via increased NO and bradykinin 
production (72).  Endothelin 1 regulates the contractile responses in a similar manner with ET A 
and ET B receptors predominantly modulating vasoconstriction and relaxation respectively (44, 
48).  The increased availability and functionality of ET B receptor signaling mediates the early 
relaxation and diminished stress generation during pregnancy (44, 75).  Under our experimental 
conditions, the endothelium-dependent relaxation response to acetylcholine was not different 
between main uterine arteries from pregnant and non-pregnant rats.  This is in agreement with a 
report citing unaltered muscarinic receptor function in the uterine artery during pregnancy (85).  
However, our results are in contrast to other studies that did report changes in the endothelium-
dependent relaxation responses (42, 86).  The contrasting results from those studies may reflect 
several different experimental conditions including: different species, higher doses of 
acetylcholine and smaller diameter uterine blood vessels investigated. 
 
The responses of the first order mesenteric artery differed from those of the uterine artery 
responses discussed above as the maximum stress generations in response to phenylephrine, 
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endothelin 1 or serotonin were not significantly different between the vessel segments from the 
pregnant and non-pregnant animals.  The EC50 values for these agents were also not different 
suggestive of a lack of influence of pregnancy on the contractile sensitivity of the larger vessels 
in the mesenteric arcade.  However, a lower stress generation was observed in vessel segments at 
intermediate concentrations of phenylephrine (0.1 – 10.0 µM) in the pregnant group as compared 
to the non –pregnant group.  A possible explanation may be related to a modest variation in 
receptor subtype distribution and/or availability with pregnancy (179).  The relaxation response 
at higher concentrations of endothelin 1 was larger in naive pregnant segments when compared 
to naïve non-pregnant segments.  This may be due to reported enhanced ET B receptor 
expression/coupling associated with the vasodilatory state during with pregnancy (51, 219).  In 
our studies, the relaxation response to acetylcholine in the mesenteric artery was not different 
between the two groups in contrast to the previous observations from other species (34, 41).  
When compared to uterine vessels, the mesenteric vessel segments were less responsive to 
changes associated with pregnancy and we attribute this to an extensive remodeling seen in the 
uterine vasculature, but not in the mesenteric vasculature (41, 42) and the alterations in the 
receptor distribution in the two vascular beds (2, 44, 65). 
 
The contractile responses of the aortic segments to -adrenergic stimulation and maximum stress 
generation to endothelin 1 stimulation were not different between the naïve pregnant and non-
pregnant groups.  However, EC50 value was increased in the naïve pregnant group suggesting a 
lower sensitivity to endothelin 1 and thought to involve a larger role for the ET B receptor 
signaling during pregnancy (8, 17).  The muscarinic receptor mediated relaxation response to 
acetylcholine was greater in the naïve pregnant group along with a lower EC50 value, suggestive 
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of greater sensitivity of this blood vessel to endothelium-dependent relaxation during pregnancy.  
In total, these observations from the thoracic aortic segments support a shift in vascular 
contractility to the pro-vasodilatory state with a physiologically diminished pressor response 
during pregnancy. 
 
Beyond the direct effect of ligand-receptor modulation of vascular reactivity, downstream 
signaling can often modify/modulate the vessel contractile responses.  One such signaling 
pathway involves the Rho-Rho-kinase (ROCK) complex.  HA1077 inhibits ROCK enzymes by 
reducing the inhibition on myosin dephosphorylation contributing to a relaxation response (59) 
which diminishes the stress generated by agonist stimulation.  RhoA-ROCK pathway plays a 
dual role in mediating the contractile response by inhibiting the myosin dephosphorylation of 
vascular smooth muscle cells (VSMC) (59). In addition, ROCK is reported to increase 
contractility by reducing the expression of eNOS or by reducing the enzyme activity, thus 
lowering NO generation (137).  A difference in the contribution of ROCK activity on the 
contractile responses between the naïve pregnant and non-pregnant vessel segments was seen 
only in the main uterine artery segments.  Our observations are supported by the previous studies 
reporting reduced ROCK activity during pregnancy in the uterine vasculature (67), while the 
EC50 values remained the same between the two groups in all three vessels, suggesting a similar 
sensitivity to ROCK inhibition.  The RhoA, ROCK and eNOS mRNA expression in the aortic 
tissue homogenates were not significantly different between the naïve pregnant and non-pregnant 
groups, suggesting that the expression of these proteins may not be changed during pregnancy.  
However, direct protein measures were not performed and a conclusion as to the mechanism by 
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which the Rho-ROCK signaling pathway may be modulated in pregnancy was not completely 
elucidated. 
 
The umbilical vein is the critical vessel carrying blood from the placental circulation to the fetus.  
The variability of the contraction and relaxation responses of the umbilical vein we observed was 
not correlated to gestational age.  Overall, similar contractile responses were reported in a study 
using a mouse model (18-19 days of gestation) where they also do not observe a gestational day 
related differential responses in either umbilical arteries or veins (24).  Based on the observations 
that we had no significant change associated with gestation day, all the umbilical vein reactivity 
data were combined for the comparisons with nanoparticle/vehicle exposed groups to be 
discussed elsewhere.  We did find significant differences in both fetal and placental weight gain 
over the gestation days studied.  The changes in the placental weight on each day corresponded 
to the magnitude of the fetal weight gain.  Based on these observations, the fetal and placental 
weight gain were analyzed after re-grouping them according to the specific gestation day, 
assuming that an overall change in the umbilical vein reactivity can affect the blood supply to the 
fetus affecting the fetal weight gain even within a day of gestation.  We can also conclude that 
the 24 hours post-exposure time point will be important in identifying any acute nanoparticle 
exposure related change in the fetal growth. 
  
In conclusion, significant differences in the vascular tissue contractility were observed between 
pregnant and non-pregnant life stages.  The most prominent differences were in the main uterine 
artery and in relaxations associated with a reduction in the ROCK activity during pregnancy.  
Overall, the contractile responses were diminished during pregnancy supporting an enhanced 
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vasodilatory state.  Most of the differences identified in the wire myographic studies were 
compatible with the descriptions in literature.  These results provide a baseline for further 
experimental comparison to identify changes in the contractile responses following vehicle or 
carbon nanoparticle exposure.  We would thus hypothesize any increase in the contraction 
responses in the uterine and umbilical vessels may thus produce a detectable difference in the 
weight gain within each day of gestation towards the later stages of pregnancy.
  
 
CHAPTER 4 
PVP formulated Fullerene (C60) increases Rho-kinase dependent Vascular Tissue 
Contractility in Pregnant Sprague Dawley Rats 
 
4.1.   Introduction  
Engineered fullerenes and their derivatives are designed for various industrial and biomedical 
applications increasing the probability of occupational, therapeutic and/or environmental 
exposure.  Intratracheal delivery of C60 fullerenes is reported to translocate through the alveolar 
capillary barrier by transcytosis (136), resulting in access to the vascular compartment and their 
deposition in endothelial cells.  Alternatively, fullerenes and their derivatives used for different 
biomedical applications such as drug/gene delivery and as contrast agents in diagnostic imaging 
(192, 193) maybe introduced directly into the vascular compartment.  While the site and extent 
of C60 distribution within the pulmonary and extra-pulmonary tissues depends on the size of 
particle agglomerates and route of exposure, once exposed and distributed into the circulation 
C60 has a very low clearance from the body, remaining in organs/tissues as long as 180 days 
post-exposure (98, 186).  Considering their size and penetrability to tissues and subcellular 
locations (10), C60 can potentially alter intracellular signaling pathways in cells associated with 
the vascular walls and impact vascular function.  The current evidence on toxicity of fullerenes 
and its derivatives on different cell types and tissues are controversial.  They have been described 
as a molecule with antioxidant properties (i.e. a free radical sponge) as well as a pro-
inflammatory agent (45, 140, 156, 242).  A commonly used coating/suspension medium for C60 
is polyvinylpyrorrolidone (PVP), a water soluble polymer reported to be inert (112), but the 
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PVP-C60 combination is reported to be toxic (214).  With expanding use of C60 based products, 
it is also essential to understand how C60 exposure could potentially influence maternal and fetal 
vascular tissue contractility, as they can be used to identify both adverse effects and new 
mechanisms that can be utilized for biomedical applications.  Any such impact on vascular 
contractility can be crucial in life stages such as pregnancy as blood supply to fetus/es can be 
altered affecting intrauterine growth. 
 
Nanoparticle exposures in non-pregnant life stages are known to change vascular reactivity of 
different vascular beds (37, 139).  The extensive proliferative and remodeling environment 
within the uterine and placental vasculature particularly during late stages of pregnancy may 
make it more vulnerable to effects of nanoparticle exposure.  Pregnancy is a unique 
physiological state in which the uterine vasculature undergoes expansive remodeling influenced 
by both systemic hormonal changes and localized variations in uterine circulation, which are 
dependent on the site and stage of pregnancy (153).  The normal physiological changes in uterine 
vasculature during pregnancy are predominantly vasodilatory, mediated by augmented basal 
production of endothelium derived dilator factors including nitric oxide (149, 153).  In contrast 
Rho kinase activity, a potent pro-contraction process (32) is diminished in the normal pregnancy 
(67) and we suggest may be a potential target for explaining changes in the contractile responses 
of vascular tissues following nanoparticle exposure.  The evidence for ultrafine particulate matter 
exposure and its association with pregnancy induced hypertension and low birth weight (94, 171) 
suggest that nanoparticles such as C60 exposure may also have aggravated effects on pregnancy 
as their smaller size and relatively high surface area to mass ratio increases the possibility of 
biological and chemical interactions within the vascular system.  Following intravenous 
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administration in pregnant rats 
14
C labeled C60 was reported to distribute to both maternal and 
fetal organs.  The same study also reported differences in the distribution pattern of radiolabelled 
C60 between pregnant and non-pregnant life stages (202) which is presumed to be due to 
changes in vascular reactivity of various vascular beds during pregnancy.  The effects of C60 
exposure on maternal/fetal vascular reactivity have not been extensively investigated despite the 
possibility of occupational, general environmental and therapeutic/diagnostic exposures during 
pregnancy. 
 
Our interests were to identify how PVP formulated C60 (C60/PVP) exposure affects the vascular 
responses during pregnancy and whether those changes could impact intrauterine fetal growth.  
We hypothesized that exposure to PVP formulated C60 via intravenous or intratracheal 
administration would enhance the contractile responses of uterine and placenta derived blood 
vessels during pregnancy, potentially reducing fetal blood supply. 
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4.2. Methods and Materials 
4.2.1. Characterization of nanoparticles and suspensions 
C60 was commercially procured from Sigma-Aldrich (St.  Louis MO, USA, Catalog# 379646) 
and formulated with polyvinylpyrorrolidone (PVP) (Sigma-Aldrich, St.  Louis MO, USA; 
Catalog# 234257) at RTI International (Research Triangle Park, NC, USA).  These were non-
functionalized particles and hydrophobic, therefore needed to be suspended in the non-polar 
solvent PVP.  A Malvern Zetasizer NanoZS (Malvern Instruments, Worcestershire, UK) with a 
633 nm laser source, a detection angle of 173 degree, and a clear disposal zeta cell was used to 
determine the zeta potential and the material size of the dosing suspensions.  Measurements were 
carried at 25 °C using the following protocol: 1) 1
st
 size determination; 2) zeta potential 
measurement; 3) 2
nd 
size determination.  The time elapsed between the two size determinations 
was approximately 8 minutes. The average particle size was measured after 38 minutes of 
preparation to ensure that the suspensions remained stable at the time of delivery to rats. 
 
4.2.2. Sprague Dawley rats 
Ten to twelve week old timed-pregnant and non-pregnant female Sprague Dawley rats were 
purchased from Charles River Laboratories (Raleigh, NC, USA).  All rats were individually 
housed under 12 hour light/dark cycles with standard rat chow and water provided ad libitum.  
Body weights were monitored (two readings taken three days apart) during a one-week 
acclimation in Department of Comparative Medicine’s animal facility at East Carolina 
University (ECU) to ensure progression of the pregnancy.  Initially, two gestational age groups 
were evaluated: gestational days (GD) 14 - 16 and GD 17 - 19.  In addition, a third experiment 
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group composed of aged matched non-pregnant Sprague Dawley was also studied.  All animal 
handling procedures were approved by ECU Institutional Animal Care and Use Committee (see 
Appendix). 
 
4.2.3. C60/PVP Exposure/dosing 
Rats were anesthetized using 2 - 3% isoflurane (Webster Veterinary, USA) dispersed in oxygen 
for all exposure procedures.  Each exposure group: PVP formulated C60 (C60/PVP), PVP 
control or naïve group contained a minimum of eight animals.  A dried aliquot of C60/PVP or 
PVP was resuspended in sterile 0.9% saline (0.9% NaCl, B. Braun Medical Inc., CA, USA) just 
before administration.  The suspension was cup-horn sonicated for 2 minutes using a Misonix 
ultrasonic liquid processor at 65% amplitude and a total energy of 10,817 joules (Model 1510R-
MTH, Branson Ultrasonics Corp. Danbury, CT, USA).  Twenty-four hours prior to sacrifice 28 
µg of C60/PVP suspension (93.3 μg/kg body weight) in 200 µl was administered intravenously 
(IV) through the tail vein using a 25G needle.  Two hundred microliters of 1.4% PVP in saline 
was administered as the vehicle control.  A group of non-pregnant rats was also exposed to IV 
C60/PVP or PVP to determine effects of life stage on vascular reactivity.  Additionally, a group 
of GD 17 - 19 pregnant rats were exposed to the same dose and volume of C60/PVP or PVP by 
intratracheal instillation (IT), as described by Wang et al (224), to allow for comparison of 
vascular effects of C60/PVP exposure as influenced by route of exposure.  A set of pregnant and 
non-pregnant female rats of the same age not exposed to C60/PVP or PVP were used as naïve 
controls (see Chapter 3). 
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4.2.4. Blood pressure measurements 
We assessed effects of C60/PVP exposure on maternal blood pressure and resting heart rate in 
the IV C60/PVP or PVP exposed groups (which demonstrated changes in the contractile 
response in more than one vascular bed) and the naïve group.  A CODA Monitor - non-invasive 
blood pressure system (Kent Scientific, CT, USA) with the tail-cuff was used to follow systemic 
blood pressure and heart rate changes while the rats were held in rodent restraining bags (AIMS 
Inc. USA), on a 37ºC heat pad without anesthesia.  Rats were acclimated to the tail-cuff three 
days before blood pressure measurements to minimize changes in blood pressure and heart rate 
associated with the stress of handling.  These measurements were carried out at GD 10 (i.e. mid-
second trimester), before exposure and 24 hours post-exposure (i.e. immediately before sacrifice: 
GD 17-19, mid-third trimester).  The mean of three readings from each animal at each time point 
was used for comparison. 
 
4.2.5. Ultrasonography of the rat heart 
Two dimensional cardiac ultrasonography was performed under anesthesia with 2 - 3% 
isoflurane (Webster Veterinary, USA) dispersed in oxygen at GD 10, before exposure and 24 
hours post exposure (i.e. immediately before sacrifice: GD 17-19) using Vevo 2100 High 
Resolution Imaging System (FujifilmVisual Sonics Inc. Toronto, Canada).  Vevo 2100 PC 
Workstation Only-Version 1.1.2 software was used to calculate the ejection fraction using 2 - 3 
images from parasternal long axis view of the heart at each time point and confirmed using the 
parasternal short axis view. 
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4.2.6. Tissue and sample collection 
Twenty-four hours post-exposure, rats were anesthetized in a transparent receptacle containing 
gauze soaked with 70% isoflurane (Webster Veterinary, USA) in propylene glycol (Amersco, 
OH, USA).  After induction of plane 3 level of anesthesia, the animals were subjected to a 
midline incision and euthanized by pneumothorax.  One milliliter of blood was withdrawn 
directly from the maternal right ventricle.  Fetal blood from each dam was collected from three 
fetuses from the mid-uterine region, pooled and considered as one sample.  Maternal and fetal 
serum were prepared by centrifugation of the whole blood (20,400 x g for 30 minutes at 4°C), 
snap frozen and stored at – 80°C for subsequent cytokine analysis. 
 
The two uterine horns with fetuses, small intestinal loop with superior mesenteric arcade and 
thoracic aorta were carefully excised without tension and placed in ice cold physiological saline 
solution (PSS; mM) 140 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgSO4, 1.2 MOPS (3-[N-morpholino]-
propane sulfonic acid), 5.6 D-glucose, 0.02 EDTA, and a pH of 7.4.  Vascular segments of 0.5 – 
2.0 mm length from the main uterine artery (diameter 150 - 300 μm), first order mesenteric 
artery (diameter 150 - 250 μm), and thoracic aorta (diameter 2 - 3 mm) were isolated and cleaned 
of adhering connective tissue and fat.  Segments of the main uterine artery were isolated from the 
arterial loop supplying the mid-uterine region, avoiding distal embryos to minimize site 
dependent changes in vascular reactivity (153).  Two umbilical veins (diameter 400 - 550 μm) 
from umbilical cords of different fetuses from the mid-uterine region were isolated from each 
exposed/naive dam.  Segments from the thoracic aorta and main uterine artery unused for 
vascular studies were snap-frozen and stored at – 80°C for subsequent RNA, protein and 
histological analysis. 
63 
 
4.2.7. Bronchoalveolar lavage and lung histology 
Broncoalveolar lavage (BAL) and cell counts were performed on rats 24 hours post-exposure as 
described by Wang et al (224).  Briefly, the right lung of each rat was lavaged in situ four times 
with ice-cold Hanks balanced salt solution (26.25 mL/kg body weight) and all BAL fluids were 
centrifuged.  Then the total cells were counted, 20,000 cells were centrifuged using a Cytospin 
IV (Shandon Scientific Ltd., Cheshire, UK) and stained with a three-step hematology stain 
(Richard Allan Scientific, Kalamazoo, MI, USA).  The differential cell count was determined by 
morphology, evaluating 300 cells per slide.  The unlavaged left lung was fixed and stained for 
histology as described by Wang et al (224).  Briefly, the left lung was inflated with 10% neutral 
buffered formalin fixative for 24 - 72 hours, processed, embedded in paraffin and 5 μM sections 
were mounted on slides.  The sections were stained with hematoxylin and eosin and evaluated 
using light microscopy. 
 
4.2.8. Cytokine analysis  
Selected serum cytokines and chemokines (IL6, IL10, TNFα, CCL2, PAI1, VEGF, INFγ, and 
IL1β) were assessed using Milliplex MAP Cytokine/Chemokine Panel and Immunoassay (EMD 
Millipore MA, USA).  Serum cardiovascular disease markers (PAI1 and vWF) were assessed 
using Milliplex MAP Rat Cardiovascular Panel and Immunoassay (EMD Millipore MA, USA) 
from both maternal and fetal serum according to the manufacturer’s directions.  Assays were run 
using a Luminex 100/200 (Luminex, Austin, TX) and results reported using Luminex 
xPONENT® software versions 2.3/3.1. 
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4.2.9. Wire myographic studies 
All vessel segments were mounted into a DMT 610M multi-channel myograph system (Danish 
Myo Technology, Aarhus N, Denmark) using 40 μm wires or pins and bathed in PSS bubbled 
with medical grade air at 37ºC.  Optimal resting tension for each arterial vessel segment was 
established at 90% of internal circumference (IC) produced at tensions equivalent to 100 mmHg 
(13.3 kPa).  Subsequently, segments that developed a stress response greater than 1 mN/mm
2
 to a 
potassium depolarization (109 mM K
+ 
PSS with equal molar substitution for Na
+
 with K
+
) were 
considered viable.  Endothelial function was assessed by pre-stimulating with 1.0 µM 
phenylephrine followed by 3.0 μM acetylcholine, an intact endothelium was considered present 
when the acetylcholine induced relaxation was >70% (>20% for uterine vessels) of the 
phenylephrine steady state stress.  All three arterial vessel preparations were then subjected to 
cumulative concentrations of phenylephrine (0.001 – 30 µM), endothelin 1 (0.0001 – 1 µM) and 
acetylcholine (0.0001 – 30 µM).  Cumulative concentration responses to angiotensin II (0.0001 – 
0.1 µM) and serotonin (0.001 – 1 µM) were studied for uterine and mesenteric arteries 
respectively.  The force generated by each vessel segment at each concentration was recorded 
and normalized to surface area to calculate the active stress generated in response to the stimuli.  
Cumulative concentrations of the Rho-kinase inhibitor HA1077 (0.001 – 10 µM) were applied to 
arterial segments during phenylephrine pre-contraction in order to identify the contribution of 
Rho-kinase activity in mediating changes in the contractile response following C60/PVP 
exposure. 
 
Following equilibration, umbilical vein segments were stretched and set to an IC equal to 90% of 
the IC when the wall tension is equivalent to 20 mmHg (5.1 kPa) (100).  As these vessel 
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segments are reported to not respond to most agonists (100), viability was assessed using K
+
PSS, 
pre-contracted with thromboxane-mimetic U46619 (1 µM) and subjected to cumulative 
concentrations of acetylcholine (0.0001 – 30 µM), followed by 1 µM sodium nitroprusside. 
 
4.2.10. mRNA and protein analysis in aortic tissue homogenates 
Aortic tissue homogenates from the thoracic aortic samples collected 24 hours post-exposure to 
C60/PVP or PVP were utilized for mRNA and protein analysis.  Half of the stored thoracic 
artery segments were homogenized in Trizol reagent (Invitrogen Corp. Grand Island, NY, USA) 
using a Minibeads Beater (Biospec Products, Bartlesville, OK, USA).  The total mRNA was 
extracted, converted to cDNA and Real-Time PCR was done.  The fold changes in the 
expression were calculated using the ΔΔCt method as described previously (221).  The fold 
changes were calculated in comparison to naïve controls of pregnant and non-pregnant rats, 
following normalization to either of two housekeeping genes: GAPDH and ACTB (βactin).  The 
other half of the samples was homogenized using a glass motor and pestle on ice with T-Line 
Laboratory Stirrer (Talboys Engineering Corp. Thorofare, NJ, USA) with a modified 
radioimmunoprecipitation assay (RIPA) buffer at a ratio of 10 l buffer /mg tissue weight.  
Protein concentration in the homogenate was determined using the Bradford Protein Assay (Bio 
Rad, Hercules, CA, USA) and read using a Bio-Tek Synergy HT microplate reader with Gen 5 
software (Bio-Tek Instruments, Winooski, VT).  Equal protein quantities from each sample were 
used for a 96-well ROCK Activity Assay (Cell Biolabs Inc. San Diego, CA, USA), carried out 
according to the manufacturer’s instructions. 
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4.2.11. Measurement of the fetal parameters 
The body weights of pregnant dams were recorded just before sacrifice and the litter size was 
recorded before the uterine vessel isolation.  Three fetuses from each dam were isolated from the 
mid-uterine region after isolation of uterine and umbilical vessel segments and individual 
weights were measured using Ohaus Explorer Analytical Balance (Ohaus Corporation, NJ, 
USA).  The placentae attached to the selected fetuses were also weighed. 
 
4.2.12. Statistics 
GraphPad Prism 5 software (San Diego, CA) was used for statistical analysis.  Data is presented 
as mean ± SEM (standard error of mean) and differences were considered statistically significant 
if p < 0.05 .  Repeated measures analysis of variance (ANOVA) (114) and Bonferroni post hoc 
test were used to compare the concentration/dose responses.  Each concentration response curve 
was also compared across treatment groups using a regression analysis by examining the best-fit 
value (114).  EC50 values for concentration responses in myographic studies were calculated 
using the Hill equation.  For agonists with biphasic responses (endothelin 1 and angiotensin II) 
EC50 values were calculated only for the contraction phase.  Relaxation phase was considered 
separately and percentage of relaxation from the maximum stress was compared using a two-
tailed t test.  A two tailed t test was used compare mean EC50, umbilical vein stress generation, 
fetal/placental weight, mRNA, protein and cytokine expression levels between different 
treatment groups. 
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4.3. Results 
4.3.1. Particle size distribution and zeta potential  
The zeta potentials of both PVP and C60/PVP suspensions were within the range of 0.8 - 1.5 mV 
for all samples, indicating low suspension stability for these samples.  Particle size data 
presented as intensity based hydrodynamic diameter (z-average) and second order polydispersity 
index (PDI), obtained by using CONTIN algorithm, for both PVP and C60/PVP saline 
suspensions show good agreement between triplicates as well as between size measurements for 
both C60/PVP and PVP saline suspensions (Table 4.1).  As reported in Table 4.1, the following 
was observed: 1) Suspension of C60/PVP in saline has larger particle size than PVP saline blank; 
2) The size variation between measurements 1 and 2 (within 8 minutes) is within 0.5%; 3). The 
average particle size of C60/PVP saline remained within 0.5% for at least 38 minutes.  A change 
was observed in the size distribution between measurements #1 and #2 with a decrease in the 
large particle fraction in second measurement #2 (data not shown). 
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Table  4.1.   Hydrodynamic diameter (Z- average, nm) and Polydispersity Index (PDI) of   
  PVP and C60/PVP saline suspensions 
 Meas.  #1 Meas.  #2 Average 
d., nm PDI d., nm PDI d., nm PDI 
As-
Prepared 
Samples 
PVP 36.3 1.0 33.6 1.0 
34.9 ± 
1.9 
1.0 
C60/PVP 370.4 0.357 372.1 0.326 
371.3 ± 
1.2 
0.342 ± 
0.015 
Samples at 
38 minutes 
after 
Preparation 
PVP ND ND ND ND ND ND 
C60/PVP 371.9 0.329 367.2 0.320 
369.6 ± 
3.3 
0.325 
± 0.005 
 
ND = not determined 
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4.3.2. Maternal blood pressure, heart rate and ejection fraction  
The resting systolic, diastolic, mean blood pressures, heart rate and calculated ejection fraction at 
GD 10, immediately before IV exposure and 24 hours post IV exposure are reported in Table 
4.2.  The differences of these parameters between pre- and post- exposure were not statistically 
significant. 
Table  4.2.  Cardiovascular parameters of pregnant Sprague Dawley rats  
 Time naive PVP C60/PVP 
SBP 
(mmHg) 
GD 10  140.5 ± 9.3 130.8 ± 8.1 128.5 ± 8.7 
Pre-exposure (GD 16-18) 154.7 ± 12.8 140.3 ± 11.3 160.3 ± 13.1 
Post-exposure (GD 17-19) - 135.3 ± 16.9 145.5 ± 6.6 
DBP 
(mmHg) 
GD 10  112.3 ± 6.0 100.3 ± 9.7 101.0 ± 9.5 
Pre-exposure (GD 16-18) 125.8 ± 16.4 104.0 ± 14.1 107.0 ± 10.9 
Post-exposure (GD 17-19) - 107.3 ± 18.9 110.8 ± 4.4 
MBP 
(mmHg) 
GD 10  120.7 ± 6.4 110.0 ± 8.9 112.0 ± 9.9 
Pre-exposure (GD 16-18) 135.1 ± 15.0 116.0 ± 13.2 136.8 ± 10.9 
Post-exposure (GD 17-19) - 116.0 ± 18.3 124.0 ± 5.3 
HR (bpm) 
GD 10  388 ± 11 388 ± 10 374 ± 5 
Pre-exposure (GD 16-18) 390 ± 17 406 ± 22 375 ± 18 
Post-exposure (GD 17-19) - 371 ± 37 390 ± 19 
EF (%)
  
GD 10  78.6 ± 2.5 78.1 ± 0.9 86.4 ±1.2 
Pre-exposure (GD 16-18) 81.6 ± 1.2 80.8 ± 3.6 80.1± 2.5 
Post-exposure (GD 17-19) - 80.8 ± 2.1 84.3 ±1.6 
 
The mean and the SEM are reported (n = 4 - 5).  SBP: systolic blood pressure, DBP: diastolic 
blood pressure, MBP: mean blood pressure, HR: heart rate, EF: ejection fraction, GD: 
gestational day, GD 10: gestational day 10 (i.e. mid-second trimester), pre-exposure: just before 
intravenous administration of C60 or PVP, post-exposure: 24 hours following exposure to 
intravenous C60/PVP or PVP (i.e. just before sacrifice)
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4.3.3. Maternal serum cytokine analysis 
The mean values of maternal serum cytokines 24 hours following exposure to C60/PVP or PVP 
are reported in Table 4.3.  The mean CCL2 level in the naïve pregnant rats was 65% lower than 
the naïve non-pregnant rats and was also relatively low with IV PVP (by 78.5%) or IV C60/PVP 
(by 63.6%) in the pregnant rats, when compared to the non-pregnant rats with the same exposure.  
Similarly, the mean levels of TNF were reduced in the naïve (by 83.4%) and IV PVP (by 
81.7%) in the pregnant group, when compared to the non-pregnant.  The IFNγ level was reduced 
by 73.5% in the pregnant group following IV C60/PVP exposure.  The mean VEGF level was 
8.5 fold higher in the naïve pregnant rats compared to the non-pregnant, but was significantly 
reduced following exposure to IT PVP or IT C60/PVP.  The pro-thrombotic agent PAI1 was 
77.9% higher in pregnant rats exposed to IV C60/PVP when compared to IT C60/PVP.  Overall, 
the serum cytokine levels were lower in the IT exposed rats when compared to both naïve and IV 
exposed rats.
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Table  4.3.   Cytokine levels in the maternal serum 24 hours post exposure to C60/PVP  
or PVP 
The mean and the SEM are reported for maternal cytokines (n = 4 - 9). 
Cytokine NP-naive 
NP-IV 
PVP 
NP-IV 
C60/PVP 
P-naive 
P-IV 
PVP 
P-IV 
C60/PVP 
P-IT 
PVP 
P-IT 
C60/PVP 
IL1β 
(pg/ml) 
56.0 ± 
38.5 
18.9 ± 8.2 
22.4 ± 
10.3 
14.6 ± 7.1 4.5 ± 2.8 3.6 ± 2.4 1.0 ± 0.6 0.1 ± 0.1 
IL6 
(pg/ml) 
1245.0 ± 
826.0 
50.2 ± 
37.1 
311.6 ± 
149.9 
77.9 ± 
72.8 
42.5 ± 
36.3 
57.1 ± 
54.5 
98.8 ± 
64.4 
0.0 
IL10 
(pg/ml) 
21.7 ± 9.0 3.8 ± 1.4 8.8 ± 3.3 5.8 ± 3.7 2.7 ± 2.7 2.3 ± 2.3 2.5 ± 2.5 0.0 
INFγ 
(pg/ml) 
338.4 ± 
135.3 
148.8 ± 
64.8 
149.7 ± 
38.9 
198.5 ± 
52.5 
100.4 ± 
53.9 
52.7 ± 
17.7
#
 
105.0 ± 
46.6 
40.3 ± 
31.4 
CCL2 
(pg/ml) 
823.2 ± 
223.9 
445.8 ± 
78.8 
470.8 ± 
66.4 
288.1 ± 
96.0 
95.9 ± 
30.1 
171.4 ± 
51.4 
140.0 ± 
63.7 
78.9 ± 
25.4 
VEGF 
(pg/ml) 
53.7 ± 
15.4 
33.9 ± 6.7 33.9 ± 8.3 
510.2 ± 
111.9 
414.6 ± 
96.8 
370.8 ± 
124.0 
103.2 ± 
52.6
# 
119.8 ± 
63.6
#
 
TNFα 
(pg/ml) 
40.9 ± 
12.8 
34.9 ± 3.6 
34.5 ± 
10.6 
6.8 ± 3.9 6.4 ± 3.4 14.4 ± 5.6 4.0 ± 3.1 1.5 ± 1.5 
PAI1 
(pg/ml) 
N/A N/A N/A 
918.7 ± 
222.6 
1410.0 ± 
63.7 
1669.0 ± 
240.1
#
 
1365.0 ± 
42.8 
954.8 ± 
96.8 
vWF 
(ng/ml) 
N/A N/A N/A 
236.6 ± 
159.8 
108.6 ± 
101.2 
144.1 ± 
67.7 
37.4 ± 
16.8 
39.7 ± 
14.4 
 
P = pregnant, NP = non-pregnant, N/A = not available  
* indicates p < 0.05  when compared to PVP exposed by the same route, # indicates p < 0.05  
when compared to naïve,  indicates p < 0.05  when compared to same treatment in non-
pregnant and  indicates p < 0.05  when compared between the two routes of exposure. 
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4.3.4. Maternal Bronchoalveolar Lavage (BAL) cell counts and histology 
The number of macrophages in the BAL cell counts was increased in the pregnant rats following 
exposure to IT PVP (161.9%), IT C60/PVP (257.9%), IV PVP (115.3%) and IV C60/PVP 
(92.5%) and was also relatively higher than the corresponding exposure groups in the non-
pregnant rats (Figure 4.1.A).  The neutrophil counts were increased by 47 fold following IT PVP 
exposure and by 33 fold following IT C60/PVP exposure only during pregnancy (Figure 4.1.C).  
Eosinophils were detected only in IV PVP or C60/PVP exposed pregnant and non-pregnant 
groups (Figure 4.1.D).  Mild inflammatory changes were seen in the histological sections of the 
lungs from IT PVP or IT C60/PVP exposed pregnant rats (images not shown). 
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Figure 4.1. Bronchoalveolar lavage cell counts 24 hours post-exposure to C60/PVP or 
PVP 
The mean and the SEM of macrophages (A), epithelial cells (B), neutrophils (C) and eosinophils 
(D) per milliliter of bronchoalveolar lavage fluid after 24 hours exposure to C60/PVP or PVP are 
reported  (n = 4 - 8).  * indicates p < 0.05  using a two tailed t test. 
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4.3.5. Responses of arterial segments 24 hours following intravenous (IV) C60/PVP   
 administration 
Significant changes in vascular reactivity following C60 exposure were seen only in late 
gestational stage (GD 17 – 19) group and all subsequent studies and analysis utilized data from 
this gestational age range. 
4.3.5.1. Main uterine artery 
Twenty-four hours following IV C60/PVP exposure there was 2.8 mN/mm
2 
(55.3%) increase in 
the maximum stress generating ability in response to phenylephrine in the uterine artery 
segments when compared to IV PVP exposed segments (Figure 4.2.A) in the pregnant group.  A 
similar pattern of response with ~1 mN/mm
2
 increase in the force generation capacity was seen 
for endothelin 1 (22.5%, Figure 4.2.C) and angiotensin II (29%, Figure 4.2.E) stimulation 
without changes in EC50  (Table 4.4).  The overall stress generation ability of the uterine vessel 
segments from naïve pregnant animals was smaller than those vessels from naïve non-pregnant 
animals.  The myographic assessment of uterine arterial segments from non-pregnant female rats 
revealed no differences in the responses following C60/PVP or PVP exposure (Figure 4.2.B, D, 
F and H and Table 4.4). 
 
Relaxation responses from the peak force generated at higher concentrations of endothelin 1 
were 13.7 ± 2.2% for C60/PVP, PVP 21.8 ± 3.9% and 31.29 ± 12.29 % for naïve.  Relaxation 
responses from the peak force generated at higher concentrations of angiotensin II were 33.3 ± 
11.3 % for C60/PVP, 37.4 ± 5.3% for PVP and 30.3 ± 10.1% for naive.  The relative relaxation 
(%) to acetylcholine under 30 µM phenylephrine pre-contraction was not affected by C60/PVP, 
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but the calculated EC50 value increased by 156% suggesting that a higher concentration of 
acetylcholine was needed to generate the relaxation response following IV C60/PVP exposure 
(Figure 4.2.G and Table 4.4). 
 
Figure 4.2.   Changes in the contractile responses of the main uterine artery following                                                                  
  intravenous exposure to C60/PVP 
The changes in the contractile responses were assessed by wire myography of the main uterine 
artery 24 hours post-exposure to intravenous (IV) PVP formulated C60 (C60/PVP) or PVP from 
17 - 19 days pregnant (A, C, E and G) and non-pregnant female (B, D, F and H) Sprague 
Dawley rats.  The stress generation in response to cumulative concentrations of phenylephrine 
(PE; A and B), endothelin 1 (ET-1; C and D) and angiotensin II (ANG II; E and F) are plotted.  
The percentage relaxation from a 30 µM phenylephrine pre-stimulation stress level in response 
to cumulative concentrations of acetylcholine (Ach; G and H) is graphed.  * indicates p < 0.05  
compared to PVP using repeated measures ANOVA (n = 4 - 8).  The p values were derived 
following the comparison of each concentration response curve across treatment groups using a 
regression analysis by examining the best-fit value. 
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Table  4.4.   Mean calculated EC50 values for the cumulative concentration responses of 
the main uterine artery, plotted in Figure 4.2 and 4.6 
EC50 values were calculated using the Hill equation on cumulative concentration response 
curves. 
 
C60/PVP: PVP formulated C60, P: pregnant, NP: non-pregnant, PE: phenylephrine, ET-1: 
endothelin 1, ANG II: angiotensin II, Ach: acetylcholine and HA1077: thromboxane agonist.   
* indicates p < 0.05  compared to PVP while # indicates p < 0.05  compared to naïve using a two 
tailed t test (n = 4 - 8). 
  
Agonist P/NP 
EC50 (mean ± SEM) 
Naïve PVP C60/PVP 
PE (µM) 
P 0.33 ± 0.10 0.52 ± 0.03 0.38 ± 0.10 
NP 1.08 ± 0.25 0.58 ± 0.03 0.66 ± 0.17 
ET-1 (nM) 
P 3.36 ± 0.59 3.97 ± 1.44 6.10 ± 1.48 
NP 24.27 ± 11.08 8.08 ± 5.50 28.95 ± 15.07 
ANG II (nM) 
P 2.53 ± 0.75 1.84 ± 0.53 1.54 ± 0.32 
NP 1.61 ± 0.27 3.07 ± 0.80 3.31 ± 0.82
#
 
Ach (µM) 
P 0.32 ± 0.05 0.25 ± 0.07 0.64 ± 0.13*
#
 
NP 0.73 ± 0.43 0.45 ± 0.16 0.48 ± 0.09 
HA (µM) 
P 1.21 ± 0.21 1.05 ± 0.39 1.83 ± 0.50 
NP 1.10 ± 0.33 1.58 ± 0.26 1.25 ± 0.20 
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4.3.5.2. First order mesenteric artery 
The stress generation in response to phenylephrine, endothelin 1 and serotonin stimulation of 
mesenteric artery segments from pregnant animals was not different between IV C60/PVP or 
PVP exposed groups (Figure 4.3.A, C and E).  The contractile responses in the mesenteric artery 
segments from pregnant animals were diminished by ~50% in both PVP and C60/PVP groups 
for endothelin 1 (49.6% with PVP and 61.7% with C60/PVP) and serotonin (41.3% with PVP 
and 46.9% with C60/PVP) when compared to the naïve controls (Figure 4.3.C and E).  The 
overall stress generation of mesenteric artery segments to stimulation from pregnant animals was 
smaller than from non-pregnant animals.  The only difference in the contractile responses in 
vessel segments from non–pregnant animals was seen with endothelin 1 stimulation with ~ 16% 
increase in the maximum stress generation following C60/PVP or PVP exposure (Figure 4.3. B, 
D, F and H and Table 4.5). 
 
The relaxation response at higher concentrations of endothelin 1 were attenuated for C60/PVP 
19.5 ± 4.1 %, PVP 25.1 ± 7.2 % as compared to the naïve 58.7 ± 13.4 % group.  The relaxation 
response to acetylcholine was increased in the vessel segments from PVP exposed rats when 
compared to vessel segments from C60/PVP exposed rats by 9.6 % in pregnant group and by 
19.9% in non-pregnant group (Figure 4.3.G & H). 
 
 
 
 
 79 
 
Figure 4.3.   Changes in the contractile responses of the mesenteric artery following 
intravenous exposure to C60/PVP 
The changes in the contractile responses were assessed by wire myography of the first order 
mesenteric artery 24 hours post-exposure to intravenous (IV) PVP formulated C60 (C60/PVP) or 
PVP from 17 - 19 days pregnant (A, C, E and G) and non-pregnant female (B, D, F and H) 
Sprague Dawley rats.  The stress generation in response to cumulative concentrations of 
phenylephrine (PE; A and B), endothelin 1 (ET-1; C and D) and serotonin (5HT; E and F) are 
plotted.  The percentage relaxation from a 30 µM phenylephrine pre-stimulation stress level in 
response to cumulative concentrations of acetylcholine (Ach; G and H) is graphed.  * indicates p 
< 0.05  compared to PVP while # indicates p < 0.05  compared to naïve using repeated measures 
ANOVA (n = 4 - 8).  The p values were derived following the comparison of each concentration 
response curve across treatment groups using a regression analysis by examining the best-fit 
value. 
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Table  4.5.   Mean calculated EC50 values for the cumulative concentration responses of 
the mesenteric artery, plotted in Figures 4.3 and 4.6 
EC50 values were calculated using the Hill equation on cumulative concentration response 
curves. 
 
C60/PVP: PVP formulated C60, P: pregnant, NP: non-pregnant, PE: phenylephrine, ET-1: 
endothelin 1, Ach: acetylcholine, 5HT: serotonin and HA1077: thromboxane agonist.   
# indicates p < 0.05  compared to naïve using a two tailed t test (n = 4 - 8). 
  
Agonist P/NP 
EC50 (mean ± SEM) 
Naïve PVP C60/PVP 
PE (µM) 
P 1.56 ± 0.33 0.84 ± 0.37 0.87 ± 1.30 
NP 0.99 ± 0.21 2.00 ± 0.35
#
 1.76 ± 0.58 
ET-1 (nM) 
P 5.39 ± 1.27 2.96 ± 1.44 2.30 ± 0.70
#
 
NP 21.16 ± 11.80 3.70 ± 5.50 9.86 ± 6.52 
5HT (µM) 
P 0.27 ± 0.19 0.13 ± 0.02 0.08 ± 0.03
#
 
NP 0.30 ± 0.02 0.61 ± 0.21 0.45 ± 0.61 
Ach (µM) 
P 0.04 ± 0.01 0.08 ± 0.06 0.07 ± 0.02 
NP 0.06 ± 0.03 0.04 ± 0.05 0.06 ± 0.02 
HA (µM) 
P 1.43 ± 0.29 1.87 ± 0.28 0.81 ± 0.49 
NP 0.99 ± 0.43 0.69 ± 0.31 0.47 ± 0.10 
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4.3.5.3.  Thoracic aorta 
The maximum stress generation in response to phenylephrine (0.001 – 10 µM) was 15.7% larger 
in the C60/PVP exposed segments when compared to PVP (Figure 4.4.A).  Similarly, the 
endothelin 1 mediated stress generation was 19.4% greater following IV C60/PVP exposure 
when compared to either PVP or naïve controls in the pregnant rats (Figure 4.4.C).  The 
relaxation response to acetylcholine (0.001 – 10 µM) were not different between PVP and 
C60/PVP exposed and naïve thoracic aortic segments (Figure 4.4.E).  No differences were 
detected in non-pregnant thoracic aortic segments following C60/PVP or PVP exposure (Figure 
4.4.B, D, and F and Table 4.6). 
 
Figure 4.4.   Changes in the contractile responses of the thoracic aorta following 
intravenous exposure to C60/PVP 
The changes in the contractile responses were assessed by wire myography in the thoracic aorta 
24 hours post-exposure to intravenous (IV) PVP formulated C60 (C60/PVP) or PVP from 17 - 
19 days pregnant (A, C and E) and non-pregnant female (B, D and F) Sprague Dawley rats.  The 
stress generation in response to cumulative concentrations of phenylephrine (PE; A and B) and 
endothelin 1 (ET-1; C and D) are plotted.  The percentage relaxation from a 10 µM 
phenylephrine pre-stimulation stress level in response to cumulative concentrations of 
acetylcholine (Ach; E and F) is graphed.  * indicates p < 0.05  compared to PVP while # 
indicates p < 0.05  compared to naïve using repeated measures ANOVA (n = 4 - 8).  The p 
values were derived following the comparison of each concentration response curve across 
treatment groups using a regression analysis by examining the best-fit value. 
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Table  4.6.   Mean calculated EC50 values for the cumulative concentration responses of 
the thoracic aorta, plotted in Figures 4.4 and 4.6 
EC50 values were calculated using the Hill equation on cumulative concentration response curves  
 
C60/PVP: PVP formulated C60, P: pregnant, NP: non-pregnant, PE: phenylephrine, ET-1: 
endothelin 1, Ach: acetylcholine and HA1077: thromboxane agonist.   
# indicates p < 0.05  compared to naïve using a two tailed t test (n = 4 - 8). 
  
Agonist P/NP 
EC50 (mean ± SEM) 
Naïve PVP C60/PVP 
PE (µM) 
P 0.13 ± 0.02 0.06 ± 0.01 0.07 ± 0.01 
NP 0.07 ± 0.02 0.11 ± 0.01 0.12 ± 0.04 
ET-1 (nM) 
P 71.88 ± 17.84 39.39 ± 6.75 21.52 ± 9.84
#
 
NP 12.79 ± 4.63 9.99 ± 2.45 10.24 ± 2.93 
Ach (µM) 
P 0.06 ± 0.01 0.05 ± 0.01 0.09 ± 0.02 
NP 0.12 ± 0.03 0.10 ± 0.03 0.08 ± 0.01 
HA (µM) 
P 2.12 ± 0.35 2.03 ± 0.18 2.51 ± 0.16 
NP 2.41 ± 0.54 2.02 ± 0.18 1.70 ± 0.31 
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4.3.6. Responses of arterial segments 24 hours following intratracheal (IT) C60/PVP 
administration 
Twenty-four hours following intratracheal instillation of PVP formulated C60 in pregnant rats 
there was 2.75 mN/mm
2 
(76.2%) greater stress generation in the uterine artery segments in 
response to phenylephrine stimulation when compared to vessel segments from PVP treated 
animals (Figure 4.5.A).  When compared to naïve, stress generation was reduced by 48.6% 
following IT exposure to PVP.  The response to endothelin 1 (Figure 4.5.B) was similar to 
previously described uterine artery segments from IV C60/PVP exposed rats with the relaxation  
response at the higher concentrations of endothelin 1 being attenuated for C60/PVP (14.3 ± 6.2 
%), PVP (16.0 ± 2.1 %) compared to naïve (31.2 ± 12.2 %).  The relaxation responses of the 
main uterine artery to acetylcholine and all contraction/relaxation responses of the mesenteric 
artery and aortic segments were not significantly different between the IT C60/PVP or PVP 
exposures (data not shown). 
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Figure 4.5.   Changes in the contractile responses of the main uterine artery following    
  intratracheal instillation of C60/PVP  
The changes in the contractile responses were assessed by wire myography of the main uterine 
artery 24 hours post-exposure to intratracheally instilled (IT) PVP formulated C60 (C60/PVP) or 
PVP from 17 - 19 days pregnant Sprague Dawley rats.  The stress generation in response to 
cumulative concentrations of phenylephrine (PE; A) and endothelin 1 (ET-1; B) are plotted.  # 
indicates p < 0.05  compared to naïve using repeated measures ANOVA (n = 5 - 8).  The p 
values were derived following the comparison of each concentration response curve across 
treatment groups using a regression analysis by examining the best-fit value. 
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4.3.7. Contribution of Rho-kinase activity on the vascular tissue contractility 
4.3.7.1. Maintenance of stress in the presence of Rho kinase inhibitor 
The segments of the main uterine artery from pregnant rats exposed to IV C60/PVP required 
higher concentrations of the Rho-Kinase (ROCK) inhibitor HA1077 to maximally relax a 
phenylephrine pre-contraction, as the C60/PVP exposed segments relaxed 30.8% less than the 
PVP and 15.0% less than the naïve controls at the highest HA1077 concentration (Figure 4.6.A 
and E).  Similarly, the maximum relaxation was 18.4% less in the C60/PVP group compared to 
the naïve segments of the thoracic aorta from pregnant rats.  In contrast with these contractile 
responses, the mesenteric vessel segments, exposed to C60/PVP had ~ 24% greater relaxation 
responses to the mid-range concentrations of HA1077 as compared to responses of segments 
from PVP and naïve controls, but these differences were not statistically significant (Figure 
4.6.C).  The only differences seen in the responses of vessel segments from non-pregnant rats 
were the 8.0 % lower relaxation with C60/PVP and 13.0% lower with PVP when compared to  
naïve, at highest concentrations of HA1077 in uterine artery segments (Figure 4.6.B, D and F). 
 
Figure 4.6.  Changes in the stress generation in the presence of Rho-kinase inhibitor 
The reduction in stress generation is reported as the percentage relaxation from a phenylephrine 
(30 µM for uterine/mesenteric arteries and 10 µM for aorta) pre-stimulation stress level in 
response to cumulative additions of a Rho kinase inhibitor (HA1077).  These responses were 
assessed by wire myography 24 hours post-exposure to intravenous PVP formulated C60 
(C60/PVP) or PVP from 17 - 19 days pregnant (A, C and E) and non-pregnant female (B, D and 
F) Sprague Dawley rats.  A and B: main uterine artery; C and D: first order mesenteric artery; E 
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and F: thoracic aorta.  * indicates p < 0.05  compared to PVP while # indicates p < 0.05  
compared to naïve using repeated measures ANOVA (n = 4 - 6).  The p values were derived 
following the comparison of each concentration response curve across treatment groups using a 
regression analysis by examining the best-fit value. 
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4.3.7.2. RhoA, ROCK expression and activity in aortic tissue homogenates 
RhoA, ROCK1 and ROCK2 mRNA expression levels from the C60/PVP groups were not 
significantly increased in aortic tissue homogenates when compared to PVP groups in both 
pregnant and non-pregnant rats.  However, the overall fold changes for these targets when 
compared to the naïve controls were higher in the pregnant group (data not shown).  No 
significant changes were seen in the total ROCK activity of aortic tissue homogenates following 
C60/PVP treatment as assessed by the ROCK activity assay (data not shown). 
 
 
4.3.8.   Changes in the fetal components following C60 exposure 
4.3.8.1. Changes in umbilical vein contractility 
The contractility of the umbilical vein was assessed in IV C60/PVP exposed and controls fetuses.  
The stress generation was increased by 65.5% in the presence of K
+
PSS and by 65.8% in the 
presence of 1 µM of the thromboxane mimetic (U46619) in umbilical vein segments from IV 
C60/PVP exposed rats when compared to the PVP controls (Figure 4.7.A).  These vessels did not 
display any response to acetylcholine.  The relaxation response to 1.0 µM SNP with a stable 
U46619 pre-contraction was diminished by 9.49% in the IV C60/PVP exposure group, but was 
not statistically significant (Figure 4.7.B). 
  
 90 
 
Figure 4.7.   Changes in stress generation of the umbilical vein following intravenous     
  exposure to C60/PVP 
A: changes stress generation as assessed by wire myography in response to K
+
 depolarization 
(109 mM K
+
PSS) and thromboxane agonist (1 µM U46619) of the umbilical vein 24 hours post-
exposure to intravenous PVP formulated C60 (C60/PVP) or PVP from 17 - 19 days pregnant 
Sprague Dawley rats(n = 6 - 8).  B: percentage relaxation in response to sodium nitroprusside (1 
µM SNP) following 1 µM U46619 pre-contraction (n = 6 - 8). 
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4.3.8.2. Changes in the fetal and placental weight 
Since there was a significant weight gain in fetuses during each day of gestation, we have 
reported the weights after re-grouping them according to GD at sacrifice.  Mean weights of 
pregnant dams at the time of sacrifice were not significantly different between treatment groups 
(mean ± SEM): C60/PVP 280.5 ± 5.8 g (n = 8), PVP 295.1 ± 9.3 g (n = 8) and naïve 287.2 ± 
10.98 g (n = 10).  The mean litter size and range were not different between the intravenous 
exposure groups:  C60/PVP 11.4 (9 - 14), PVP 11.3 (8 - 13) and naïve 10.6 (8 - 13).  We did not 
observe any gross external morphological abnormalities of the fetuses.  Mean fetal weights from 
the IV C60/PVP exposed group and controls are reported in Figure 4.8.A, while the placental 
weights are in Figure 4.8.B.  The fetal weight was reduced in the C60/PVP exposed group by 
12.1% compared to the PVP exposed group and by 16.0% compared to the naïve group on GD 
19.  The fetal/placental weights were not different in the IT C60/PVP exposed groups (data not 
shown). 
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Figure 4.8.   Changes in fetal and placental weight following intravenous exposure to    
  C60/PVP 
Changes in fetal (A) and placental (B) weight 24 hours post-exposure to intravenous C60/PVP or 
PVP from 17 - 19 days pregnant Sprague Dawley rats.  * indicates p < 0.05  compared to PVP 
using a two tailed t test (n = 6 – 15 fetuses). 
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4.3.8.3. Fetal serum cytokine analysis 
The serum cytokines of pooled fetal serum are reported in Table 4.7.  The mean levels of 
cytokine of  IL1β and IFNγ were increased in the fetal serum samples (86.0% and 322.9% 
compared to naïve) following maternal IV PVP exposure but were reduced (by 43.4% and 31.3% 
compared to naive) with maternal IV C60/PVP exposure. 
 
Table 4.7.   Cytokine levels in the fetal serum 24 hours post-exposure to C60/PVP or PVP 
The mean and the SEM are reported for fetal cytokines (n = 4 - 6). 
Cytokine  naive IV PVP IV C60/PVP 
IL1β (pg/ml) 1455.0 ± 372.5 2712.0 ± 610.9 794.2 ± 281.6* 
IL6 (pg/ml) 75.7 ±16.8 1624.0 ± 979.8 82.59 ± 57.95 
IL10 (pg/ml) 70.0 ± 17.0 584.4 ± 267.2 55.2 ± 17.0 
INFγ (pg/ml) 283.3 ± 42.5 1198.0 ± 294.5
#
 194.7 ± 84.0* 
CCL2 (pg/ml) 903.4 ± 310.8 1041.0 ± 215.7 721.9 ± 86.0 
VEGF (pg/ml) 469.5 ± 83.0 557.7 ± 112.7 407.8 ± 33.3 
TNFα (pg/ml) 5.9 ± 5.9 23.5 ± 19.5 8.4 ± 6.8 
 
* indicates p < 0.05  when compared to PVP exposed by the same route while # indicates p < 
0.05  when compared to naïve.  
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4.4. Discussion 
Our hypothesis of an increase in the contractile response of the main uterine artery and thoracic 
aorta following intravenous exposure to PVP formulated C60 (C60/PVP) would occur during 
late stages of pregnancy was supported by the main observation in this study.  In addition, we 
found a concomitant increase in stress generation of the umbilical vein associated with a 
reduction in fetal weight supporting a suggestion that exposure to C60 fullerene during 
pregnancy may negatively impact fetal development by altering vascular supply to the fetus.  
However, we also found a profound PVP induced dilator effect, which was as strong as the C60 
contractile effect but in general was in the opposite direction.  Underpinning the increased stress 
generation ability was evidence for increased involvement of Rho-kinase signaling in C60/PVP 
exposed vessel segments, suggesting a possible mechanism underlying the changes in vascular 
tissue response following C60/PVP exposure.  To our knowledge, this is the first study to assess 
the effects of C60 on altering vascular tissue contractility during pregnancy by either IT or IV 
routes of administration. 
 
The inherent insolubility of C60 in physiologically compatible media has led to the development 
of various dispersal methods for C60 applications in vitro and in vivo.  These include the use of 
polymers, surfactants, cyclodextrin, liposome, solvent exchange or nanomilling (6, 90, 128, 173, 
185, 217, 237).  We opted to utilize a suspension of polymer-wrapped C60 using 
polyvinylpyrrolidone (PVP), since PVP is often considered biologically compatible, with its use 
as a plasma expander, as a binder and most recently its approved use in cosmetics (106, 237, 239).  
As indicated by the measured zeta potential, the C60/PVP suspension was inherently unstable.  
However, the minimal change in the polydispersity index, suggests reasonable homogeneity in 
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the size distribution within the suspension.  A decrease in the number of larger diameter particles 
after 38 minutes (data not shown) of the suspension could not be accounted for as agglomeration 
of suspended particles, but may be explained by gravitational forces which removed larger 
particles from the active measurement area.  Despite these physical effects on measurements 
over the time span to generate and deliver the suspension, the average particle size remained 
within 0.5% of the mean size determination.  The average particle diameter was determined for 
our suspension (370 nm) using a 29 kDa PVP and is in reasonable agreement with the diameter 
reported for the C60/PVP complex Radical Sponge
®
 (680 nm) using the 60-80 kDa PVP 
polymer (238). 
 
We were specifically interested in understanding how the vascular responses were sensitive to 
changes in life stage (i.e. pregnancy) as meditated by the Rho signaling pathway and chose to 
investigate the pharmacological responses of vascular segments from different vascular beds, by 
two routes of exposure using a single dose (93.3 µg/kg) of this C60/PVP formulation.  Previous 
studies have shown that intratracheal instillation of 100 µg (3-4 times higher than the dose we 
have used)  of C60 in rats resulted in a pulmonary burden half-life of about 15 days (184) with 
minimal pulmonary inflammation 3 days after exposure (145).  When C60 was administered 
intravenously to male rats once per day for four days (approximately 929 µg of C60 total), C60 
accumulation in the lungs was evident from 1 day post-exposure out to 28 days post-exposure 
(98).  Compared to other above and other studies (202, 214, 241) the dose we used is a relatively 
low dose and coincides more with an acute exposure.  We recognize that due to the complexity 
of the study, there are limitations of using a single dose/time point in toxicological studies.  
Future detailed time and/or dose-response studies will have to be carried out to evaluate 
 96 
 
appropriate endpoints for incorporation of these findings into risk assessment.  The two routes of 
exposure (IT and IV) were chosen to mimic occupational (pulmonary exposure by IT) and 
therapeutic (by IV) exposure.  The choice of a 24 hour post-exposure time point was based on 
the consideration of reported distribution and clearance of nanoparticles which most often occurs 
within that time frame (98, 143) and provides a reasonable time to assess the vascular effects 
following acute exposure.  Additionally, with a gestational period of 20 - 22 days in rats 24 hour 
accounts for approximately 5% of total gestation, a time frame in which fetal growth and 
organogenesis is significant. 
 
In an effort to understand the impact of C60 exposure on the systemic cardiovascular function, 
we chose to evaluate the fundamental blood pressure and cardiac function of the rats prior to and 
24 hours after the administration of the single dose of the C60 or its vehicle.  The systemic blood 
pressure was measured by tail cuff and we recognize that there is a potential limitation of the 
sensitivity of this non-invasive blood pressure measurement, which needs to be considered in 
interpreting the data reported Table 4.2 as it has a limited ability to detect changes of less than 10 
mmHg, which could be significant if altered during pregnancy.  The ultrasound measurements 
were significantly more sensitive, but those results were also supportive of a minimal impact of 
C60 exposure on basal cardiovascular function.  These results are not to say that if the 
cardiovascular system were challenged by an additional stress there would not be apparent 
changes in the blood pressure or cardiac function as it is postulated that exposure to particular 
materials may not have direct impacts on basal function but blunt the physiological reserve of the 
system in response to additional challenges (119).  These kinds of experiments were not 
performed but would be the focus of future studies. 
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Several changes in the abundance of circulating cytokines may have contributed to the vascular 
responses observed during pregnant and non-pregnant life stages to either PVP or C60/PVP.  The 
suppression of inflammatory cytokines in the naïve pregnant group may be due to overall 
suppressed immune responses mediated by pregnancy related hormones (96).  These baseline 
differences are consistent even after the exposure to PVP or C60/PVP suggesting that the 
variances observed are largely due to physiological differences in the life stage rather than the 
exposure to nanomaterials.  The increase in pro-inflammatory agent TNF and endothelial 
derived pro-thrombotic agent PAI1 levels within the pregnant group following IV C60/PVP 
exposure suggests the initiation of an endothelium mediated inflammatory response. 
 
Distinct variations were also evident in the inflammatory responses in lungs between the 
pregnant and non-pregnant life stages.  Macrophages and neutrophils were increased in BAL 
fluid during pregnancy following exposure to PVP, which was further increased following 
C60/PVP administration by either IT or IV routes.  We believe that this type of response would 
support an increased reactiveness of the innate immune barriers (96) in response higher 
pathogenic susceptibility during pregnancy.  In contrast, the unchanged eosinophil count 
suggests that these responses to PVP and C60/PVP exposure are a protective; particle 
engulfment based responses rather than a hypersensitivity reaction.  Our findings are in 
agreement with others that have reported activation of alveolar macrophages and presence of 
cytokines as a clearance response to pulmonary exposure to C60 (156, 186) and other 
nanoparticles (20).  These cellular responses were highest at 24 hours post exposure and waned 
over the course of 7 days (20).  Even following intravenous delivery most of the nanoparticles 
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are anticipated to be filtered and retained in the lungs and liver (202), resulting in profiles of cell 
differential and cytokine expression that may be similar to those from a direct pulmonary 
exposure. These phenomena may be recapitulated with regard to inflammatory cells presence 
following IV C60/PVP exposure seen in our study. 
 
Apart from the indirect effects mediated through pulmonary inflammation and circulating 
cytokines, there may also be direct effects of C60 on the vascular contractile responses as 
suggested by the variances observed with the two routes of exposure.  With C60/PVP exposure 
the pattern of change in contraction remains the same, but the magnitude of stress generation is 
higher with IV route as the vascular endothelium may be encountering more particles.  
Additionally, the variability seen in the maximum stress generated with IT C60/PVP exposure is 
smaller following IV C60/PVP exposure, which may also be attributed to amount of C60 directly 
delivered to tissues by IV administration.  The response to PVP also varied between different 
routes of administration and vascular beds studied raising concerns of a vehicle/formulation 
effect.  When compared to the naïve, it is evident that PVP alone reduced the stress generating 
response, which is reversed and augmented by C60/PVP combination bringing it closer to the 
naïve conditions.  However, a clear vehicle vs. C60 toxicity effect cannot be easily addressed due 
to the insolubility of pristine C60 and we were unable to measure the stress generation induced 
by C60 alone.  Due to differences in permeation of the lipid bilayer by C60 and their derivatives, 
there are different toxicity profiles (165), and non-derivatized C60 aggregates are considered 
more toxic (177).  Hydroxylated fullerenols, which are considered water soluble and less toxic, 
can be used as an alternative in biomedical applications to eliminate vehicle induced effects 
associated with C60/PVP usage. 
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We observed that the uterine arteries of naïve pregnant rats produced relatively lower stress 
generation when compared to the naive non-pregnant vessel segments.  Within the pregnant 
group, exposure to C60/PVP increased stress generation in the uterine artery generating a 
response profile similar to that of the naïve non-pregnant state.  The overall changes in vascular 
contraction were smaller in the non-pregnant rats following IV C60/ PVP administration 
suggesting a higher susceptibility to changes by C60/PVP exposure in the pregnant state.  
Additionally, these changes were further confined to the late gestational stage (GD 17 - 19) as 
the early gestational days we examined (GD 14 - 16) were relatively resistant to C60 exposure 
induced effects.  We did not observe significant differences of the mesenteric artery segments 
suggesting the low sensitivity of the mesenteric vascular bed to C60 when compared to uterine 
vasculature during pregnancy.  A possible explanation for the different vascular bed responses 
may be related to changes in vascular remodeling (41) and the expression of mediators such as 
PPARγ during pregnancy that are known to influence contractile responses of the two vascular 
beds (65). 
 
Our data suggests that IV C60/PVP exposure during pregnancy increases the vascular contractile 
response of the uterine artery to several agonists including phenylephrine, endothelin 1 and 
angiotensin II.  Similar responses were seen with the thoracic aorta suggesting a common 
contractile regulatory pathway involved in the C60/PVP exposure.  The RhoA-Rho kinase 
(ROCK) pathway is such a regulatory process associated with the various agonists investigated 
in this study (59).  ROCK activity may be contributing in several ways to increase the contractile 
response in VSMC such as regulation of intracellular calcium and changing the phosphorylation 
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status of the MLCP (59).  Several observations in our study support the hypothesis of an increase 
in ROCK activity.  C60/PVP exposure irrespective of the route sensitizes the contractile response 
to both phenylephrine and endothelin 1 and manifests as augmented stress generation in uterine 
and thoracic aorta preparations.  Secondly, the relaxation response of C60/PVP exposed vessel 
segments to ROCK inhibitor HA1077 was attenuated.  While HA1077 may also inhibit other 
protein kinases, it is believed that it selectively inhibits ROCK in the concentration range used in 
this study (43).  Thirdly, PAI1, a circulating endothelial derived pro-thrombogenic agent which 
is associated with RhoA-ROCK expression in the endothelial cells (135) was increased following 
IV C60/PVP exposure.  Alternatively, up regulation of RhoA and ROCK are also known to be 
associated with reduced expression/activation of endothelial nitric oxide synthase (eNOS) (56, 
127), thereby reducing the relaxation response leading to enhanced contraction.  In this study, we 
observed minor differences in acetylcholine mediated eNOS dependent relaxation in the isolated 
vessels.  However, the mRNA and protein activity of RhoA, ROCK1 and ROCK2 in the aortic 
tissue homogenates did not significantly increase following C60/PVP exposure.  The sample 
size, post-exposure time points examined, limitations of the assays, post-transcriptional and post-
translational modifications of these proteins could have contributed to these discrepancies.  
Based on all these observations, we can hypothesize that the Rho-ROCK pathway contributes to 
the changes in contractile response though PAI1 in the endothelial cells. 
 
Although overall systemic effects of exposure to C60/PVP on blood pressure and cardiac output 
were not evident, the significant increase in contractile responses in uterine and umbilical 
vasculature could have negative implications on fetal blood supply, which was supported by the 
measured reduction in fetal weight particularly towards later gestation periods.  Similar changes 
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in fetal weight were reported following other nanoparticle exposures (52, 241) and higher doses 
of C60 exposure have demonstrated potential harmful effects on embryogenesis (214).  The 
reduction in fetal weight can also be independent of the blood supply and may be due to 
C60/PVP that is distributed in fetal organs (202).  Litter size and body weight of the dams were 
not different between naïve/exposed groups, therefore can be considered to have no effect on 
fetal weights reported in this study.  The placental weight does not change significantly during 
late stages of pregnancy and the increase in weight on GD 17 could be attributed to placental 
edema as a result of the inflammatory response following particle exposure.  However, the 
limited cytokine profile does not support a profound inflammatory response in the fetal side 
following C60/PVP exposure. 
 
In conclusion, the findings we present suggest that intravenous exposure to PVP formulated C60 
during late stages of pregnancy increases the vascular tissue contractile response of the main 
uterine artery through elements of Rho-Rho-kinase signaling.  The concomitant increase in the 
contractile response of the umbilical vein leads to a reduction in fetal weight suggesting an 
intrauterine growth restriction during late stages of pregnancy.  The results from this study also, 
highlight the importance of selecting the appropriate formulation/vehicle for nanoparticle/C60 
delivery to target tissues in biomedical applications, minimizing the potential for unanticipated 
vascular effects.  
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CHAPTER 5 
Intratracheal instillation of Multi-Walled Carbon Nanotubes Increases Rho-kinase 
Independent Vascular Tissue Contractility in Pregnant Sprague Dawley Rats 
 
5.1. Introduction  
Single- and Multi-walled carbon nanotubes (SWCNTs and MWCNTs) are being increasingly 
designed and produced for various industrial and biomedical applications such as tracers of 
malignant cells, immunomodulators, contrast agents and as scaffolds in tissue engineering (73, 
159).  Pulmonary exposure to MWCNTs are reported to be associated with adverse effects 
similar to asbestos exposure (148) involving impairment in pulmonary function (224) and 
activation of inflammatory responses in mesothelial cells (134).  MWCNTs are known to be 
taken-up by bronchial epithelial cells, increase pro-inflammatory cytokine production and induce 
cytotoxicity in in vitro studies (68, 79).  When considering their bio-distribution, MWCNTs 
translocate to the lymph nodes following intratracheal instillation (3, 161) and potentially to 
other extra-pulmonary organs leading to various toxico-pathologies (143, 167).  There are a few 
studies focusing on extra-pulmonary, cardiovascular effects of inhaled/instilled MWCNTs that 
report MWCNT exposure effects such as translocation to liver, kidney and heart.  The extra-
pulmonary effects of MWCNT exposure is reported to be associated with impairment of 
endothelium dependent relaxation in coronary arterioles (198) and increased coronary vascular 
tone enhancing indices of ischemia reperfusion injury (212).  The adverse pulmonary effects 
following occupational exposure to carbon nanotubes have been studied extensively in non-
pregnant animal models (27, 161, 218).  The consequences of MWCNT exposure on the 
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peripheral vascular system are yet to be studied adequately, particularly in unique physiological 
stages of pregnancy. 
 
A pregnant female can be exposed to MWCNTs by inhalation during occupational exposures in 
industry or in research laboratories (27, 39, 69, 208).  With the expanding use in biomedical 
applications pregnant mothers might also be exposed to MWCNTs primarily by the intravenous 
route (234).  Previous studies on MWCNT exposure during pregnancy have reported minimal 
effects on fetal development and maternal well-being following oral exposure to 8 - 1000 
mg/kg/day of MWCNTs (110).  The expansive vascular remodeling that takes place during 
pregnancy (149, 152, 153) may predispose the maternal and fetal vasculature to be sensitive to 
biological responses following nanomaterial exposures by other routes (i.e. pulmonary and 
intravenous) where increased concentrations of MWCNTs may directly reach the circulation.  
The consequence of any changes in vascular reactivity can potentially negatively impact 
placental blood supply reducing fetal growth and development.  On the other hand, diverse 
suspensions and dispersion media have been used in MWCNT exposure studies (63, 226) which 
can contribute to the differences in or lack of reported toxicity, that could also be related to the 
route of exposure.  There is a significant lack of information available on studies of pulmonary 
exposure to MWCNTs during pregnancy and how it affects the contractility of uterine and 
placental vasculature.  Following acute intravenous exposure, pristine carbon nanotubes are 
redistributed to the reticulo-endothelial system (82, 234) with a significant proportion remaining 
in blood (4). This is in contrast to functionalized forms, which are reported to be excreted 
unchanged via the kidney (101, 190).  It can be assumed that these nanotubes come in direct 
contact with the vascular endothelium during their distribution process and this interaction can 
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potentially induce changes in vascular reactivity during pregnancy by various mechanisms.  
These potential mechanisms may include receptor modulation and alterations in the intracellular 
signaling such as the RhoA-Rho kinase pathway, which is already reported to be involved in 
altering vascular conditions  with other particulate matter exposures (204, 248).  
 
The fundamental hypothesis for the experiments described in this chapter of the dissertation was 
that MWCNT exposure during pregnancy will increase the contractile responses in uterine and 
placenta derived blood vessels by increasing the rho-kinase activity.  We also hypothesized that 
there will be differential effects on the contractile responses dependent on the route of exposure 
and the vascular bed location.  Intratracheal instillation and intravenous administration was used 
as the two routes of exposure to identify these differential effects within thoracic aorta, 
mesenteric and uterine arterial segments. 
  
 105 
 
5.2. Methods and Materials 
5.2.1.  MWCNT suspensions for exposure  
Multi-walled carbon nanotubes (MWCNTs) were a generous gift from NanoTechLabs Inc.  
(Yadkinville, NC, USA) and the dry powder form was previously characterized (224).  The 
commercial grade, non-functionalized, hydrophobic carbon based nanotubes were suspended in 
non-polar solvents/dispersion media prior to in vivo exposure.  MWCNTs for intratracheal 
instillation was suspended in 10% clinical grade surfactant (Infasurf®, ONY, Inc., Amherst, NY, 
USA) in sterile 0.9% saline (0.9% NaCl, B. Braun Medical Inc., CA, USA) as previously 
described (224) to a concentration of 150 µg/ml and the mixture was cup-horn sonicated for 2 
minutes at 65%  amplitude for a total energy of 10,817 Joules, using a Misonix ultrasonic liquid 
processor -1510R-MTH (Branson Ultrasonics Corp. Danbury, CT, USA).  This suspension will 
be referred to as “(S)-MWCNTs” and had been previously characterized by Wang et al in 2011 
(224).  Additionally, the MWCNTs were suspended in the dispersion media modified from 
Bihari et al (17) for intravenous administration.  Briefly, this dispersion media contained 0.6 
mg/ml rat serum albumin (Sigma, A6272), 0.01 mg/ml 1, 2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC, Sigma F-0763) in phosphate buffered saline (Sigma D5652 1X) and 
sonicated using the probe sonicator at 40% amplitude for 15 seconds.  This dispersion medium 
will be referred to as “DPPC/RSA”.  The MWCNTs  were suspended in this media with 150 
µg/ml and the  mixture was cup-horn sonicated using a Misonix ultrasonic liquid processor -
1510R-MTH (Branson Ultrasonics Corp. Danbury, CT, USA) at 65% amplitude for 2 minutes.  
This intravenous suspension will be referred to as “(D)-MWCNTs” and  was previously 
described by Wang et al in 2013 (225). 
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5.2.2. Sprague Dawley rats 
Timed pregnant and non-pregnant female, 10-12 week old Sprague Dawley rats were purchased 
from Charles River Laboratories (USA).  All rats were acclimated for one week in East Carolina 
University (ECU) Department of Comparative Medicine’s animal facility, housed under 12 hour 
light/dark cycles with standard rat chow and water provided ad libitum.  The body weight was 
monitored in the pregnant rats, once in every three days to assess the progression of pregnancy.  
All animal handling and exposure procedures were approved by the ECU Institutional Animal 
Care and Use Committee (see Appendix). 
 
5.2.3. MWCNT Exposure and dosing  
Each pregnant and non-pregnant MWCNT exposure or dispersion medium control group for 
each route of exposure included a minimum of six animals.  The pregnant rats were exposed at 
17 – 19 days of gestation, compatible with the early third trimester of human pregnancy.  Rats 
were anesthetized using 2 - 3% isoflurane (Webster Veterinary, USA) dispersed in oxygen for 
exposure procedures.  The 150 µg/ml MWCNT suspension was administered as a mass based 
dose of 100 µg/kg by weighing each rat just before the procedure and calculating the volume 
accordingly.  (S)-MWCNTs suspension or 10% surfactant was instilled intratracheally (IT) as 
previously described (212, 224) for pulmonary exposure.  A group of non-pregnant rats was 
exposed to IT (S)-MWCNTs or 10% surfactant to evaluate any aspect of life stage on vascular 
tissue contractility.  The intravenous (IV) administration of 100 µg/kg (D)-MWCNTs or 
DPPC/RSA was done in the pregnant rats through the tail vein using a 25G needle.  Ten to 
twelve weeks old, pregnant (GD 17 – 19) and non-pregnant female rats were used as were a set 
of naïve controls as described in Chapter 3. 
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5.2.4. Tissue and sample collection  
The rats were anesthetized in a transparent sealed receptacle containing gauze soaked with 70% 
isoflurane (Webster Veterinary, USA) in propylene glycol (Amersco, OH, USA), separated from 
the animal by a wire mesh.  Twenty four hours following administration of the MWCNT, there 
were subjected to a midline incision and euthanized by pneumothorax.  Whole blood (1 ml) was 
withdrawn directly from the maternal right ventricle and a pooled fetal blood sample was 
collected from at least three fetus in each pregnant dam (blood from these three fetuses were 
considered as one sample).  Maternal and fetal whole blood samples were centrifuged (20,400 xg 
for 20 minutes), serum extracted and stored in - 80°C for cytokine analysis.  Both uterine horns 
with the vascular arcades, small intestinal loop with superior mesenteric arcade and thoracic 
aorta were carefully excised and placed in ice cold physiological saline solution (PSS; mM) 140 
NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgSO4, 1.2 MOPS (3-[N-morpholino]-propane sulfonic acid), 5.6 
D-glucose, 0.02 EDTA, and a pH of 7.4).  Arterial segments with a length of 0.5 – 2.0 mm were 
isolated from the mid region of the main uterine artery (diameter 150 - 300 μm), first order 
mesenteric artery (diameter 150 - 250 μm), and thoracic aorta (diameter 2 - 3 mm). Two 
segments from umbilical veins (diameter 400 - 550 μm) from umbilical cords of different fetuses 
implanted in the mid-uterine region were isolated from each dam. 
 
5.2.5. Maternal and fetal serum cytokine analysis  
Selected serum cytokines and chemokines (IL6, IL10, TNFα, CCL2, PAI1, VEGF, INFγ, and 
IL1β) were assessed using Milliplex MAP Cytokine/Chemokine Panel and Immunoassay (EMD 
Millipore MA, USA) from maternal and fetal serum samples according to the manufacturer’s 
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directions.  Assays were run using Luminex 100/200 (Luminex, Austin, TX) and results reported 
using Luminex xPONENT® software versions 2.3/3.1. 
 
5.2.6. Wire myographic studies  
The dissected vessel segments were mounted into a DMT 610M multi-channel wire myograph 
system (Danish Myo Technology, Aarhus N, Denmark) using 40 μm wires or pins.  All vessel 
segments were bathed in PSS bubbled with medical grade air during the myographic studies.  
The optimal resting tension for each arterial segment was established at 90% of internal 
circumference (IC) produced at tensions equivalent to 100 mmHg (13.3 kPa).  A depolarization 
response with K
+
PSS (109 mM K
+ 
equal molar substitution of Na
+
) was used to assess the vessel 
viability and segments that developed a stress response of greater than 1 mN/mm
2
 were 
considered viable.  Endothelial function was assessed by adding 3.0 μM acetylcholine during a 1 
µM phenylephrine pre-contraction.  The arterial vessel segments were then subjected to 
cumulative concentrations of phenylephrine (0.001 – 30 µM), endothelin 1 (0.0001 – 1 µM) and 
acetylcholine (0.0001 – 30 µM).  Angiotensin II (0.0001 – 0.1 µM) and serotonin (0.001 – 1 µM) 
was used to study the uterine and mesenteric arteries respectively.  The force generated by each 
vessel segment at each concentration was recorded using Lab Chart (ADI Instruments, CO, 
USA).  The force was then normalized to the surface area of the vessel to determine the active 
stress generated in response to different agonists. 
 
The umbilical vein segments were stretched and set to an IC equal to 90% of the IC when the 
wall tension is equivalent to 20 mmHg (5.1 kPa) (100).  The viability was assessed using K
+
PSS.  
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The segments were pre-contracted with thromboxane-mimetic U46619 (1 µM) and subjected to 
cumulative concentrations of acetylcholine (0.0001 – 30 µM), followed by 1 µM SNP. 
 
5.2.7. Measurement of the fetal and placental weight 
Body weights of pregnant dams were recorded just before sacrifice and the litter size was 
recorded before uterine vessel isolation.  Three fetuses were isolated from each dam from the 
mid-uterine region and individual weights were measured using Ohaus Explorer Analytical 
Balance (Ohaus Corporation, NJ, USA).  The blot weights of the placentae attached to the same 
fetuses were also recorded.  
 
5.2.8. Statistical analysis 
Statistical analysis was done utilizing GraphPad Prism 5 software (San Diego, CA) and data is 
presented as mean ± SEM (standard error of mean).  Repeated measures analysis of variance 
(114) and Bonferroni post hoc test were used to compare the dose responses of different agonists 
and the differences were considered statistically significant if p < 0.05 .  In addition, each 
concentration-response curve was also compared across treatment groups using a regression 
analysis by examining the best-fit values (114).  EC50 values for concentration responses in 
myographic studies were determined using the Hill equation.  A two tailed t test was used 
compare mean EC50, umbilical vein stress generation, fetal/placental weight and cytokine 
expression levels between different treatment and control groups. 
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5.3. Results 
5.3.1.  Characterization of MWCNT suspensions  
The MWCNT suspension in 10% surfactant in saline [(S)-MWCNTs] has been previously 
characterized by Wang et al in 2011 (224).  Briefly, MWCNTs in the dry powder form was < 2 
µm in length and the diameter had a bimodal distribution with two peaks at 12.5 and 25 nm.  The 
zeta potential of the particles in (S)-MWCNTs suspension was -57.3 mV with a mean 
hydrodynamic size of 915 nm.  MWCNTs suspended in the DPPC, serum albumin and sterile 
phosphate buffered saline medium [(D)-MWCNTs] was characterized previously by Wang et al 
in 2013 (225).  The zeta potential of the particles in suspension was - 20.8 mV with a mean 
hydrodynamic size of 793 nm. 
 
5.3.2. Maternal serum cytokine analysis 
The mean values of the serum cytokine levels of pregnant and non-pregnant rats 24 hours 
following exposure to MWCNTs or dispersion media for each route of exposure are reported in 
Table 5.1.  IL1β level was increased by five fold in the pregnant group (when compared the 
naive) following IV DPPC/RSA.  TNF levels were increased more than six fold in the serum 
following exposure to both dispersion media (10% surfactant and DPPC/RSA) and also 
increased with IV (D)-MWCNT. 
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Table  5.1.  Cytokine levels in maternal serum 24 hours post-exposure to MWCNTs 
The mean and the SEM are reported for serum cytokines of pregnant and non-pregnant female 
Sprague Dawley rats (n = 5 - 8). 
Cytoki
-ne 
 
NP-
naive 
NP-IT 
10% 
surfac-
tant 
NP- IT 
(S)-
MWCNTs 
P-naive 
P-IT 
10% 
surfac-
tant 
P-IT 
(S)-
MWCNTs 
P-IV 
DPPC/ 
RSA 
P-IV 
(D)-
MWCNTs 
IL 1β 
(pg/ml) 
56.0 ± 
38.5 
10.1 ± 3.8 7.3 ± 5.4 
14.6 ± 
7.1 
42.1 ± 7.1 15.8 ± 5.7* 
70.2 ± 
17.3
#
 
45.0 ± 12.5 
IL 6 
(pg/ml) 
1245.0 
± 826.0 
640.0 ± 
208.2 
485.0 ± 
209.0 
77.9 ± 
72.8 
215.3 ± 
62.6 
183.0 ± 
128.8 
126.8 ± 
92.1 
229.4 ± 
115.5 
IL 10 
(pg/ml) 
21.7 ± 
9.0 
13.4 ± 4.8 10.2 ± 6.4 
5.8 ± 
3.7 
9.6 ± 4.4 7.3 ± 3.6 16.4 ± 6.0 9.8 ± 4.2 
INF γ 
(pg/ml) 
338.4 ± 
135.3 
189.6 ± 
33.6 
174.1 ± 
57.3 
198.5 ± 
50.5 
106.4 ± 
10.8 
131.0 ± 
36.8 
273.1 ± 
102.2 
242.0 ± 
50.1 
CCL2 
(pg/ml) 
823.2 ± 
223.9 
467.0 ± 
106.6 
540.2 ± 
248.9 
288.1 ± 
96.0 
492.9 ± 
27.0 
336.2 ± 
96.5 
510.6 ± 
54.8 
478.2 ± 
36.2 
VEGF 
(pg/ml) 
53.7 ± 
15.4 
30.1 ± 4.3 29.4 ± 7.5 
510.2 ± 
111.9 
377.4 ± 
81.1 
476.6 ± 
42.2 
421.8 ± 
63.0 
432.8 ± 
56.6 
TNF α 
(pg/ml) 
40.9 ± 
12.83 
30.3 ± 4.6 27.0 ± 8.9 
6.8 ± 
3.9 
45.3 ± 
10.2
#
 
23.9 ± 9.9 
43.7 ± 
13.3
#
 
34.1 ± 
10.4
#
 
 
IT: intratracheal instillation and IV: intravenous administration, 
P: pregnant and NP: non-pregnant, N/A: not available 
MWCNT: Multiwall carbon nanotube, 10% surfactant: 10 % surfactant in saline, (S)-
MWCNTs: MWCNT suspended in 10% surfactant, DPPC/RSA: vehicle used for IV MWCNT 
delivery and (D)-MWCNTs: MWCNT suspended in DPPC/RSA  
* indicates p < 0.05  when compared to the dispersion medium of each route , # indicates
 
p < 
0.05  when compared to naïve and indicates p < 0.05  when compared to same treatment in non 
– pregnant  
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5.3.3. Responses of arterial segments 24 hours post-exposure to intratracheal (IT) 
instillation of (S)-MWCNTs or 10% surfactant  
5.3.3.1. Main uterine artery 
The maximum stress generation was increased in response to phenylephrine by 2.6 mN/mm
2 
(37%) and to angiotensin II by 4.9 mN/mm
2 
(118%) in the main uterine artery segments 24 h 
following IT (S)-MWCNT exposure when compared to segments from naïve pregnant animals 
(Figure 5.1.A and B).  In contrast, the stress generation in response to all 3 agonists was 
diminished in uterine artery segments from non-pregnant animals following (S)-MWCNTs 
exposure (Fig 5.1.B, D and F).  The relaxation responses to acetylcholine during 30 µM 
phenylephrine pre-contraction were not different in naive, 10% surfactant and (S)-MWCNTs 
exposed pregnant groups (Figure 5.1.G), but was diminished ~ 10% following (S)-MWCNTs 
exposure in the non-pregnant group (Fig 5.1.H).  The calculated EC50 values for phenylephrine, 
angiotensin II, endothelin 1, acetylcholine and HA1077 were not different between the naive, 
10% surfactant  and (S)-MWCNTs treatment groups .  The exception was for endothelin 1, 
following (S)-MWCNTs exposure in pregnant rats, as its calculated EC50 value was significantly 
lower than the naive values (Table 5.2). 
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Figure 5.1. Changes in the contractile responses of the main uterine artery following IT 
exposure to MWCNTs 
The changes in the contractile response as assessed by wire myography of the main uterine artery 
24 hours following intratracheal instillation of (S)-MWCNT or 10% surfactant from 17 - 19 days 
pregnant (A, C, E and G) and non-pregnant female (B, D, F and H) Sprague Dawley rats.  The 
stress generation in response to cumulative concentrations of phenylephrine (PE; A and B), 
angiotensin II (ANG II; C and D) and endothelin 1 (ET-1; E and F) are plotted.  The percentage 
relaxation from a 30 µM phenylephrine pre-stimulation stress level in response to cumulative 
concentrations of acetylcholine (Ach; G and H) is graphed.  * indicates p < 0.05  compared to 
10% surfactant while 
#
 indicates p < 0.05  compared to naïve using repeated measures ANOVA 
(n = 5 - 7).  The p values were derived following the comparison of each concentration response 
curve across treatment groups using a regression analysis by examining the best-fit values. 
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Table 5.2.   Mean calculated EC50 values of cumulative concentration responses of the 
main uterine artery  
EC50 values were calculated using the Hill equation on cumulative concentration response curves 
(n = 4 - 10). 
Agonist 
P/
NP 
EC50 (mean ± SEM) 
P-naive 
P-IT 
10% 
surfactant 
P-IT 
(S)-
MWCNTs 
P-IV 
DPPC/RSA 
P-IV 
(D)-
MWCNTs 
PE (µM) 
P 0.3 ± 0.1 0.5 ± 0.1 0.7 ± 0.2 0.5 ± 0.1 0.4 ± 0.1 
NP 1.1 ± 0.2 0.6 ± 0.03 0.6 ± 0.03 N/A N/A 
ET-1 (nM) 
P 3.4 ± 0.6 2.2 ± 1.0 1.1 ± 0.3
#
 3.0 ± 0.8 2.1 ± 0.7 
NP 40.8 ± 13.6 8.9 ± 3.8 8.5 ± 4.0 N/A N/A 
ANG II 
(nM) 
P 2.5 ± 0.8 1.7 ± 0.4 2.3 ± 0.4 2.3 ± 0.4 1.8 ± 0.5 
NP 1.6 ± 0.3 2.9 ± 1.1 2.6 ± 0.9 N/A N/A 
Ach (µM) 
P 0.3 ± 0.05 0.5 ± 0.2 0.4 ± 0.08 0.7 ± 0.2 0.4 ± 0.04 
NP 0.7 ± 0.4 0.5 ± 0.3 0.6 ± 0.2 N/A N/A 
HA (µM) 
P 1.2 ± 0.2 0.8 ± 0.3 1.2 ± 0.3 0.6 ± 0.1 1.1 ± 0.2 
NP 1.1 ± 0.3 2.1 ± 0.3 1.7 ± 0.2 N/A N/A 
 
IT: intratracheal instillation and IV: intravenous administration 
P: pregnant and NP: non-pregnant, N/A: not available 
PE: phenylephrine, ET-1: endothelin 1, ANG II: angiotensin II, Ach: acetylcholine and HA: 
HA1077 Rho kinase inhibitor 
MWCNT: Multiwall carbon nanotube, 10% surfactant: 10 % surfactant in saline, (S)-
MWCNTs: MWCNT suspended in 10% surfactant, DPPC/RSA: vehicle used for IV MWCNT 
delivery and (D)-MWCNTs: MWCNT suspended in DPPC/RSA  
#
 
indicates p < 0.05  compared to naïve using a two tailed t test. 
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5.3.3.2. First order mesenteric artery 
The stress generations in response to serotonin in the first order mesenteric artery segments from 
both pregnant and non-pregnant rats were increased by ~ 4 mN/mm
2
 following IT (S)-MWCNTs 
exposure compared to 10% surfactant exposed group (Figure 5.2.E and F).  The contractile 
responses to phenylephrine and endothelin 1 and the relaxation response to acetylcholine were 
not changed following IT (S)-MWCNT exposure in the pregnant group (Figure 5.2.A, C and G).  
The EC50 for endothelin 1 mediated responses was decreased in the 10% surfactant group when 
compared to both naïve and (S)-MWCNTs exposed group (Table 5.3).  The contractile responses 
to all 3 agonists were diminished in the non-pregnant rats exposed to 10% surfactant (Figure 
5.2.B, D and F), along with an impairment of acetylcholine dependent relaxation response 
(Figure 5.2.H).  Similar to the reported uterine vessels responses, the EC50 values of the 
mesenteric arteries were not different except for endothelin 1 following (S)-MWCNT exposure 
(Table 5.3). 
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Figure 5.2.  Changes in the contractile responses of the mesenteric artery following IT 
exposure to MWCNTs 
The changes in the contractile responses were assessed by wire myography of the first order 
mesenteric artery 24 hours following intratracheal instillation (IT) of (S)-MWCNTs or 10% 
surfactant from 17 - 19 days pregnant (A, C, E and G) and non-pregnant female (B, D, F and H) 
Sprague Dawley rats.  The stress generation in response to cumulative concentrations of 
phenylephrine (PE; A and B), endothelin 1 (ET-1; C and D) and serotonin (5HT; E and F) are 
plotted.  The percentage relaxation from a 30 µM phenylephrine pre-stimulation stress level in 
response to cumulative concentrations of acetylcholine (Ach; G and H) is graphed.   * indicates 
p < 0.05  compared to 10% surfactant while 
#
 indicates p < 0.05  compared to naïve using 
repeated measures ANOVA (n = 4 - 7).  The p values were derived following the comparison of 
each concentration response curve across treatment groups using a regression analysis by 
examining the best-fit values. 
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Table 5.3.  Mean calculated EC50 values of cumulative concentration responses of the 
first order mesenteric artery  
EC50 values were calculated using the Hill equation on cumulative concentration response curves 
(n = 4 - 10).  
Agonist 
P/
NP 
EC50 (mean ± SEM) 
P-naive 
P-IT 
10% 
surfactant 
P-IT 
(S)-
MWCNTs 
P-IV 
DPPC/RSA 
P-IV 
(D)-
MWCNTs 
PE (µM) 
P 1.6 ± 0.3 2.1 ± 0.2 1.7 ± 0.2 2.7 ± 0.7 2.8 ± 0.5 
NP 1.00 ± 0.2 0.7 ± 0.2 0.8 ± 0.2 N/A N/A 
ET-1 
(nM) 
P 5.4 ± 1.3 1.4 ± 0.4
#
 5.0 ± 1.0* 2.2 ± 0.8 2.8 ± 0.7 
NP 30.0 ± 13.2 4.5 ± 1.8 6.1 ± 1.9 N/A N/A 
5HT 
(µM) 
P 0.4 ± 0.05 0.4 ± 0.1 1.2 ± 0.8 0.4 ± 0.05 0.3 ± 0.04 
NP 0.3 ± 0.02 0.2 ± 0.03 0.3 ± 0.1 N/A N/A 
Ach (µM) 
P 0.04 ± 0.01 0.03 ± 0.01 0.3 ± 0.26 0.07 ± 0.03 0.04 ± 0.04 
NP 0.06 ± 0.03 0.2 ± 0.1 0.08 ± 0.02 N/A N/A 
HA (µM) 
P 1.4 ± 0.3 0.4 ± 0.2 0.7 ± 0.2 0.9 ± 0.1 1.4 ± 0.3 
NP 1.0 ± 0.4 1.4 ± 0.2 2.2 ± 0.5 N/A N/A 
 
IT: intratracheal instillation and IV: intravenous administration 
P: pregnant and NP: non-pregnant, N/A: not available 
PE: phenylephrine, ET-1: endothelin 1, Ach: acetylcholine, 5HT: serotonin and HA: HA1077 
Rho kinase inhibitor 
MWCNT: Multiwall carbon nanotube, 10% surfactant: 10 % surfactant in saline, (S)-
MWCNTs: MWCNT suspended in 10% surfactant, DPPC/RSA: vehicle used for IV MWCNT 
delivery and (D)-MWCNTs: MWCNT suspended in DPPC/RSA  
* indicates p < 0.05  compared to vehicle while #
 
indicates p < 0.05  compared to naïve using a 
two tailed t test. 
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5.3.3.3. Thoracic aorta 
The contractile response to phenylephrine (0.001 – 10 µM) was reduced 0.68 mN/mm2 (25.4%) 
following (S)-MWCNT exposure in the thoracic aortic segments during pregnancy (Figure 
5.3.A).  The contractile response to endothelin 1 was increased in both (S)-MWCNTs and 10% 
surfactant exposed segments with a relaxation response to endothelin 1 at the highest 
concentration in the (S)-MWCNT exposed pregnant group (Figure 5.3.C).  The contractile 
responses to phenylephrine and endothelin 1 were not affected by (S)-MWCNT or 10% 
surfactant exposure in the non-pregnant female rats (Figure 5.3.B and D).  The acetylcholine 
(0.001 – 10 µM) mediated relaxation response was not different in the pregnant group (Figure 
5.3.E), but was increased in both (S)-MWCNTs and 10% surfactant exposed non-pregnant aortic 
segments when compared to the naïve (Figure 5.3.F).  The EC50 values were not different for the 
contractile and relaxation responses following (S)-MWCNT exposure (Table 5.4). 
 
Figure 5.3. Changes in the contractile responses of the thoracic aorta following IT 
exposure to MWCNTs 
The changes in the contractile responses were assessed by wire myography of the thoracic aorta 
24 hours following intratracheal instillation of (S)-MWCNT or 10% surfactant  from 17 - 19 
days pregnant (A, C and E) and non-pregnant female (B, D and F) Sprague Dawley rats.  The 
stress generation in response to cumulative concentrations of phenylephrine (PE; A and B) and 
endothelin 1 (ET-1; C and D) are plotted.  The percentage relaxation from a 10 µM 
phenylephrine pre-stimulation stress level in response to cumulative concentrations of 
acetylcholine (Ach; E and F) is graphed.  * indicates p < 0.05  compared to 10% surfactant while 
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#
 indicates p < 0.05  compared to naïve using repeated measures ANOVA (n = 4 - 8).  The p 
values were derived following the comparison of each concentration response curve across 
treatment groups using a regression analysis by examining the best-fit values. 
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Table 5.4. Mean calculated EC50 values of cumulative concentration responses of the 
thoracic aorta  
EC50 values were calculated using the Hill equation on cumulative concentration response curves 
(n = 4 - 10).  
Agonist 
P/
NP 
EC50  (mean± SEM) 
P-naive 
P-IT 
10% 
surfactant 
P-IT 
(S)-
MWCNTs 
P-IV 
DPPC/RSA 
P-IV 
(D)-
MWCNTs 
PE (µM) 
P 0.1 ± 0.02 0.2 ± 0.04 0.2 ± 0.06 0.1 ± 0.03 0.1 ± 0.02 
NP 0.07 ± 0.02 0.1 ± 0.02 0.1 ± 0.02 N/A N/A 
ET 1 
(nM) 
P 71.9 ± 17.8 13.8 ± 2.9 25.9 ± 14.7 12.4 ± 5.1
#
 13.3 ± 5.1
#
 
NP 12.8 ± 4.6 18.0 ± 4.8 15.5 ± 2.7 N/A N/A 
Ach 
(µM) 
P 0.06 ± 0.01 0.1 ± 0.02 0.1 ± 0.05 0.1 ± 0.02 0.1 ± 0.04 
NP 0.1 ± 0.03 0.04 ± 0.01 0.06 ± 0.02 N/A N/A 
HA (µM) 
P 2.1 ± 0.4 2.0 ± 0.3 1.9 ± 0.4 1.8 ± 0.3 2.6 ± 0.2* 
NP 2.4 ± 0.5 1.8 ± 0.2 1.7 ± 0.1 N/A N/A 
 
IT: intratracheal instillation and IV: intravenous administration, 
P: pregnant and NP: non-pregnant, N/A: not available 
PE: phenylephrine, ET-1: endothelin 1, Ach: acetylcholine and HA: HA1077 Rho kinase 
inhibitor 
MWCNT: Multiwall carbon nanotube, 10% surfactant: 10 % surfactant in saline, (S)-
MWCNTs: MWCNT suspended in 10% surfactant, DPPC/RSA: vehicle used for IV MWCNT 
delivery and (D)-MWCNTs: MWCNT suspended in DPPC/RSA  
* indicates p < 0.05  compared to vehicle while #
 
indicates p < 0.05  compared to naïve using a 
two tailed t test.
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5.3.4. Responses of arterial segments 24 hours post-exposure to intravenous (IV) 
administration (D)-MWCNTs or DPPC/RSA  
Twenty four hours following IV administration (D)-MWCNTs or DPPC/RSA in pregnant rats, 
there was an increase in the stress generation in the uterine artery segments in response to 
phenylephrine, endothelin 1 and angiotensin II stimulation when compared to naïve vessel 
segments (Figure 5.4.A ,B and C) where both administrations increased the stress generation to a 
similar magnitude (3 - 4 mN/mm
2
) and with a similar concentration response profile.  The 
relaxation responses of the main uterine artery to acetylcholine were not changed by IV (D)-
MWCNT exposure (Figure 5.4.D). 
 
An increase in contractile response in the mesenteric artery segments was seen at higher doses of 
phenylephrine following (D)-MWCNT exposure (Figure 5.5.A). All other contractile/relaxation 
responses of the mesenteric artery and aortic segments were not significantly different between 
the (D)-MWCNTs or DPPC/RSA exposure groups (Figure 5.5.B - D and Figure 5.6.A - C).  The 
EC50 values for all responses are reported in Tables 5.2 - 5.4 and were not different with the 
exception for endothelin 1 in the thoracic aortic segments following (D)-MWCNTs or 
DPPC/RSA exposure (Table 5.4). 
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Figure 5.4. Changes in the contractile responses of the main uterine artery following IV 
exposure to MWCNTs  
The changes in the contractile responses were assessed by wire myography of the main uterine 
artery segments 24 hours following intravenous administration of (D)-MWCNT or DPPC/RSA 
from 17 - 19 days pregnant (A, B, C and D) Sprague Dawley rats.  The stress generation in 
response to cumulative concentrations of phenylephrine (PE; A), angiotensin II (ANG II; B) and 
endothelin 1 (ET-1; C) are plotted.  The percentage relaxation from a 30 µM phenylephrine pre-
stimulation stress level in response to cumulative concentrations of acetylcholine is graphed 
(Ach; D).  
#
 indicates p < 0.05  compared to naïve using repeated measures ANOVA (n = 5 - 8).  
The p values were derived following the comparison of each concentration response curve across 
treatment groups using a regression analysis by examining the best-fit values. 
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Figure 5.5. Changes in the contractile responses of the mesenteric artery following IV 
exposure to MWCNTs 
The changes in the contractile responses were assessed by wire myography of the first order 
mesenteric artery segments 24 hours following intravenous administration of (D)-MWCNT or 
DPPC/RSA from 17 - 19 days pregnant (A, B, C  and D) Sprague Dawley rats.  The stress 
generation in response to cumulative concentrations of phenylephrine (PE; A), endothelin 1 (ET-
1; B) and serotonin (5HT; C) are plotted.  The percentage relaxation from a 30 µM 
phenylephrine pre-stimulation stress level in response to cumulative concentrations of 
acetylcholine (Ach: D) is graphed.  
#
 indicates p < 0.05  compared to naïve using repeated 
measures ANOVA (n = 4 - 7).  The p values were derived following the comparison of each 
concentration response curve across treatment groups using a regression analysis by examining 
the best-fit values. 
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Figure 5.6. Changes in the contractile responses of the thoracic aorta following IV 
exposure to MWCNTs  
The changes in the contractile responses were assessed by wire myography of the thoracic aortic 
segments 24 hours following intravenous administration (D)-MWCNT or DPPC/RSA from 17 - 
19 days pregnant (A, B and C) Sprague Dawley rats.  The stress generation in response to 
cumulative concentrations of phenylephrine (PE; A) and endothelin 1 (ET-1; B) are plotted.  The 
percentage relaxation from a 10 µM phenylephrine pre-stimulation stress level in response to 
cumulative concentrations of acetylcholine 1 (Ach; C) is graphed.  The p values were derived 
following the comparison of each concentration response curve across treatment groups using a 
regression analysis by examining the best-fit values (n = 4 - 8). 
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5.3.5. Contribution of Rho-kinase activity on the vascular tissue contractility following  
exposure to MWCNTs 
Minor differences were observed in the relaxation responses to cumulative concentrations of 
Rho-kinase (ROCK) inhibitor HA1077 during the stable phenylephrine pre-contraction for 
segments from all three vascular beds, regardless of pregnancy state or route of exposure to the 
MWCNT (Figure 5.7 and 5.8)  The EC50 values for the concentration responses are reported in 
Tables 5.2 - 5.4 and were not significantly different following MWCNT exposure except within 
the IV (D)-MWCNT exposure group during pregnancy. 
 
Figure 5.7. Changes in stress generation in the presence of a Rho-kinase inhibitor 
following IT exposure to MWCNTs  
The reduction in stress generation is reported as the percentage relaxation from a phenylephrine 
(30 µM for uterine/mesenteric arteries and 10 µM for aorta) pre-stimulation stress level in 
response to cumulative additions of a Rho kinase inhibitor (HA1077).  All responses were 
assessed by wire myography 24 hours following intratracheal instillation of (S)-MWCNT or 10% 
surfactant from 17 - 19 days pregnant (A, C and E) and non-pregnant female (B, D and F) 
Sprague Dawley rats. Panels A and B: main uterine artery; C and D: first order mesenteric 
artery; E and F: thoracic aorta.   
#
 indicates p < 0.05  compared to naïve using repeated measures 
ANOVA (n = 4 - 6).  The p values were derived following the comparison of each concentration 
response curve across treatment groups using a regression analysis by examining the best-fit 
values. 
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Figure 5.8.  Changes in stress generation in the presence of a Rho-kinase inhibitor 
following IV exposure to MWCNTs  
The reduction in stress generation is reported as the percentage relaxation from a phenylephrine 
(30 µM for uterine/mesenteric arteries and 10 µM for aorta) pre-stimulation stress level in 
response to cumulative additions of a Rho kinase inhibitor (HA1077).  All responses were 
assessed by wire myography 24 hours following intravenous administration of (D)-MWCNT or 
DPPC/RSA from 17 - 19 days pregnant Sprague Dawley rats.  Panel A: main uterine artery; B: 
first order mesenteric artery; C: thoracic aorta.  * indicates p < 0.05  compared to vehicle while # 
indicates p < 0.05  compared to naïve using repeated measures ANOVA (n = 4 - 6).  The p 
values were derived following the comparison of each concentration response curve across 
treatment groups using a regression analysis by examining the best-fit values. 
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5.3.6. Changes in the fetal components following MWCNT exposure 
5.3.6.1. Changes in umbilical vein contractility  
The reactivity of the umbilical vein (vessel from the placenta to the fetus) was assessed 
following both IT and IV administration.  Stress generation during K
+
PSS and 1 µM of 
thromboxane mimetic (U46619) stimulations were not significantly different in umbilical vessel 
segments between MWCNT exposed and naïve animals (Figure 5.9.A - D).  The umbilical vein 
segments did not respond to acetylcholine and the relaxation response to 1 µM SNP with a stable 
U46619 pre-contraction was not different following MWCNT exposure (Figure 5.9.E and F). 
 
Figure 5.9.  Changes in contractile responses of the umbilical vein following maternal 
exposure to MWCNTs 
The changes stress generation in the umbilical vein segments were assessed by wire myography 
in response to 109 mM K
+
 depolarization (A and B) and 1 µM thromboxane agonist (U46619, B 
and D) 24 hours post- exposure to intratracheal instillation (IT) of (S)-MWCNT or 10% 
surfactant (A and C) or intravenous administration (IV) of (D)-MWCNT or DPPC/RSA (B and 
D) from 17 - 19 days pregnant Sprague Dawley rats (n = 12).  The percentage relaxation in 
response to sodium nitroprusside (SNP) following U46619 (1 µM) pre-contraction in the 
umbilical vein 24 hours post- exposure to intratracheal instillation of (S)-MWCNT or 10% 
surfactant (E) or intravenous administration of (D)-MWCNT or DPPC/RSA is graphed ( F) (n = 
12). 
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5.3.6.2. Changes in fetal and placental weight 
Mean weights of pregnant dams at the time of sacrifice were not significantly different between 
treatment groups (mean ± SEM): (S)-MWCNTs 298.2 ± 12.0 g (n = 6), 10% surfactant 291.0 ± 
10.8 g (n = 6), (D)-MWCNTs 305.8 ± 7.8 g (n = 6), DPPC/RSA 333.4 ± 24.9 g (n = 6), and 
naïve 287.2 ± 10.9 g (n = 10).  The mean and range of litter size were also not different between 
the exposure groups: (S)-MWCNTs 10.7 (8-13), 10% surfactant 10.5 (10-11), (D)-MWCNTs 9.8 
(9-11), DPPC/RSA 10.5 (9-12) and naïve 10.6 (8 -13).  Mean weights of the fetuses are reported 
in Figure 5.10.A and B, after re-grouping them according to gestational day (GD).  The mean 
fetal weight was reduced following MWCNT exposure by both routes and was evident across all 
gestational days studied following intravenous exposure.  Gross external morphological 
abnormalities were not seen in the fetuses.  An increase in the mean placental weight was 
observed following MWCNT exposure by both routes (Fig 5.10.C and D). 
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Figure 5.10. Changes in the fetal and placental weight following exposure to MWCNT  
Changes in fetal (A and B) and placental ( C and D) weight 24 hours post-exposure to 
intratracheal instillation (IT) of (S)-MWCNT or 10% surfactant (A and C) or intravenous 
administration (IV) of (D)-MWCNT or DPPC/RSA ( B and D) in 17 - 19 days pregnant Sprague 
Dawley rats.  * indicates p < 0.05  when compared using a two tailed t test (n = 6 - 15). 
GD = day of gestation
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5.3.6.3. Fetal serum cytokine analysis 
The cytokines levels in the fetal serum were not significantly changed following exposure to 
MWCNT or dispersion media by either route of administration and are reported in Table 5.5. 
 
Table 5.5.  Cytokine levels in fetal serum 24 hours post-exposure to MWCNTs 
The mean and the SEM are reported for serum cytokines from fetuses from 17-19 days pregnant 
Sprague Dawley rats (n = 4 - 6). 
 
IT: intratracheal instillation and IV: intravenous administration, 
MWCNT: Multiwall carbon nanotube, 10% surfactant: 10 % surfactant in saline, (S)-
MWCNTs: MWCNTs suspended in 10% surfactant, DPPC/RSA: vehicle used for IV MWCNT 
delivery and (D)-MWCNTs: MWCNT suspended in DPPC/RSA  
# 
indicates p < 0.05 when compared to naïve  
  
Cytokin
e  
naive 
IT 
10% 
surfactant 
IT  
(S)-MWCNTs 
IV  
DPPC/RSA 
IV  
(D)-MWCNTs 
IL 1β 
(pg/ml) 
1455.0 ± 
372.5 
1597.0 ±310.3 1657.0 ± 699.4 1932.0 ± 861.7 1500.0 ± 375.9 
IL 6 
(pg/ml)  
75.7 ±16.8 277.0 ± 78.5 
#
 64.9 ± 55.4 120.4 ± 86.5 58.7 ± 55.9 
IL 10 
(pg/ml) 
70.0 ± 17.0 76.0 ± 13.5 49.7 ± 6.1 117.2 ± 56.9 66.8 ± 12.2 
INF γ 
(pg/ml) 
283.3 ± 42.5 324.5 ± 96.4 278.7 ± 30.6 405.8 ± 139.0 355.9 ± 139.0 
CCL2 
(pg/ml) 
903.4 ± 
310.8 
986.7 ± 137.7 836.6 ± 60.3 991.2 ± 184.6 813.2 ± 113.3 
VEGF 
(pg/ml) 
469.5 ± 83.0 483.8 ± 59.3 457.2 ± 52.2 620.2 ± 127.5 512.1 ± 47.0 
TNF α 
(pg/ml) 
5.9 ± 5.9 3.3 ± 3.3 11.5 ± 5.9 6.7 ± 4.2 3.1 ± 2.3 
 139 
 
5.4. Discussion 
Twenty-four hours following intratracheal instillation of 100 µg/kg of (S)-MWCNTs, we 
observed an increase in the contractile responses of the main uterine artery along with a 
reduction in the fetal weight gain.  Minimal changes in the contractile responses were seen in the 
vessel segments from the other vascular beds studied.  These increased contractile responses 
were not associated with comparable changes in relaxation responses with Rho kinase inhibition, 
suggesting that other mechanisms besides Rho-Rho kinase may be underlying these functional 
alterations.  To our knowledge, this is the first attempt to identify changes in the contractile 
responses of vascular tissue following exposure to MWCNTs during pregnancy.  It is also one of 
the few attempts to investigate the contribution of the dispersion medium to changes in the 
contractile responses of blood vessels in naïve pregnant and non-pregnant rats. 
 
The reported zeta potentials of (S)-MWCNTs and (D)-MWCNTs suggest that both suspensions 
have a relatively good stability with minor agglomerate formation.  The minor differences in the 
hydrodynamic size and zeta potential in different suspensions may not contribute significantly to 
modify the regulation of vessel behavior via MWCNT exposure by different routes. 
 
The changes in the maternal serum cytokine levels reported in our study does not indicate any 
preferential shift towards a Th1 or Th2 type of immune response as IFNγ (Th1), IL6 and IL10 
(Th2) levels are not affected following exposure to MWCNTs by either route of administration.  
The increase in TNFα levels appears to be robustly influenced by both dispersant media (10% 
surfactant and DPPC/RSA) rather than MWCNTs and may potentially induce a Th1 type 
response, which is detrimental during pregnancy (36).  This conclusion is also supported by the 
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reduction in fetal weight seen with both (D)-MWCNTs and DPPC/RSA.  An increase in IL1β 
level is seen with both 10% surfactant and DPPC/RSA suggesting an immunological response to 
both dispersion media, which is down-regulated by the addition of MWCNTs.  Previous studies 
have reported both type Th1 and Th2 type immune responses following acute exposure to 
MWCNTs with increased levels of TNFα, IL1β, IL6, IL10, and MCP1 (33, 38) early after 
exposure and reported to wane over time (39), supporting the low levels we measured at 24 
hours post-exposure. 
 
When trying to understand the MWCNT induced changes, it is important to recognize that 10% 
surfactant used as a vehicle for suspending the MWCNTs also induces a notable increase in 
stress generation in response to agonist stimulation compared the constrictive responses from 
naïve animal group.  The main uterine artery segments from pregnant rats demonstrated a clear 
shift towards the naïve non-pregnant phenotype in response to phenylephrine and angiotensin II 
following IT exposure to (S)-MWCNTs.  We suggest that (S)-MWCNTs may have a combined 
effect of both MWCNTs and surfactant.  However, synthetic lung surfactant based suspensions 
are well established for studying pulmonary exposure effects of MWCNTs (170) and we chose to 
use the same for our study and were surprised to see such a vascular response.  Responses seen 
with intravenous exposure to MWCNTs may also be due to the properties of the dispersant 
medium rather than due to nanotubes.  The dispersant medium is known to affect the cellular 
uptake of the nanoparticles (71) and hence can affect the overall cellular function.  We did not 
proceed to do non-pregnant comparisons in this exposure group as the differences in the 
contractile responses were attributed to DPPC/RSA suspension and not to IV MWCNT 
exposure.  Both of these dispersant media (i.e. 10% surfactant and DPPC/RSA) can contribute to 
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the composition of protein or lipid corona associated with the nanoparticles in the biological 
systems (115, 116, 226).  Most of the effects we see as nanoparticle mediated effects can be 
induced by components of this protein corona, which are determined by the medium of 
dispersion, and the membranes they pass through prior to reaching the pulmonary tissues, 
vascular endothelium or smooth muscle cells. 
 
Considering the contractile responses of the main uterine artery, overall stress generation in 
segments from the naïve pregnant rats was lower compared to the response from naive non- 
pregnant rats, which is in line with the normal vasodilatory response associated with pregnancy 
(149, 153).  The calculated EC50 values for endothelin 1 were changed in segments from all three 
vessels studied, suggesting an altered sensitivity to endothelin 1 or changes in endothelin 
receptor distribution with pregnancy.  In contrast to the non-pregnant group, a significant 
increase in the contractile responses was evident only with the pregnant uterine artery segments, 
following (S)-MWCNT exposure.  These observations suggest that pregnancy may render the 
uterine vasculature more susceptible to MWCNT exposure induced changes in contractility.  The 
differences seen in permeability to nanoparticles, cytokines and differential inflammatory 
expression during these two life stages may be contributing to how MWCNT exposure may alter 
the physiology.   
 
Compared to the uterine vasculature, the overall stress generation of mesenteric artery and 
thoracic aortic segments in response to contractile stimulation were not significantly different 
between naïve pregnant and non-pregnant animals.  This relationship was not altered following 
MWCNT exposure by either route.  The only difference in responses was observed at higher 
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concentration of serotonin in the mesenteric artery, where we observed a higher stress 
generation/lower relaxation response following (S)-MWCNT exposure.  We interpret this to be 
related to the limited extent of remodeling that occurs in the mesenteric artery and thoracic aorta 
with pregnancy and renders them less vulnerable to MWCNT induced changes compared to the 
uterine artery.   
 
The alterations in the contractile responses observed in this study are in the same direction as for 
the potentiation of stress generation in these the vasculature associated with a variety of disease 
or pathological conditions and have been linked to elements of the calcium sensitization process 
of contraction regulation by the Rho-Rho-kinase pathway (7, 32, 174).  As reported in figures 5.7 
and 5.8, there were small differences in the sensitivity to Rho kinase inhibition in all three 
vascular beds following exposure to MWCNTs or dispersion media by either route of exposure.  
However, a distinct pattern of differences in Rho kinase activity that would be compatible with 
the observed changes in the contractile responses was not evident with MWCNT exposure, 
suggesting that the rho kinase activity was not a mechanism to augment the stress generation 
observed.  Other mechanisms postulated to enhance force generation include generation of 
reactive oxygen species (155), increased oxidative stress (189) and enhanced cyclooxygenase 
signaling (175), which may all be contributing to our observed augmentation of stress generation 
in the vascular segments studied.  SWCNTs have shown to increase oxidative stress and alter the 
mitochondrial signaling following intrapharyngeal instillation (109).  MWCNTs, which have a 
similar subunit structure, may also affect the cardiovascular functions by comparable 
mechanisms but have yet to be fully investigated.  Previous in vitro studies including proteomics 
analysis have shown that cellular functions and pathways comprising generalized gene 
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transcription and protein translation are affected by direct exposure to MWCNTs (70, 221).  
Alternatively, the changes in the vascular system may be mediated through the production and 
release to the circulation the pro-inflammatory cytokines such as IL6 and IL8  bronchial 
epithelial cells (79).  MWCNTs can also translocate following pulmonary exposure via 
instillation and reach the extra-pulmonary sites (3, 167) including the vasculature leading to a 
local inflammatory response.  Our in vitro studies done with human aortic endothelial cells 
indicate increased expression of endothelial inflammatory markers following exposure to (S)-
MWCNTs (221) (discussed in chapter 6)  and may support such a mechanism for cytokine 
production from one cell type which can influence other vascular tissues  
 
Intratracheal instillation has been suggested to deliver less well dispersed MWCNTs to the lung 
epithelium and has less adverse effects when compared to short term inhalational exposure (130, 
187).  On the other hand, instillation exposes the animal to an acute, higher concentration of 
nanoparticles compared to inhalational exposure over a long period (130).  If this phenomenon 
holds true for our model, then the observations from this study might be in line with the outcome 
of long-term inhalational exposure such as in an occupational/research environment.  Exposure 
levels have been identified in laboratory and industrial facilities (208) handling MWCNTs.  
Current proposed guidelines by the National Institute for Occupational Safety and Health 
(NIOSH) limits nanotube exposure to 7 μg/m3 (1) and  a human occupational exposure of 5 
mg/m
3 
during a 8-hour day and 40-hour work week equate to approximately 20 μg of SWCNT 
aspiration in a mouse model (188).  Considering these guidelines and compared to other 
inhalational/instillation studies (27), 100 µg/kg dose used in the current study is a relatively 
lower dose.  Dose response studies for higher doses of exposure during pregnancy are required 
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before applying these findings for nanomedical or toxicological purposes.  Previous studies with 
inhalational exposure to MWCNTs for 24 – 168 hours have identified a maximal impairment of 
endothelium dependent relaxation in coronary arterioles at 24 hours (198).  Therefore, the 24-
hour post-exposure time point in this study should be also able to identify changes in the 
contractile responses in extra-pulmonary vascular beds.  Even during intravenous exposure 
MWCNTs redistribute mainly to the lung and liver tissues (228) as pulmonary and hepatic 
circulations may be functioning as a filters during the first pass metabolism.  The pulmonary 
reactions to MWCNT deposition in such circumstances may be initiating the inflammatory 
reactions (162, 169) contributing to changes in the contractile responses. 
 
Considering the responses of the fetal side, neither MWCNTs nor dispersion medium induced 
significant changes in umbilical vein segments, suggesting that these exposures may only be 
affecting the maternal side of the circulation.  However, effects were seen in the mean fetal 
weight following MWCNT exposure via both routes.  The IV exposure to (D)-MWCNTs 
appeared to be more effective at reducing the fetal growth as a reduction in weight was observed 
as early as GD 17 while it was only seen on GD 19 following IT exposure to (S)-MWCNTs.  The 
placental transfer of the nanoparticles is affected by multiple factors including the particle size, 
dispersion medium and the stage of the pregnancy (99) which could contribute to effects on fetal 
growth.  The inflammatory responses of either maternal or fetal tissue to the MWCNTs could 
influence fatal weight gain.  These also support that the nanoparticles studied at this dose range 
and time point may not be crossing the placenta as compatible changes were not seen between in 
maternal and fetal cytokines.  The cytokines levels in the fetal serum were not changed following 
exposure to MWCNTs or dispersion media suggesting that the differences in the fetal weight 
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gain may be more a reflection of limited blood supply due to increased contraction observed in 
the uterine vascular segments.  
 
In summary, the observations in this study suggest that the increase in the vascular contractile 
responses following MWCNT exposure in the female Sprague Dawley rats are influenced by 
multiple factors including the life stage (pregnant or non-pregnant), route of exposure, medium 
of dispersion of  MWCNTs and the target vascular bed.  Multiple agonist-mediated responses are 
differentially affected as they mediate the contractile mechanism through different signaling 
cascades.  We probed the contribution of Rho kinase activity to account for these changes in 
constriction but were unable to find compatible changes in the sensitivity to Rho kinase 
inhibition and force augmentation suggesting that other mechanisms may be underlying these 
functional alterations.  Both IT and IV administration of MWCNTs can contribute to reduce the 
fetal growth, subjecting the dam to adverse pregnancy outcomes.  Further toxicological 
evaluations are needed to identify the time of exposure and dose dependent effects of MWCNT 
exposure during pregnancy.  
  
  
 
CHAPTER 6 
Carbon Nanoparticle Directed Gene and Protein Expression in Aortic Endothelial Cells 
Contributing to the Changes in Vascular Tissue Contractility 
Acknowledgments  
Reproduced in part from the following citation 
Multi-walled carbon nanotube directed gene and protein expression in cultured human aortic 
endothelial cells is influenced by suspension medium.  Vidanapathirana AK, Lai X, Hilderbrand 
SC, Pitzer JE, Podila R, Sumner SJ,  Fennell TR,  Wingard CJ, Witzmann FA, Brown JM, 
Toxicology. 2012; 302(2-3):114-22. Epub 2012/10/03 
 
6.1.   Introduction  
With advancement of nanotechnology, novel carbon based nanomaterials are being engineered 
and thereby expanding their use in various industries.  Biomedical applications of nanomaterials 
are equally advancing with the use of nanocatalysts, dendrimers and nanosensors for both 
therapeutic and diagnostic applications.  Following functionalization, carbon based  
nanoparticles including multiwalled carbon nanotubes (MWCNTs) and fullerenes (C60) are 
useful as tracers of sentinel lymph nodes (108) vascular grafts designs, antigen (15) and drug 
delivery tools by both passive and active targeting (129, 191, 193).  The unique physicochemical 
properties of the nanoparticles such as high electrical conductivity, large surface area to mass 
ratio, strength and functionalization potential make them versatile in many applications (40).  
These emerging trends in nanotechnology increase the environmental and occupational exposure 
to nanomaterials via inhalation and therapeutic exposure via intravenous administration, 
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resulting in potential health risks to various populations.  In order to use nanomaterials as a 
successful vehicle for drug, gene or antigen delivery, they should be compatible with the internal 
biological environment and act as inert substances.  As with any drug, the demarcation between 
therapeutic and toxic doses for nanoparticles and identification of the factors that potentiate 
toxicity is crucial in determining their pharmacological relevance.  
 
Due to their small size, nanomaterials merit attention for their effects on the cardiovascular 
system due to potential increases in their penetrability to different tissues and to sub-cellular 
locations.  Engineered nanoparticles can enter the systemic circulation through different routes.  
The main pathway that has been studied is pulmonary exposure and subsequent translocation out 
of the lung following exposure to both C60 and MWCNTs (3, 136).  This route of exposure is 
generally thought to result in relatively low concentrations of nanoparticles in the systemic 
circulation in contrast to those following intravenous administration (93, 109, 218).  In addition, 
nanoparticles are also known to translocate immediately to the lymphatic system as early as six 
hours following inhalational exposure (3).  Using intravenous nanomaterials for diagnostics or 
drug delivery could lead to higher concentrations in blood (101, 229).  Nanoparticle exposure via 
any of these routes imposes a risk to the vascular endothelium that serves as a critical interface 
between blood and tissue.  Any disruption in endothelial function or alteration in permeability 
can account for alterations in the overall functioning of the associated organ or tissue.  These 
alterations can also influence the contractile responses of the vascular smooth muscle cells 
resulting in changes in contractile responses, which could be underlying the changes reported in 
chapters 3-5. 
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There is increasing evidence for effects of the ‘protein corona’ that is associated with 
nanoparticles when they are applied to in vitro and in vivo systems.  The serum proteins that 
adhere to the surface of nanoparticles and form the protein corona affect the transport and 
metabolism of nanoparticles (115).  The dispersal state and associated functionalization of 
MWCNTs are known to correlate with intracellular distribution and pro-fibrotic changes of the 
murine lung (226).  Considering this evidence, the medium used for suspension becomes critical 
in designing nanomaterials for intravenous drug delivery.  It could also provide an explanation to 
the differential effects that we have observed in our in vivo and ex vivo studies with two routes of 
exposure using different suspensions of nanoparticles. 
 
We hypothesized that in vitro exposure of aortic endothelial cells to carbon based nanoparticles 
(C60 and MWCNTs) results in increased expression of inflammatory markers that is dependent 
upon the suspension media used to disperse the nanoparticles.  We have used several dispersion 
media to be compatible with the media used for different routes of exposure as described in 
Chapters 4 and 5.  We focused on a limited number of cell adhesion molecules and inflammatory 
cytokines associated with endothelial cell activation.  We also hypothesized that the exposure to 
these carbon based nanomaterials will increase RhoA and Rho-kinase (ROCK) proteins and 
reduce the expression of eNOS in the endothelial cells leading to enhanced vascular tissue 
contractility. 
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6.2. Material and Methods 
6.2.1. C60 suspensions and characterization 
C60 was commercially procured from Sigma-Aldrich (St. Louis MO, USA, Catalog# 379646 
and was formulated with polyvinylpyrorrolidone (PVP) (Sigma-Aldrich, St. Louis MO, USA; 
Catalog# 234257) at RTI International (Research Triangle Park, NC, USA).  The dried forms of 
these C60/PVP or PVP formulations were reconstituted with 0.9% saline (0.9% NaCl, B. Braun 
Medical Inc., CA, USA), just before in vitro delivery to a concentration of 0.14 mg/ml and was 
cup-horn sonicated for 2 min, at 65% amplitude for a total energy of 10,817 Joules using a 
Misonix ultrasonic liquid processor (Model 1510R-MTH, Branson Ultrasonics Corp. Danbury, 
CT, USA).  The characterization was done as described in Chapter 4 section 4.2.1.  
 
6.2.2. MWCNT suspensions and characterization 
Multi-walled carbon nanotubes (MWCNTs) were a generous gift from NanoTechLabs Inc. 
(Yadkinville, NC, USA).  The dry powder form of the MWCNTs were previously characterized 
(224) by transmission and scanning electron microscopy to obtain length, diameter distribution 
and elemental composition; Raman spectra; and the surface area, pore volume and pore size 
distribution of the MWCNTs were obtained based on the Brunauer-Emmett-Teller (BET) 
equation (22) and the Barrett-Joyner-Halenda (BJH) method (12).  The MWCNTs were 
suspended in 1 mg/ml suspensions in either 10% clinical grade surfactant (Infasurf®, ONY, Inc., 
Amherst, NY, USA) in saline [(S)-MWCNTs, was used for intratracheal instillation of 
MWCNTs as described in Chapter 5] or in culture medium [(M)-MWCNTs] and the mixture was 
cup-horn sonicated for 65% amplitude for 2 minutes with a total energy of 10,817 joules using a 
Misonix ultrasonic liquid processor -1510R-MTH (Branson Ultrasonics Corp. Danbury, CT, 
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USA).  The hydrodynamic size distribution, a parameter describing the effective diameter of a 
diffusing particle, was characterized using dynamic light scattering (Nanosizer S90, Malvern 
Instruments, UK).  The zeta potential, the primary indicator for describing the surface charge and 
stability of MWCNT suspension, was determined using a zeta potential device (Zeta ZS, 
Malvern Instruments, UK).  Additionally, MWCNTs were suspended in the dispersion media 
modified from Bihari et al (17) as described in Chapter 5 (used for intravenous MWCNT 
delivery) and will be referred to as “DPPC/RSA”.  The MWCNT suspension of  1 mg/ml was 
made and the mixture was cup-horn sonicated using a Misonix ultrasonic liquid processor -
1510R-MTH (Branson Ultrasonics Corp. Danbury, CT, USA) at 65% amplitude for 2 minutes 
with a total energy of 10,817 joules.  This suspension will be referred to as “(D)-MWCNTs” in 
this study and its was previously described by Wang et al in 2013 (225).  
 
6.2.3. Cell culture 
Human aortic endothelial cells (HAEC) and rat aortic endothelial cells (RAEC) were used to 
identify the responses of endothelial cells following exposure to carbon based nanoparticles.  
HAEC were purchased from Cascade Biologics (Eugene, OR, USA) and cultured as 
recommended by the manufacturer, in Medium 200 with low serum growth supplement (LSGS, 
Life Technologies, Carlsbad, CA, USA) and antibiotics (Primocin 50 µg/1000ml, InvivoGen, 
SanDiego, CA, USA).  RAEC were purchased from Cascade Biologics (Eugene, OR, USA) and 
grown with Dulbecco's Modified Eagle Medium (DMEM).  These cell cultures were maintained 
at 37
º
C in 5% humidified CO2.  Culture medium was changed every 48 hours until reaching 
>80% confluence, then subsequently changed every 24 hours.  Cells were detached using 
0.025% Trypsin with 0.01% EDTA and Trypsin neutralizer solution, PBS containing 0.5% 
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newborn bovine serum (Life Technologies, Carlsbad, CA, USA) to obtain subcultures for C60 
and MWCNT treatment.  Cell viability was assessed 2, 6 and 24 hours after treatment with 
nanoparticles or suspension media using two different assays (MTS assay and a live/dead cell 
assay).  Since both assays did not reveal significant changes in cell viability following both types 
of nanoparticle exposure, these cells were used for further gene and protein expression analysis. 
 
6.2.4. Exposure of HAEC and RAEC to nanoparticles  
Confluent (>90%)  HAEC or RAEC in passages 3-6 were used for this study.  Each six well 
plate was seeded with 300,000 - 400,000 cells/well and treated with two doses; 1 and 10 µg/cm
2
 
of C60/PVP, (M)-MWCNTs, (S)-MWCNTs or (D)-MWCNTs.  Untreated cells and cells treated 
with equal volumes of PVP, 10% surfactant or DPPC/RSA were used as the controls.  The total 
volume of fluid in each well in a six well plate during the exposure in was 1 ml and the 
approximate height of the fluid column was 0.1 cm.  The final concentration of the PVP, 10% 
surfactant or DPPC/RSA (i.e. the dispersion media) in the cell culture medium following 
treatment was 0.95%. 
 
6.2.5. Cell Viability 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, CA, USA) was used to 
assess cell viability following 2, 6 and 24 hours of treatment with C60/PVP, (M)-MWCNTs, (S)-
MWCNTs or (D)-MWCNTs.  Cell culture supernatant was removed and 100 µl of phenol red 
free Dulbecco's Modified Eagle's Medium (DMEM) with 20 µl of the MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent 
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was added to each cell.  The cells were incubated at 37
º
C in 5% humidified CO2 for 30 minutes.   
A Synergy HT (Biotek VT, USA) plate reader was used to measure the absorbance at 490 nm.   
Cellular viability was calculated using the equation: % cellular viability = 100 x (test sample 
absorbance/control absorbance).  In addition, HAEC following 24 hours of exposure to (M)-
MWCNTs or (S)-MWCNTs were assessed for cell viability using the Live/Dead 
Viability/Cytotoxicity Kit for mammalian cells (Molecular Probes, Invitrogen detection 
technologies, OR, USA).  Samples were stained with Calcein AM and Ethidium homodimer 
under the manufacturer’s instructions and flow cytometric analysis was done for 10000 cell 
events using an Accuri C6 flow cytometer (BD Accuri Cytometers Ann Arbor, MI, USA). 
 
6.2.6. Real time-PCR 
Total RNA isolated from HAEC or RAEC was collected using Trizol reagent and chloroform 
degradation 2 h following exposure to C60 or MWCNTs.  mRNA was quantified using a 
Nanodrop 2000 spectrophotometer (Thermo Scientific, USA) and reverse transcribed to cDNA 
using the Quanti-Tect reverse transcription kit (Qiagen, USA).  We measured the expression of 
VCAM1, CCL2, ICAM1, SELE, and IL8 by quantitative real time-PCR using Quantitect primer 
assays and SYBR green master mix (Qiagen, USA).  The cycle threshold (CT) values for the 
targets and the internal reference were obtained using an Applied Biosystems StepOnePlus Real-
Time PCR system (ABI, Carlsbad, CA, USA).  In our preliminary experiments, the expression of 
five housekeeping genes (B2M, HPRT1, RPL13A, GAPDH and ACTB) following MWCNT 
treatment was assessed using a PCR array.  Since there were no significant differences in the 
level of mRNA expression across housekeeping genes, target cDNA levels were normalized to 
the internal reference: GAPDH, using the ΔΔCt method.  Three or four independent experiments 
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were used to determine the average fold changes for each target gene.  In addition, real time-PCR 
was also done by using primers for Rho A, ROCK1 and ROCK2 to identify changes in mRNA 
expression 2 and 24 hours following exposure to C60, MWCNTs or dispersion media. 
 
6.2.7. Flow cytometric analysis  
HAEC treated with 10 µg/cm
2
 of (M)-MWCNTs or (S)-MWCNTs for 2, 6 and 24 h were 
detached using 0.025% Trypsin ETDA (Life Technologies, Carlsbad, CA, USA) and 
resuspended in flow cytometry staining buffer (eBioscience, CA, USA).  10 ng/ml of 
recombinant human TNFα (PeproTech, NJ, USA) was used as a positive control (180).  The anti-
human SELE (ELAM1, CD62E) conjugated with fluorescein isothiocyanate (FITC) and anti-
human VCAM1 (CD106) conjugated with phycoerythrin (eBioscience, CA, USA) antibodies 
were diluted 1:500 in the staining buffer and incubated for 30 min at room temperature in the 
dark.  After incubation, the cells were washed and resuspended in staining buffer.  Flow 
cytometric analysis was done for 10000 events using an Accuri C6 flow cytometer (BD Accuri 
Cytometers Ann Arbor, MI USA).  Data and image analysis was performed with FCS Express 4 
software (De Novo Software, Los Angeles, CA, USA).  
 
6.2.8. ELISA  
The supernatant of HAEC cultures was collected following 2, 6, and 24 h of exposure to 
MWCNTs suspended in either (M)-MWCNTs or (S)-MWCNTs.  A Duoset ELISA (R & D 
Systems, MN, USA) was used according to the manufacturer’s instructions to quantify human 
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CCL2/ MCP1 levels in the supernatant.  A Synergy HT (Biotek VT, USA) plate reader was used 
at 495 nm to detect CCL2 levels based upon a standard curve. 
 
6.2.9. Immunofluorescence imaging  
HAEC were grown on coverslips and treated with 1 and 10 µg/cm
2
 of (M)-MWCNTs or (S)-
MWCNTs for 6 hours at >90% confluence.  HAEC treated with 10 ng/ml of recombinant human 
TNF α (PeproTech, NJ, USA) for 6 hours was used as a positive control.  Following treatment, 
cells were washed with phosphate buffered saline (PBS) with 0.2% Tween.  Tris buffered saline 
(TBS), 0.2% Tween and 1% bovine serum albumin were used for blocking. The anti-human 
SELE (ELAM1, CD62E) conjugated with fluorescein isothiocyanate (FITC) and anti-human 
VCAM1 (CD106) conjugated with phycoerythrin (eBioscience, CA, USA) antibodies were used 
for staining at 1:200 dilution.  Prolong Gold Antifade reagent with DAPI (4’, 6-diamidino-2-
phenylindole, Molecular Probes, NY, USA) was used to localize the nucleus.  
Immunofluorescence imaging was performed under 40X objective on an Olympus BX41 
microscope and Olympus DP71 camera (Olympus America Inc. PA, USA). 
 
6.2.10. In-Cell Western Assay 
In vitro studies were also done with rat aortic endothelial cells (RAEC) to identify the 
contribution of the endothelial Rho mediated signaling in changing the vascular tissue 
contractility described in chapters 3-5.  RAEC cultures at  > 90% confluence were treated with 
all types of nanoparticle suspensions used for in vivo studies (Chapters 4 and 5) over a 1-10 
µg/cm
2
 dose range for 12 hours.  In-Cell Western Assay (Li-Cor Biosciences, Lincoln, NE, 
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USA) was done following 12 hours in vitro exposure to C60/PVP, (S)-MWCNTs or (D)-
MWCNTs or dispersion media to assess the changes in protein expression (200).  Briefly, the 
treated cells were immediately fixed with 3.7% formaldehyde with 1X PBS, permeabilized with 
0.1% Triton-X, blocked with Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE, 
USA), and treated with RhoA (1:1000), ROCK 1 (1:500),ROCK 2 (1:500) and eNOS (1:1000) 
primary antibodies (Santa Cruz Biotechnology Inc., USA and Cell Signaling Danvers, MA, 
USA).  IRDye 800CW Secondary Antibodies (LI-COR Biosciences, Lincoln, NE, USA) were 
used in 1:10000 dilution for target proteins and DNA were stained with DRAQ5 and Sapphire 
700 (Cell Signaling, Danvers, MA, USA) for cell number normalization.  The fluorescence was 
detected, quantified and analyzed using Li-Cor Odyssey Infrared Imaging System and software. 
 
6.2.11. Statistical Analysis 
GraphPad Prism 5 software (GraphPad, SanDiego, CA, USA) was used for statistical analysis. 
Data are presented as means ± SEM (standard error of the mean) and differences were 
considered statistically significant if p < 0.05 .  A t test was done to compare mRNA and protein 
expression levels between different treatment groups. 
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6.3. Results 
6.3.1. C60 suspension and characterization 
The zeta potentials of both PVP and C60/PVP suspensions were within the range of 0.8 - 1.5 mV 
for all samples, indicating low suspension stability for these samples.  The intensity based mean 
hydrodynamic diameter of C60/PVP was 371.3 nm and further details of characterization are 
reported in section 4.3.1 and Table 4.1. 
 
6.3.2. MWCNT suspensions and characterization 
Characterization details of the dry powder form of the MWCNTs used in this study have been 
published earlier (224) and are summarized in 6.1.  MWCNTs were suspended in either HAEC 
cell culture medium [(M)-MWCNT] or 10% pulmonary surfactant in saline [(S)-MWCNT] and 
hydrodynamic size and zeta potential were determined for the two suspensions.  The zeta 
potential was remarkably different between the two suspensions of MWCNTs (Table 6.2) 
suggesting differences in stability of the suspension.  The use of surfactant as a suspension 
medium provided better MWCNT stability based upon the zeta potential (-57 mV) versus a zeta 
potential of -15 mV in the (M)-MWCNT suspension.  The use of (S)-MWCNTs also simulates 
the MWCNTs reaching the systemic circulation by its initial suspension in the lung surfactant as 
may occur with inhalational exposure.  MWCNTs suspended in the DPPC, serum albumin and 
sterile phosphate buffered saline medium [(D)-MWCNTs] was characterized previously by 
Wang et al in 2013 (225) and is reported in table 6.2. 
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Table  6.1. MWCNT characterization  
 
R = ratio, ID = intensity of the disorder band (D-band), IG = intensity of the graphite like band (G-
band), Pore volume = MWCNT’s air volume/MWCNT’s total volume  
 
Table  6.2. Zeta potential and hydrodynamic size of different MWCNT suspensions  
Zeta potential and hydrodynamic size was calculated using the means of three separate 
suspensions each consisting of 10 independent runs.  
Characteristic MWCNTs in dry powder form 
Length  <2 µm 
Mean diameter Bimodal distribution with peaks at 12.5 nm and 25 nm 
Surface area 113.10 m
2
/g 
Pore  volume  0.68 cm
3
/g 
Raman spectra Strong disorder band at 1350 cm
-1
 ,    R=ID/IG = 0.65 
Elemental analysis 5% weight Fe catalyst 
    (M)-MWCNTs (S)-MWCNTs (D)-MWCNTs 
Mean hydrodynamic size (nm) 970 915 793 
Zeta potential (mV) -15.3 -57.3 -20.8 
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6.3.3 Cell viability following nanoparticle treatment 
HAEC and RAEC exposure to 1 and 10 µg/cm
2 
of C60 or MWCNTs in both types of 
suspensions for up to 24 hours did not result in cytotoxicity (Table 6.3 and 6.4).  Treated and 
untreated cells showed a mean cell viability of more than 87.7 %, as assessed by the MTS assay 
and the mean dead cells were less than 5.6% as determined by the Live/Dead cell assay. 
 
Table 6.3. Cell viability following C60/PVP treatment of RAEC 
Cell viability was determined using the MTS assay and the mean of 3 experiments are reported 
(% of cell viability) following 2, 6 and 24 h treatment of RAEC with PVP or C60/PVP.  The 
mean of 3 experiments are reported.  SD = standard deviation  
 
  
Treatment 
MTS Assay 
(% of cell viability  ± SD) 
2 h 6 h 24 h 
cell culture medium only 100 100 100 
PVP 97.8 ± 0.1 97.4 ± 3.1 91.4 ± 0.1 
10 mg/cm
2 
C60/PVP 98.6 ± 9.7 98.2 ± 5.3 92.3 ± 3.2 
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Table 6.4. Cell viability following MWCNT treatment of HAEC 
Cell viability was determined using the MTS assay and the mean of 3 experiments are reported 
(% of cell viability).  In addition, following 2, 6 and 24 h treatment of HAEC with MWCNTs or 
vehicle, cells were stained with an ethidium homodimer to delineate dead cells and analyzed by 
flow-cytometry to calculate the percentage of dead cells.  The mean of 3 experiments are 
reported.  SD = standard deviation  
  
Treatment 
MTS Assay 
(% of cell viability ± SD) 
Live/Dead Assay 
(% of dead cells ± SD) 
2 h 6 h 24 h 2 h 6 h 24 h 
cell culture 
medium only 
95.8 ± 1.1 101.9 ± 2.8 102.2 ± 2.5 2.8 ± 0.6 3.3 ± 0.7 3.6 ± 1.8 
1 mg/cm
2 
(M)-MWCNTs 
104.7 ± 
12.4 
98.4 ± 2.5 98.41 ± 1.4 3.8 ± 1.4 3.6 ± 0.8 1.9 ± 0.2 
10 mg/cm
2
 
(M)-MWCNTs 
110.8 ± 7.1 95.4 ± 4.0 87.71 ± 0.6 5.6 ± 1.0 4.6 ± 1.0 3.5 ± 0.8 
10% surfactant 
in saline 
96.1 ± 9.1 92.8 ± 3.2 108.9 ± 1.9 1.6 ± 0.4 1.4 ± 0.3 4.2 ± 0.4 
1 mg/cm
2
 
(S)-MWCNTs 
101.1 ± 4.4 92.1 ± 1.4 108.9 ± 0.8 2.8 ± 0.9 2.6 ± 0.3 2.8 ± 0.5 
10 mg/cm
2
 
(S)-MWCNTs 
101.4 ± 3.7 97.2 ± 3.7 112.9 ± 2.3 4.6 ± 0.8 4.6 ± 0.3 4.5 ± 0.8 
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6.3.4. Changes in gene expression of nanoparticle treated endothelial cells  
To determine effects of C60 and MWCNTs on endothelial cells, expression of  key inflammatory 
markers related to endothelial cell biology was examined 2 hours following treatment of HAEC 
with 1 and 10 µg/cm
2 
MWCNTs and RAEC with 1 and 10 µg/cm
2 
C60/PVP.  A minimal 
increase in CCL2 mRNA was seen with 10 µg/cm
2 
C60/PVP exposure
 
(Figure 6.1).  The 
expression of mRNA for VCAM, SELE, IL8 and CCL2 were up regulated with exposure to 10 
µg/cm
2 
(S)-MWCNTs, but not to (M)-MWCNTs (Figure 6.2).  The ΔCt values did not 
significantly vary between the two vehicle controls for any gene studied except for CCL2 (Table 
6.5).  CCL2 and SELE were significantly increased, while VCAM1 displayed a mean 75-fold 
increase with (S)-MWCNT treatment but did not reach statistical significance.  In contrast, an 
increase in mRNA of these genes was not found with either of the two doses of (M)-MWCNTs.  
Based on these observations, further analysis of protein expression was performed only on the 
MWCNT exposed endothelial cells. 
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Figure 6.1.  mRNA expression of markers of endothelial activation in C60/PVP exposed    
  RAEC 
Mean fold change in mRNA expression of cell adhesion molecules and chemokines in rat aortic 
endothelial cells (RAEC) treated for 2 h with 10 µg/cm
2
 C60/PVP. A. CCL2; B. VCAM1; C. 
SELE.  The mean fold change represents the fold-change above vehicle treated RAEC and is 
based on 3 - 4 independent experiments.  * indicates p<0.05, when compared between the 
treatment groups, using a one tailed t test. 
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Figure 6.2.  mRNA expression of markers of endothelial activation in MWCNT exposed 
HAEC 
Mean fold change in mRNA expression of cell adhesion molecules and chemokines in HAEC 
treated for 2 h with 1 µg/cm
2
 and 10 µg/cm
2
 of (M)-MWCNTs or (S)-MWCNTs. A. CCL2; B. 
VCAM1; C. SELE; D. IL8; E. ICAM1.  The mean fold change represents the fold-change above 
vehicle treated HAEC and is based on 3 - 4 independent experiments.  * indicates p<0.05, when 
compared between the treatment groups, using a one tailed t test.  
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Table 6.5. Mean ΔCt values of the vehicle controls 
Mean ΔCt values of the vehicle controls were assessed with real-time PCR, for the genes studied 
for mRNA expression levels.  The mean of 3-6 experiments are reported. 
mRNA 
ΔCt value 
(mean ± SEM) 
medium 
(untreated cells) 
10% surfactant 
CCL2 6.766 ± 0.280   10.01 ± 0.885 * 
VCAM 10.97 ± 0.540 12.51 ± 0.918 
SELE 12.27 ± 1.276 12.21 ± 0.860 
IL8 6.786 ± 0.637 5.618 ± 0.272 
ICAM1 7.781 ± 0.242 8.890 ± 0.477 
 
*indicates p<0.05, compared to the medium/untreated cells.  
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6.3.5. Expression of cell adhesion molecules following MWCNT treatment of HAEC 
Based on mRNA expression patterns, we performed flow cytometric analysis for VCAM1 and 
SELE at 2, 6 and 24 h following treatment with 10 µg/cm
2
 of (M)-MWCNTs or (S)-MWCNTs.  
Representative histograms are shown for each time point in Figure 6.3.  A minimal increase in 
VCAM1 was observed over time with MWCNT treatment.  Similar changes were not evident 
with SELE at any time point with either suspension (data not shown).  Surface protein expression 
of VCAM1 and SELE was confirmed by immunofluorescence imaging of HAEC grown on 
coverslips to avoid trypsinization effects.  Similar to results obtained by flow cytometry, a 
minimal increase in VCAM1 and SELE following exposure to 10 μg/cm2 of (S)-MWCNTs was 
observed (Figure 6.4).  Changes in VCAM1 and SELE expression were not seen at 1 μg/cm2 
with either of the MWCNT suspensions. 
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Figure 6.3. VCAM1 protein expression in MWCNT exposed HAEC 
Representative flow cytometry histograms for VCAM1 following 2, 6 and 24 h of treatment with 
10 µg/cm
2
 MWCNTs.  A-C. HAEC treated with (M)-MWCNTs; D. HAEC treated with 10 
ng/ml of TNFα for 6 h (positive control); E-G. HAEC treated with (S)-MWCNTs.  10000 cell 
events were analyzed for each time point.  Mean fluorescence intensity is represented by the 
numbers associated with each curve. 
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Figure 6.4. VCAM1 and SELE protein expression in MWCNT exposed HAEC 
Representative immunofluorescence images of HAEC stained for VCAM1 and SELE following 
treatment with 10 μg/cm2 (M)-MWCNTs (A-D), 10 μg/cm2 (S)-MWCNTs (E-H) and TNFα 
(positive control; I-L) for 6 h.  The nucleic acid stain DAPI (blue) localizes the nucleus.  FITC 
(green) represents SELE staining and phycoerythrin (red) represents VCAM1 staining, which are 
mainly localized on the cell surface/cytoplasm.  40X magnification. 
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6.3.6. HAEC production of CCL2 following MWCNT treatment 
CCL2 protein levels were examined in the supernatant of HAEC treated 10 µg/cm
2
 of (M)-
MWCNTs or (S)-MWCNTs.  Significant changes were seen at 6 and 24 h following treatment of 
HAEC with 10 µg/cm
2 
of (S)-MWCNTs (Figure 6.5).  In contrast, but consistent with mRNA 
expression, treatment of HAEC with (M)-MWCNTs did not induce significant differences in 
CCL2 levels.  
 
Figure 6.5. CCL2 protein expression in MWCNT exposed HAEC 
CCL2 protein concentration measured by ELISA in the HAEC supernatant following treatment 
with 10 µg/cm
2
 MWCNTs for 6 and 24 h. Each sample was analyzed in triplicate.  The mean 
concentration of CCL2 represents data from 4-6 independent experiments.  * indicates p<0.05 
when compared using a two tailed t test (n = 3 - 5).  
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6.3.7. RhoA, ROCK and eNOS mRNA and protein expression in RAEC  
The mRNA expression of  RhoA, ROCK1, ROCK2  and eNOS was not significantly changed in 
RAEC with 2 and 24 h treatment with C60/PVP or (D)-MWCNTs or (S)-MWCNTs or any 
suspension media (PVP, DPPC/RSA or 10% surfactant) when compared to untreated samples 
(Figures 6.6 and 6.7).  The protein expression was increased for RhoA (26.4%), ROCK II 
(52.1%) and eNOS (28.1%) 12 hours in vitro exposure to 10 µg/cm2 C60/PVP as assessed by the 
In-cell Western Assay (Figure 6.8).  Similar changes were not seen with either (D)-MWCNTs 
(Figure 6.9) or (S)-MWCNTs (Figure 6.10) after 12 hours of exposure.  
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Figure 6.6. RhoA-ROCK associated mRNA expression in C60/PVP or PVP exposed      
  RAEC 
Mean fold change in mRNA expression of RhoA (A), ROCK 1 (B), ROCK 2 (C) and eNOS (D) 
in rat aortic endothelial cells (RAEC) treated for 12 h with 1 µg/cm
2
 and 10 µg/cm
2
 C60/PVP or 
PVP.  The mean fold-change represents the fold-change above untreated RAEC and is based on 
3 independent experiments. 
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Figure 6.7. RhoA-ROCK associated mRNA expression in (D)-MWCNTS or DPPC/RSA   
  exposed RAEC 
Mean fold change in mRNA expression of RhoA (A), ROCK 1(B), ROCK 2 (C) and eNOS (D) in 
rat aortic endothelial cells (RAEC) treated for 12 h with 1 µg/cm
2
 and 10 µg/cm
2
 (D)-MWCNTS 
or DPPC/RSA.  The mean fold-change represents the fold-change above untreated RAEC and is 
based on 3 independent experiments.
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Figure 6.8.   RhoA, ROCK and eNOS protein expression in C60/PVP exposed RAEC  
Rat aortic endothelial cells (RAEC) were treated in vitro with C60/PVP at 1-10 µg/cm
2
 
concentration range for 12 h.  RhoA (A), ROCK 1 (B), ROCK 2 (C) and eNOS (D) expression 
was assessed by In-cell Western assay.  The expression of the target proteins (700 nm reading) 
were normalized to the cell number (800 nm reading) and then normalized to the untreated 
control (considered as 100%).  * indicates p < 0.05  when compared between treatment groups 
using a two tailed t test (n = 3 - 5).  
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Figure 6.9.   RhoA, ROCK and eNOS protein expression in (D)-MWCNTs or DPPC/RSA   
  exposed RAEC  
Rat aortic endothelial cells (RAEC) were treated in vitro with (D)-MWCNTs at 1-10 µg/cm
2
 
concentration range or DPPC/RSA for 12 h.  RhoA (A), ROCK 1 (B), ROCK 2 (C) and eNOS 
(D) expression was assessed by In-cell Western assay.  The expression of the target proteins (700 
nm reading) were normalized to the cell number (800 nm reading) and then normalized to the 
untreated control (considered as 100%, n = 3 - 5).  
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Figure 6.10.   RhoA, ROCK and eNOS protein expression in (S)-MWCNTs or 10%    
  surfactant exposed RAEC  
Rat aortic endothelial cells (RAEC) were treated in vitro with (S)-MWCNTs at 1-10 µg/cm
2
 
concentration range or 10% surfactant for 12 h.  RhoA (A), ROCK 1 (B), ROCK 2 (C) and 
eNOS (D) expression was assessed by In-cell Western assay.  The expression of the target 
proteins (700 nm reading) were normalized to the cell number (800 nm reading) and then 
normalized to the untreated control (considered as 100%, n = 3 - 5).  
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6.4. Discussion 
In this study, we found a moderate, but significant increase in the expression of different 
inflammatory genes and proteins in aortic endothelial cells following direct exposure to 
MWCNTs that was dependent on the suspension of MWCNTs.  These changes included an 
increase in the expression of chemokines and cell adhesion molecules with in vivo exposure to 
MWCNTs; however, similar inflammatory responses were not observed with C60/PVP 
exposure.  In general, we observed greater cell responses with (S)-MWCNTs allowing us  to 
suggest that the biomolecules attached to MWCNTs, as well as the suspensions zeta potential 
and the hydrodynamic size may all contribute to activation of the endothelium and subsequent 
intracellular signaling pathways.  We also observed an increase in the RhoA and ROCK protein 
expression in the aortic endothelial cells exposed to C60/PVP, but not to MWCNTs, suggestive 
of a promotion of the Rho signaling in the endothelial cells and presumably contributing to the 
increased contractile responses observed in the isolated vessel studies reported in Chapter 4.  
 
We compared the effects of two different types of carbon based nanoparticles (C60 and 
MWCNTs) in this study to identify the contribution of their physicochemical properties on 
endothelial cell activation following direct exposure.  MWCNT suspensions were used to 
simulate and investigate two different aspects of exposure.  The (M)-MWCNTs or (D)-
MWCNTs were utilized to simulate a direct exposure to the endothelium, as might be 
experienced following intravenous administration of nanotubes for diagnostic/therapeutic 
purposes and under the experimental conditions of our in vivo studies.  On the other hand, during 
an inhalational exposure, MWCNTs will encounter the surfactant lining of the alveolar 
epithelium before they are translocated to the systemic circulation across the alveolar capillary 
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membrane.  Hence, we suspended the MWCNT in 10% surfactant in saline [(S)-MWCNTs] for 
intratracheal instillation and the same suspension was also used for in vitro studies.  The in vitro 
approach allowed us to studying a direct, impact of C60 and MWCNTs on endothelial cells 
without the confounding influence of inflammatory cells and/or autonomic nervous system 
activation associated with inhalational exposure on potential cardiovascular system changes. 
 
The differences observed between C60 and MWCNT treatments can be correlated to the 
variations in the size and the zeta potential of the two nanoparticles.  C60 has a significantly 
lower hydrodynamic (371.3 nm) size, potentially allowing them to reach the intracellular 
compartments of endothelial cells by internalization.  This is supported by the observation of 
minimal cell surface mediated effects and increased expression of intracellular Rho signaling 
associated proteins.  Conversely, the relatively larger hydrodynamic size of MWCNTs (> 750 
nm) in all suspensions may be contributing to the activation of endothelial cell surface receptors 
as suggested by the increase in the various markers of endothelial cell activation including 
SELE, VCAM 1 and CCL2.  A recent study using MWCNTs in pulmonary surfactant and serum 
suspensions in a cell free medium identified markedly varying patterns of biomolecules 
adsorption to the nanotubes (63).  The implications of this observation were also demonstrated in 
our in vitro model findings.  Considering the size of the nanoparticles and previous evidence on 
translocation (3), it may be reasonable to assume that the phospholipid and protein coating that 
forms on the C60 or MWCNTs can also be translocated along with the nanoparticles across the 
alveolar capillary membrane to the circulatory system.  These particles loaded with scavenger 
proteins can potentially reach cellular and sub-cellular locations of the endothelial cell of 
different tissues and alter the intracellular signaling pathways. 
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The low zeta potential (0.8 - 1.5 mV) in the C60/PVP suspension is suggestive of a low stability 
with higher agglomeration potential that may be contributing the minimal endothelial 
inflammatory responses observed in this study.  The variances in zeta potentials seen in our 
characterization data are also indicative of differences in dispersion and stability of MWCNTs in 
the three different media that reflects protein corona formation.  Even though the hydrodynamic 
sizes of the MWCNTs in suspensions are similar initially, they agglomerate at different rates, 
which are indicted by the changes in the zeta potential.  This underlies the difference in cellular 
responses to MWCNTs with different suspensions.  According to our data, the presence of (S)-
MWCNTs initiates a greater inflammatory response when compared with the (M)-MWCNTs, a 
response which is augmented by increasing the dose of  MWCNTs. This apparent increase in cell 
activation by (S)-MWCNTs suggests that the more negative zeta potential of the MWCNTs 
significantly contributes to toxicity.  However, future studies should address the protein or lipid 
components that form the MWCNT corona in these suspensions to study and how they influence 
these responses.  Interestingly, a recent study reported on how the dispersal state of MWCNTs 
determined by the purity and suspension medium effected both in vitro and in vivo pro-fibrotic 
changes and intracellular localization of MWCNTs in lung epithelial cells (226).  Overall, the 
observations in our in vitro system suggests that the medium used for nanoparticle dispersion  
and the route of exposure may have a major impact on any inflammatory responses of the 
vascular endothelium, which may underlie the differential responses observed in the in vivo 
studies described in Chapters 4 and 5. 
 
Another interesting finding in our study was the lack of cytotoxicity in endothelial cells 
following either the C60 or MWCNT exposure.  A minimal cytotoxicity in PVP formulated C60 
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suspensions have been previously reported, supporting our findings (55) however, cytotoxic 
effects of pristine C60 have also been reported (176, 255).  When compared with the previous 
studies, we did not find significant changes in cell viability or large fold changes in IL8 mRNA 
(223) expression with either of the MWCNT suspensions.  Most of the cytotoxic changes seen in 
the other studies were significant but moderate in magnitude (157, 243).  The contrasting results 
are most likely attributed to the dissimilarities in the type, dose, manufacturer, batch and 
contaminants of C60 and MWCNTs used in the different studies.  Though the pure graphene 
sheets that are the fundamental building units of MWCNTs are considered relatively inactive, 
residual materials (50) and adjuvant compounds that bind to them in the suspension media could 
be the cause of underlying toxicity. Our characterization of the MWCNTs used in this study had 
relatively low contamination with metals and we adhered to all possible laboratory measures to 
prevent contamination with endotoxin and oxidative changes during storage and handling. 
Considering the in vitro approach, the source, type and passage of endothelial cells and 
components of the cell culture medium can also influence the level of cytotoxicity. Our 
conclusion is further supported by the findings of a recent study based on human umbilical vein 
endothelial cells, which reported reduced cytotoxicity of SWCNTs when they are bound to blood 
proteins (64). 
 
The dosimetry of the nanoparticles used in vitro will greatly affect cytotoxicity and cell 
activation (78).  Our doses were based on mass for both C60 and MWCNTs since we wanted to 
compare the effects of the exposure at the same mass of two different types of carbon based 
nanomaterials.  The doses we used for the treatment of endothelial cells can be considered as 
relatively high for an inhalational exposure.  However, they can also be considered as low and 
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high doses (1 and 10 µg/cm
2
) for an intravenous delivery depending on the blood concentration 
expected to be achieved in diagnostic or therapeutic applications.
 
 A recent assessment in a 
research laboratory producing MWCNTs found total particulate concentrations ranging from 37 
μg/m3 – 430 μg/m3 during airborne exposure to MWCNT in the absence of exposure controls 
(69).  The exact calculations on how these levels apply to endothelial cells remain to be 
determined based upon translocation and/or bio-distribution studies.  
 
As for MWCNTs use, we utilized the same material, but with different suspension media.  Since 
we observed a significant difference in stability of the MWCNT suspensions, it is likely that 
surface area may change with time and therefore influence the responses we observed.  As 
shown by the changes in mRNA and protein levels of CCL2, we did observe that 10% surfactant 
in saline may influence the cytotoxicity potential of the MWCNT suspensions and a similar 
association was observed in the isolated vessel studies following intratracheal instillation of (S)-
MWCNTs.  Considering that under normal physiological conditions, surfactant is not 
encountered by endothelial cells and therefore could potentially initiate an inflammatory 
response in the endothelial cells upon contact.  However, the presence of MWCNTs along with 
surfactant further aggravates the inflammatory response as evidenced by the up regulation of 
mRNA levels of cell adhesion molecules.  To identify the net effect incurred by the MWCNTs 
and to eliminate the potential effect of the vehicle control to our data, we have normalized each 
MWCNT treated HAEC findings to the respective vehicle control (i.e. 10% surfactant). 
 
We identified a distinct inflammatory type endothelial cell activation only with the exposure to 
MWCNTs and not following C60 exposure.  This observation may reflect previous reports 
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finding of anti-inflammatory and anti-oxidant type properties of different C60 suspensions (45, 
121).  The mRNA for VCAM1, SELE and CCL2 were expressed relatively high in the HAEC 
treated with (S)-MWCNTs. SELE and VCAM1 are cell adhesion molecules expressed on 
endothelial cells and mediate adhesion of leukocytes to vascular endothelium (14, 158).  
Similarly, the mRNA and protein expression of VCAM1, ICAM1, IL8 and SELE have been 
reported to be elevated in endothelial cells following exposure to SWCNTs (254), alumina (144) 
and several metal nanoparticles (203).  CCL2 (MCP1) is member of C-C chemokine family, 
which recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury, infection, 
and inflammation (25, 47, 240).  CCL2 is also associated with the regulation of angiogenesis 
(197), increased cytokine production (181) and systemic inflammatory responses (215).  In our 
study, CCL2 mRNA expression was increased with both C60 and MWCNT exposure in the 
endothelial cells.  Up-regulation of these adhesion proteins and chemokine indicates the 
exposures to these nanomaterial suspensions are conditioning intracellular and intercellular 
processes in favor of inflammation.  In addition to being endothelial markers, cell adhesion 
molecules will also influence the adjacent elements such as adherent leukocytes and vascular 
smooth muscle cells necessitating a need for future in vitro co-culture models or in vivo studies.  
While CCL2 protein levels correlated with mRNA expression patterns, the same was not true for 
VCAM1 or SELE, which were only slightly increased with MWCNT exposure.  This 
discrepancy between the mRNA and the protein levels of these chemokines and inflammatory 
markers in our study indicates that there are likely other pathways including post-transcriptional 
modifications that are activated and regulate the translation of mRNA to protein or influence 
protein turnover and degradation. 
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RhoA and ROCK2 proteins were increased in our in vitro studies with RAEC in a manner 
complimentary to the responses seen in isolated vessels 24 hours following C60 or MWCNT 
exposure as described in Chapters 3-5.  These proteins were increased only with C60 exposure 
and not with MWCNT exposure in the RAEC.  Similarly, we observed a significant increase in 
the amount of Rho kinase inhibitor (HA1077) required to attenuate the stress generated by 
phenylephrine in the C60 exposed vessel segments suggesting an increased Rho kinase activity 
following C60 exposure.  The increase in the Rho - ROCK signaling can be contributing in 
multiple ways to the endothelial activation response, inflammatory response and the increase in 
the contractile response of VSMC.  Previous studies have reported that the up-regulation of 
ROCK signaling via different stimuli will induce the production of MCP1/CCL2 (91, 183), IL8 
(183), ICAM1(88) and VCAM 1(107).  These inflammatory cytokines could contribute to an 
increased vasoconstriction by promoting the syntheses of vasoconstrictor agents such as 
endothelin 1 and angiotensin II.  They also increase the production of reactive oxygen species 
and can influence the Ca
2+
 signaling further promoting the contractile responses in vascular 
tissues.  Increased ICAM1, VCAM1 and SELE have been reported to be associated with slow 
coronary flow (216) further supporting their contribution in developing an increased contractile 
response.  However, in our study the mRNA expression was only increased with CCL2 and not 
with the other inflammatory cytokines following C60/PVP exposure in vitro. However, RhoA 
and ROCK signaling is reported to inhibit endothelial NO synthesis via inhibition of eNOS (56, 
127) and the reduction in the availability of NO promotes the uninhibited contractile response.  
The increase in the eNOS levels in RAEC in this study may be a compensatory response to PVP 
or C60/PVP mediated via the other pathways in the endothelial cells.  The limited changes in 
either Rho protein or eNOS expression seen with either of the MWCNT suspensions were 
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compatible with the observations in MWCNT exposed isolated vessel studies (Chapter 5), 
suggesting that Rho signaling was not a significant influence on the contractile responses 
following MWCNT exposure by either route.  Alternatively, the inflammatory responses may be 
contributing to the increased vascular tissue contractility with intratracheal instillation of 
MWCNTs as suggested by the increased expression of inflammatory proteins in endothelial cells 
following in vitro exposure to (S)-MWCNTs. 
 
In conclusion, our data suggest that direct exposure to MWCNTs reveals a modest inflammatory 
response from endothelial cells, which can be altered by changing the dose and suspension 
medium.  The relative low levels of up-regulation of the inflammatory proteins following 
C60/PVP and (M)-MWCNT exposure  suggest that the particle type and the dispersion medium 
will have a large influence on any potential use of nanoparticles as a mode of drug delivery.  In 
contrast, pulmonary exposure, simulating an occupational setting, may be more detrimental for 
the circulatory system if the MWCNTs consist of a pulmonary surfactant corona.  Pathways of 
mechanism that are consistent with our observations of the isolated vessels studies, are 
significant increases in the expression of RhoA and ROCK proteins with the C60/PVP exposed 
RAEC suggesting an increase in Rho signaling, but not with MWCNT exposure by either route. 
  
  
 
CHAPTER 7 
Conclusions and Future Directions 
7.1. Conclusions  
The findings of this dissertational research lead to several conclusions, which partially support 
our first hypothesis; acute exposure to C60 and MWCNTs during late stages of pregnancy 
activates vascular endothelium and increases contractile responses in uterine vasculature via 
activation of RhoA-Rho kinase (ROCK) pathway.  We also report several observations, which 
support our second hypothesis; the different physicochemical properties of C60 and MWCNTs 
will cause distinct and differential responses in aortic, uterine and mesenteric arteries. 
 
Our initial assessment of the contraction and relaxation profiles in naïve pregnant and non-
pregnant life stages of Sprague Dawley rats established a baseline for further experimental 
comparison to identify changes in the contractile responses following vehicle or CNP exposure.  
Significant differences observed in the contraction responses between pregnant and non-pregnant 
life stages suggest susceptibility to external toxicant mediated deviations.  Overall, the 
contractile responses were suppressed in the pregnant stage supporting an enhanced vasodilatory 
state despite the higher sensitivity to agonists (phenylephrine and endothelin 1), predominantly 
in the main uterine artery.  Most differences that were identified using wire myographic studies 
were compatible with the descriptions in literature, validating our technique for further studies 
with nanoparticles.  Our observations within the naïve pregnant group suggests 24 hours as an 
appropriate time point in a Sprague Dawley rat model to identify a significant change in weight 
gain due to acute external toxicant exposure.  We would thus hypothesize any increase in the 
 183 
 
contractile responses in uterine and umbilical vessels may produce a detectable difference in the 
weight gain within each day of gestation towards the later stages of pregnancy. 
 
More pronounced effects on the contractile responses following CNP exposure were seen only 
during pregnancy, which may be due to the expansive remodeling and alterations in multiple 
receptor availability/activation profiles in the pregnant life stage making it more susceptible to 
CNP mediated effects.  The evaluation of three different arterial vessels suggests a higher 
susceptibility of the main uterine artery or uterine vascular bed to manifest increased contractile 
responses following CNP exposure during pregnancy than those of the mesenteric or thoracic 
aorta. 
 
Understanding the toxic effects of non-functionalized forms of these CNP is imperative, as they 
will serve as reference points in the development of less-toxic CNP in future biomedical 
applications.  Our results from the in vivo and ex vivo studies suggest that intravenous exposure 
to C60/PVP during late stages of pregnancy increases the maximum stress generation response 
of the main uterine artery to several agonists (phenylephrine, endothelin 1 and angiotensin II) 
and of the aorta to endothelin 1.  The unchanged EC50 values following C60/PVP exposure is 
indicative of unaltered sensitivity despite an increase in stress generation, suggesting the 
underlying stress generation mechanisms are downstream of the agonist receptor interaction.  
The concomitant increase in the contraction of the umbilical vein may also be contributing to the 
reported reduction in fetal weight, suggesting an intrauterine growth restriction predisposed by 
diminished blood supply during late stages of pregnancy. 
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The observations in this study suggest an increase in the maximum stress generation responses of 
the main uterine artery following pulmonary exposure (via intratracheal instillation) to 
MWCNTs in pregnant Sprague Dawley rats.  Multiple agonist (phenylephrine, endothelin 1, 
angiotensin II and serotonin) mediated responses are differentially affected without changes in 
the sensitivity (EC50) as they mediate the contractile mechanism through different signaling 
cascades converging to several common target proteins.  The fetal weight gain was diminished 
by exposure to MWCNTs via both routes (intratracheal and intravenous) in the absence of 
increased contractile responses of umbilical veins.  This outcome is suggestive of mechanisms 
other than reduced blood supply such as nanoparticle distribution and inflammatory responses 
that may be contributing to retarded fetal growth following MWCNT exposure. 
 
Intravenous exposure to C60/PVP induces a greater increase in the contractile responses in 
multiple vascular beds (uterine, aortic and umbilical) as compared to IT exposure of the same 
material only impacted the main uterine artery response.  In contrast, IT MWCNT exposure 
increases the contractile responses, while the effects of IV exposure could be attributed to the 
suspension medium rather than to MWCNTs.  Considering the differential responses by the two 
routes of exposure, these effects could be dependent on the amount of CNP delivered to various 
vascular beds, the inflammatory responses and the properties of the protein corona associated 
with nanoparticles in different suspensions within biological systems.  Another important 
observation in both in vitro and in vivo studies was the significant responses mediated by all the 
suspension media used to deliver the carbon based non-functionalized nanomaterials for these 
studies.  These are also common suspensions reported in literature and substances such as PVP 
are already used in some nanoparticle-based products.  Hence, these observations also highlight 
 185 
 
the importance of selecting the appropriate formulation/vehicle for C60 or MWCNT delivery to 
target tissues in biomedical applications and in toxicological research to minimize the potential 
for unanticipated vascular effects.   
 
The Rho kinase mediated contractile response was attenuated in the main uterine artery in naïve 
pregnant rats as suggested by the lower concentration of Rho kinase inhibitor (HA1077) needed 
to attenuate the stress generated by adrenergic receptor stimulation.  As seen in our in vivo and ex 
vivo experiments, C60/PVP increases the contractile responses through elements of RhoA-
ROCK signaling only during pregnancy.  Compatible changes with increased RhoA and ROCK 
protein levels were seen with endothelial cell exposure to C60/PVP in the in vitro studies.  Both 
these observations suggest that RhoA-ROCK signaling elements may be playing a significant 
role in increasing the vascular tissue contractility following exposure to C60/PVP.  C60/PVP 
minimally activates the endothelium with minimal inflammation as suggested by the 
observations in the in vitro studies.  On the other hand, MWCNT instillation increases the 
vascular tissue contraction by a mechanism that is not solely associated with an increase in 
RhoA-ROCK signaling.  The mechanism of MWCNT induced vascular contractility may be 
related more to an inflammatory response via the activation of endothelial cells as suggested by 
the increase in the markers of endothelial activation in the in vitro studies.   
 
These differential effects could be attributed to the physicochemical properties of the two CNP.  
C60 is the smaller CNP in the dry form and has a lower hydrodynamic size in suspension, which 
could potentially reach sub-cellular locations activating elements of intracellular RhoA-ROCK 
signaling.  On the other hand, MWCNTs are larger in both diameter and length dimensions and 
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has a larger hydrodynamic diameter in suspension.  These properties may be contributing to 
activate the vascular endothelium via activation of the surface receptors.  Further, the greater zeta 
potential in MWCNT suspensions suggests a better dispersion of particles when compared to 
C60/PVP formulations.  These agglomeration properties may also contribute to the differential 
responses we observed both in vitro and in vivo exposure to the same mass based dose of the two 
different CNP.   
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7.2. Future Directions 
The above conclusions and observations of this study sprout multiple future directions for 
nanotoxicological, nanomedical and pregnancy related research.  From a nanotoxicological 
perspective, detailed dose response studies will have to be done for both types of nanoparticles in 
different suspensions and routes of exposure in order to apply these findings for risk assessment 
and regulatory purposes of exposure levels.  Multiple dose exposures are needed to mimic acute 
and chronic exposure, spanning greater than 24 hours.  On the other hand, a time course study 
can be done on the other stages of pregnancy including the first and second trimesters as changes 
in vascular reactivity during these transition periods can have different implications other than 
changes in the fetal weight.  Implantation, embryogenesis and organogenesis can be affected in 
such conditions resulting in miscarriages, birth defects and manifestations of different diseases in 
later life stages. 
 
Pristine, non-polar, non-functionalized nanoparticles were used in the current study for the 
assessment of their effects on contractile responses during pregnancy.  It is reported that 
nanoparticles that are functionalized with hydroxyl, carboxyl, amino or PEG (polyethylene 
glycol diamine) components are less toxic as studied in in vitro systems.  Therefore, the next step 
would be to use these functionalized, biocompatible nanoparticles to study their toxicological 
effects on vasculature during pregnancy.  These future studies may help to eliminate the adverse 
vascular effects of the pristine nanoparticles or suspension media and suggest them as platforms 
for drug delivery or other nanomedical applications.  Alternative suspensions to replace PVP, 
DPPC and surfactant based solutions along with a detailed analysis of the components in the 
protein corona need to be considered in future studies on medical and cosmetic products, as these 
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formulations/suspension media may be contributing to the effects that we attribute to 
nanoparticle exposures. 
 
The contribution of RhoA-ROCK signaling on increasing the vascular tissue contractility 
following C60 exposure was evident with the observations in the current study.  Further detailed 
mechanistic assessments of this pathway need to be carried out in relation to nanoparticle 
exposure.  Use of pressurized vessel systems and fluorescent imaging techniques can be used to 
study further detailed physiological responses including the changes in Ca
2+
 sensitivity following 
CNP exposure.  The specific protein isoforms, active/inactive forms and the intracellular 
locations of CNP activity on RhoA-ROCK pathway need to be specified in order to use it as a 
therapeutic target for nanoparticle mediated toxicities.  Administration of a specific inhibitor of 
these target proteins immediately following unintentional/intentional exposure to C60 may be 
able to rescue the adverse vascular and fetal effects. 
 
Finally, to identify the translational applications of this study these findings can be extended to 
susceptible human populations.  Retrospective, descriptive studies on human populations who 
have already been inadvertently exposed to CNP either by occupational or environmental 
exposure may reveal pregnancy related adverse outcomes such as pregnancy induced 
hypertension, preeclampsia, low birth weight, birth defects and complications in later life stages.  
Individuals subjected to medical procedures using CNP formulations can also be used for these 
studies within the ethical limitations.  
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